PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
7933655-10	1994	When the relation between Lp(a) and other factors was studied, there was positive correlation with TC, beta Lp and LDLC, and a significant negative correlation with TRG.	Bexarotene	165-168	lipoprotein(a)	Homo sapiens	26-31
7636877-1	1995	Structural modifications of the retinoid X receptor (RXR) selective compound 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2- naphthyl)ethenyl]benzoic acid (LGD1069), which is currently in phase I/IIA clinical trials for cancer and dermatological indications, have resulted in the identification of increasingly potent retinoids with > 1000-fold selectivity for the RXRs.	Bexarotene	77-156	retinoid X receptor alpha	Homo sapiens	32-51
7636877-1	1995	Structural modifications of the retinoid X receptor (RXR) selective compound 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2- naphthyl)ethenyl]benzoic acid (LGD1069), which is currently in phase I/IIA clinical trials for cancer and dermatological indications, have resulted in the identification of increasingly potent retinoids with > 1000-fold selectivity for the RXRs.	Bexarotene	77-156	retinoid X receptor alpha	Homo sapiens	53-56
7636877-1	1995	Structural modifications of the retinoid X receptor (RXR) selective compound 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2- naphthyl)ethenyl]benzoic acid (LGD1069), which is currently in phase I/IIA clinical trials for cancer and dermatological indications, have resulted in the identification of increasingly potent retinoids with > 1000-fold selectivity for the RXRs.	Bexarotene	158-165	retinoid X receptor alpha	Homo sapiens	32-51
7636877-1	1995	Structural modifications of the retinoid X receptor (RXR) selective compound 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2- naphthyl)ethenyl]benzoic acid (LGD1069), which is currently in phase I/IIA clinical trials for cancer and dermatological indications, have resulted in the identification of increasingly potent retinoids with > 1000-fold selectivity for the RXRs.	Bexarotene	158-165	retinoid X receptor alpha	Homo sapiens	53-56
34931381-3	2022	METHODS: Oral cancer and leukoplakia cell lines were treated with the PPARgamma agonist (pioglitazone) and RXRalpha activator (bexarotene).	Bexarotene	127-137	retinoid X receptor alpha	Homo sapiens	107-115
33809931-5	2021	An RXR agonist, bexarotene, suppressed the cytotoxicity of MeHg.	Bexarotene	16-26	retinoid X receptor alpha	Homo sapiens	3-6
34931381-7	2022	Combination treatment with pioglitazone and bexarotene increases PPARgamma DNA binding activity and IVL promoter activity (p < 0.01 and p < 0.0001).	Bexarotene	44-54	peroxisome proliferator activated receptor gamma	Homo sapiens	65-74
34931381-11	2022	CONCLUSIONS: Targeting the PPARgamma/RXRalpha heterodimer with pioglitazone and bexarotene was effective in this preclinical project.	Bexarotene	80-90	peroxisome proliferator activated receptor gamma	Homo sapiens	27-36
34931381-11	2022	CONCLUSIONS: Targeting the PPARgamma/RXRalpha heterodimer with pioglitazone and bexarotene was effective in this preclinical project.	Bexarotene	80-90	retinoid X receptor alpha	Homo sapiens	37-45
34830251-2	2021	Bexarotene treatment elicits side-effects by provoking or disrupting other RXR-dependent pathways.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	75-78
34830251-7	2021	These results demonstrate that modification of partial agonists such as NEt-4IB and potent rexinoids such as bexarotene can lead to compounds with improved RXR selectivity, decreased cross-signaling of other RXR-dependent nuclear receptors, increased LXRE-heterodimer selectivity, and enhanced anti-proliferative potential in leukemia cell lines compared to therapeutics such as 1.	Bexarotene	109-119	retinoid X receptor alpha	Homo sapiens	156-159
34830251-7	2021	These results demonstrate that modification of partial agonists such as NEt-4IB and potent rexinoids such as bexarotene can lead to compounds with improved RXR selectivity, decreased cross-signaling of other RXR-dependent nuclear receptors, increased LXRE-heterodimer selectivity, and enhanced anti-proliferative potential in leukemia cell lines compared to therapeutics such as 1.	Bexarotene	109-119	retinoid X receptor alpha	Homo sapiens	208-211
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	Bexarotene	111-121	heme oxygenase 1	Homo sapiens	169-174
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	Bexarotene	111-121	protein kinase C alpha	Homo sapiens	179-184
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	Bexarotene	111-121	heme oxygenase 1	Homo sapiens	314-319
34681275-6	2021	Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively.	Bexarotene	111-121	protein kinase C alpha	Homo sapiens	324-329
34681275-8	2021	Bexarotene treatment had a comparable doxorubicin-sensitizing effect in HMOX1-transfected cells and desloratadine in PRKCA-transfected cells.	Bexarotene	0-10	heme oxygenase 1	Homo sapiens	72-77
34638488-4	2021	Bexarotene, the only FDA-approved RXR agonist, is still used to treat cutaneous T-cell lymphoma.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	34-37
34603059-2	2021	We have previously shown that bexarotene, an agonist of retinoid X receptor (RXR) approved for cancer therapy, promotes the specification and differentiation of skeletal muscle progenitors.	Bexarotene	30-40	retinoid X receptor alpha	Homo sapiens	56-75
34142331-3	2021	Our results showed that pharmacologically activating RXR-alpha with bexarotene significantly accelerated hematoma clearance and alleviated neurological dysfunction after ICH.	Bexarotene	68-78	retinoid X receptor alpha	Homo sapiens	53-62
34142331-5	2021	Mechanistically, bexarotene promoted the nuclear translocation of RXR-alpha and PPAR-gamma, as well as reducing neuroinflammation by modulating microglia/macrophage reprograming from the M1 into the M2 phenotype.	Bexarotene	17-27	retinoid X receptor alpha	Homo sapiens	66-75
34142331-5	2021	Mechanistically, bexarotene promoted the nuclear translocation of RXR-alpha and PPAR-gamma, as well as reducing neuroinflammation by modulating microglia/macrophage reprograming from the M1 into the M2 phenotype.	Bexarotene	17-27	peroxisome proliferator activated receptor gamma	Homo sapiens	80-90
34603059-2	2021	We have previously shown that bexarotene, an agonist of retinoid X receptor (RXR) approved for cancer therapy, promotes the specification and differentiation of skeletal muscle progenitors.	Bexarotene	30-40	retinoid X receptor alpha	Homo sapiens	77-80
34568544-6	2021	The calculations revealed that cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibit main protease and ACE2 receptors more effectively than the well-known drug hydroxychloroquine when used against COVID-19.	Bexarotene	84-94	angiotensin converting enzyme 2	Homo sapiens	121-125
34447379-0	2021	The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.	Bexarotene	26-36	retinoid X receptor alpha	Homo sapiens	41-44
34447379-3	2021	By stimulating human naive CD4 T-cells in the presence of Treg or Th17 skewing cytokines, we show that bexarotene also tips the human Treg/Th17 axis in favor of Treg induction, but unlike murine cells this occurs independently of atRA and retinoic acid receptor signaling.	Bexarotene	103-113	CD4 molecule	Homo sapiens	27-30
34359683-5	2021	We experimentally tested bexarotene as a potential BRF2 inhibitor.	Bexarotene	25-35	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	51-55
34359683-6	2021	We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent.	Bexarotene	14-24	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	144-148
34359683-6	2021	We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent.	Bexarotene	26-29	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	144-148
34359683-7	2021	Our data thus provide the first experimental evidence that BRF2 is a novel player in the DNA damage response pathway and that bexarotene can be used as a potential inhibitor to treat cancers with the specific elevation of oxidative stress.	Bexarotene	126-136	BRF2 RNA polymerase III transcription initiation factor subunit	Homo sapiens	59-63
34568544-7	2021	Meanwhile, bexarotene and cetilistat bind more tightly to the SARS-CoV-2 main protease and the ACE2 receptor, respectively, than remdesivir, a potential treatment for COVID-19 that is the first FDA-approved drug against this virus.	Bexarotene	11-21	angiotensin converting enzyme 2	Homo sapiens	95-99
35587315-2	2022	We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only.	Bexarotene	13-23	retinoid X receptor alpha	Homo sapiens	52-71
35320351-3	2022	We found that low-dose bexarotene (Bex) combined with the non-selective beta-blocker carvedilol (Carv) reduces proliferation of MCF10DCIS.com cells and markedly suppresses ARID1A levels.	Bexarotene	23-33	AT-rich interaction domain 1A	Homo sapiens	172-178
35592519-8	2022	Moreover, high expression of SNHG1 or SNHG3 resulted in drug resistant to AKT inhibitor VII, bexarotene, bicalutamide, dasatinib, erlotinib, and gefitinib.	Bexarotene	93-103	small nucleolar RNA host gene 1	Homo sapiens	29-34
35592519-8	2022	Moreover, high expression of SNHG1 or SNHG3 resulted in drug resistant to AKT inhibitor VII, bexarotene, bicalutamide, dasatinib, erlotinib, and gefitinib.	Bexarotene	93-103	small nucleolar RNA host gene 3	Homo sapiens	38-43
35320351-3	2022	We found that low-dose bexarotene (Bex) combined with the non-selective beta-blocker carvedilol (Carv) reduces proliferation of MCF10DCIS.com cells and markedly suppresses ARID1A levels.	Bexarotene	35-38	AT-rich interaction domain 1A	Homo sapiens	172-178
35320351-7	2022	The knock-down of ARID1A increased IGF-1R levels, prevented IGF-1R and IRS1 suppression upon Bex+Carv and stimulated proliferation.	Bexarotene	93-96	AT-rich interaction domain 1A	Homo sapiens	18-24
35320351-7	2022	The knock-down of ARID1A increased IGF-1R levels, prevented IGF-1R and IRS1 suppression upon Bex+Carv and stimulated proliferation.	Bexarotene	93-96	insulin like growth factor 1 receptor	Homo sapiens	60-66
35320351-7	2022	The knock-down of ARID1A increased IGF-1R levels, prevented IGF-1R and IRS1 suppression upon Bex+Carv and stimulated proliferation.	Bexarotene	93-96	insulin receptor substrate 1	Homo sapiens	71-75
33621639-4	2021	Bexarotene, a Retinoid X Receptor agonist, has been demonstrated to reverse behavioral deficits and to improved synaptic transmission and plasticity in murine models of AD, which was associated with the reduction of soluble Abeta peptides.	Bexarotene	0-10	histocompatibility 2, class II antigen A, beta 1	Mus musculus	224-229
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	48-58	retinoid X receptor alpha	Homo sapiens	34-37
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	48-58	kinesin family member 4A	Homo sapiens	93-97
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	48-58	forkhead box M1	Homo sapiens	113-118
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	323-333	retinoid X receptor alpha	Homo sapiens	34-37
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	323-333	kinesin family member 4A	Homo sapiens	93-97
35312737-10	2022	Interestingly, we discovered that RXR agonists (Bexarotene, and Alitretinoin) down-regulated KIF4 expression via FOXM1-mediated suppression, resulting in a substantial decrease in HBV-Pre-S1 protein attachment to HepG2-hNTCP cell surface and subsequent HBV infection in both HepG2-hNTCP and primary human hepatocyte (PXB) (Bexarotene, IC50 1.89 +- 0.98 muM) cultures.	Bexarotene	323-333	forkhead box M1	Homo sapiens	113-118
35286638-2	2022	The ruthenium complex with bexarotene was shown to bind to albumin faster than to transferrin and exhibits much the same (to albumin) binding profile in human serum.	Bexarotene	27-37	albumin	Homo sapiens	59-66
35084694-3	2022	The efficacy and safety of bexarotene and photo(chemo)therapy combination therapy were previously confirmed in Japanese patients with CTCL.	Bexarotene	27-37	TSPY like 2	Homo sapiens	134-138
6993458-4	1980	Electrophoretic analysis of sulfur-labeled proteins and methyl-labeled proteins from trg mutants, which lost the ability of chemotaxis only towards ribose, galactose and their analogs, showed that the product of trg gene was another methyl-accepting protein i.e. a methyl-accepting chemotaxis protein for ribose and galactose (trg-MCP).	Bexarotene	85-88	mcp	Escherichia coli	331-334
35221968-1	2022	Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of cutaneous T-cell lymphomas (CTCLs).	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	33-52
35221968-2	2022	Since the objective response rate of bexarotene is relatively high, with no racial differences, bexarotene can be administered to patients with phototherapy-resistant early CTCL as one of the first-line therapies in real-world clinical practice.	Bexarotene	96-106	TSPY like 2	Homo sapiens	173-177
35221968-5	2022	In this report, drug eruptions in 2 patients with CTCL treated with bexarotene diagnosed by quantitative analysis of immunohistochemical staining by digital microscopy are described.	Bexarotene	68-78	TSPY like 2	Homo sapiens	50-54
34134472-3	2022	RXRA DT448/9PP was associated with ligand-independent activity in reporter assays, with enhanced co-activator interactions, reduced engraftment in vivo, and activation of myeloid maturation transcriptional signatures that overlapped with cells treated with the potent RXRA agonist bexarotene, suggestive of constitutive activity that leads to leukemic maturation.	Bexarotene	281-291	retinoid X receptor alpha	Homo sapiens	0-4
33621639-6	2021	Bexarotene increased the expression of OPCs and intermediate oligodendrocyte progenitors (Olig2+ and O4+), and increased the number of mitotic (O4+) and myelinating mature (MBP+) oligodendrocytes.	Bexarotene	0-10	oligodendrocyte transcription factor 2	Mus musculus	90-95
33621639-6	2021	Bexarotene increased the expression of OPCs and intermediate oligodendrocyte progenitors (Olig2+ and O4+), and increased the number of mitotic (O4+) and myelinating mature (MBP+) oligodendrocytes.	Bexarotene	0-10	myelin basic protein	Mus musculus	173-176
33935706-7	2021	In the present study, we aimed to elucidate whether chronic bexarotene treatment administered to the most commonly used murine model of DS, the Ts65Dn (TS) mouse could reduce Abeta expression in their brains and improve their cognitive abilities.	Bexarotene	60-70	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	144-150
33428094-1	2021	In this study, we were aimed to investigate the neuroprotective effects of bexarotene and nicotinamide in synaptosomes incubated with amyloid-beta (Abeta).	Bexarotene	75-85	amyloid beta precursor protein	Rattus norvegicus	148-153
33428094-10	2021	On the other hand, bexarotene caused a moderate increase in SIRT1 levels with PPARgamma activation.	Bexarotene	19-29	sirtuin 1	Rattus norvegicus	60-65
33428094-10	2021	On the other hand, bexarotene caused a moderate increase in SIRT1 levels with PPARgamma activation.	Bexarotene	19-29	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	78-87
33491272-0	2021	Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.	Bexarotene	51-61	nuclear receptor subfamily 2, group C, member 2	Mus musculus	14-17
33491272-0	2021	Targeting the TR4 nuclear receptor with antagonist bexarotene can suppress the proopiomelanocortin signalling in AtT-20 cells.	Bexarotene	51-61	pro-opiomelanocortin-alpha	Mus musculus	79-98
33491272-4	2021	Bexarotene was identified as an antagonist of TR4 that can directly interact with TR4 ligand binding domain (TR4-LBD) and induces a conformational change in the secondary structure of TR4-LBD.	Bexarotene	0-10	nuclear receptor subfamily 2, group C, member 2	Mus musculus	46-49
33491272-4	2021	Bexarotene was identified as an antagonist of TR4 that can directly interact with TR4 ligand binding domain (TR4-LBD) and induces a conformational change in the secondary structure of TR4-LBD.	Bexarotene	0-10	nuclear receptor subfamily 2, group C, member 2	Mus musculus	82-85
33491272-4	2021	Bexarotene was identified as an antagonist of TR4 that can directly interact with TR4 ligand binding domain (TR4-LBD) and induces a conformational change in the secondary structure of TR4-LBD.	Bexarotene	0-10	nuclear receptor subfamily 2, group C, member 2	Mus musculus	82-85
33491272-4	2021	Bexarotene was identified as an antagonist of TR4 that can directly interact with TR4 ligand binding domain (TR4-LBD) and induces a conformational change in the secondary structure of TR4-LBD.	Bexarotene	0-10	nuclear receptor subfamily 2, group C, member 2	Mus musculus	82-85
33491272-5	2021	Bexarotene suppressed AtT-20 cell growth, proopiomelanocortin (POMC) expression and adrenocorticotropin (ACTH) secretion.	Bexarotene	0-10	pro-opiomelanocortin-alpha	Mus musculus	42-61
33491272-5	2021	Bexarotene suppressed AtT-20 cell growth, proopiomelanocortin (POMC) expression and adrenocorticotropin (ACTH) secretion.	Bexarotene	0-10	pro-opiomelanocortin-alpha	Mus musculus	63-67
33491272-5	2021	Bexarotene suppressed AtT-20 cell growth, proopiomelanocortin (POMC) expression and adrenocorticotropin (ACTH) secretion.	Bexarotene	0-10	pro-opiomelanocortin-alpha	Mus musculus	105-109
33491272-6	2021	Mechanism dissection revealed that bexarotene could suppress TR4-increased POMC expression via promoting the TR4 translocation from the nucleus to the cytoplasm.	Bexarotene	35-45	nuclear receptor subfamily 2, group C, member 2	Mus musculus	61-64
33491272-6	2021	Mechanism dissection revealed that bexarotene could suppress TR4-increased POMC expression via promoting the TR4 translocation from the nucleus to the cytoplasm.	Bexarotene	35-45	pro-opiomelanocortin-alpha	Mus musculus	75-79
33491272-6	2021	Mechanism dissection revealed that bexarotene could suppress TR4-increased POMC expression via promoting the TR4 translocation from the nucleus to the cytoplasm.	Bexarotene	35-45	nuclear receptor subfamily 2, group C, member 2	Mus musculus	109-112
33491272-8	2021	Results from in vivo mouse model also revealed that oral bexarotene administration markedly suppressed ACTH-secreting tumour growth, adrenal enlargement and the secretion of ACTH and corticosterone in mice with already established tumours.	Bexarotene	57-67	pro-opiomelanocortin-alpha	Mus musculus	103-107
33491272-8	2021	Results from in vivo mouse model also revealed that oral bexarotene administration markedly suppressed ACTH-secreting tumour growth, adrenal enlargement and the secretion of ACTH and corticosterone in mice with already established tumours.	Bexarotene	57-67	pro-opiomelanocortin-alpha	Mus musculus	174-178
33527324-6	2021	RXR agonist Bexarotene notably suppressed ex vivo expansion of CB HSCs.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	0-3
33599853-0	2021	Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARgamma/ NF-kappaB signaling pathway in C6 glioma cells.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	98-107
33416115-6	2021	LPS upregulated the expression of inflammatory cytokines and NLRP3, inhibited the expression of autophagy-related and osteogenesis-related proteins, promoted apoptosis and altered the cell cycle, which was partially inhibited by NEAT1 overexpression and promoted by bexarotene.	Bexarotene	266-276	NLR family pyrin domain containing 3	Homo sapiens	61-66
33416115-6	2021	LPS upregulated the expression of inflammatory cytokines and NLRP3, inhibited the expression of autophagy-related and osteogenesis-related proteins, promoted apoptosis and altered the cell cycle, which was partially inhibited by NEAT1 overexpression and promoted by bexarotene.	Bexarotene	266-276	nuclear paraspeckle assembly transcript 1	Homo sapiens	229-234
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	toll-like receptor 4	Mus musculus	15-19
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	myeloid differentiation primary response gene 88	Mus musculus	20-25
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	mitogen-activated protein kinase kinase kinase 7	Mus musculus	26-30
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	31-40
33389386-0	2021	Suppression of TLR4/MyD88/TAK1/NF-kappaB/COX-2 Signaling Pathway in the Central Nervous System by Bexarotene, a Selective RXR Agonist, Prevents Hyperalgesia in the Lipopolysaccharide-Induced Pain Mouse Model.	Bexarotene	98-108	cytochrome c oxidase II, mitochondrial	Mus musculus	41-46
33389386-3	2021	To elucidate these mechanisms, we investigated whether the TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in the CNS mediates the effect of bexarotene to prevent hyperalgesia in the LPS-induced inflammatory pain mouse model.	Bexarotene	143-153	toll-like receptor 4	Mus musculus	59-63
33389386-3	2021	To elucidate these mechanisms, we investigated whether the TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in the CNS mediates the effect of bexarotene to prevent hyperalgesia in the LPS-induced inflammatory pain mouse model.	Bexarotene	143-153	mitogen-activated protein kinase kinase kinase 7	Mus musculus	70-74
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	retinoid X receptor alpha	Mus musculus	43-51
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	toll-like receptor 4	Mus musculus	115-119
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	myeloid differentiation primary response gene 88	Mus musculus	121-126
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	mitogen-activated protein kinase kinase kinase 7	Mus musculus	143-147
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	194-199
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	interleukin 1 alpha	Mus musculus	205-213
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	239-244
33389386-6	2021	Bexarotene also prevented the reduction in RXRalpha protein expression associated with a rise in the expression of TLR4, MyD88, phosphorylated TAK1, NF-kappaB p65, phosphorylated NF-kappaB p65, COX-2, and IL-1beta proteins, in addition to COX-2 activity and levels of PGE2 and IL-1beta in the brains and spinal cords of the LPS-treated animals.	Bexarotene	0-10	interleukin 1 alpha	Mus musculus	277-285
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	toll-like receptor 4	Mus musculus	30-34
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	myeloid differentiation primary response gene 88	Mus musculus	35-40
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	mitogen-activated protein kinase kinase kinase 7	Mus musculus	41-45
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	46-55
33389386-7	2021	Likely, decreased activity of TLR4/MyD88/TAK1/NF-kappaB/COX-2 signaling pathway in addition to increased pro-inflammatory cytokine formation in the CNS of mice participates in the protective effect of bexarotene against hyperalgesia induced by LPS.	Bexarotene	201-211	cytochrome c oxidase II, mitochondrial	Mus musculus	56-61
33599853-0	2021	Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARgamma/ NF-kappaB signaling pathway in C6 glioma cells.	Bexarotene	0-10	nuclear factor kappa B subunit 1	Homo sapiens	109-118
33599853-2	2021	Bexarotene is a third-generation retinoid X receptor agonist that is promising in the treatment of both cancer and neurodegenerative diseases.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	33-52
33599853-3	2021	In this study, we aimed to investigate the cytotoxic and anti-proliferative effects of bexarotene in C6 glioma cells through the PPARgamma/NF-kappaB pathway.	Bexarotene	87-97	peroxisome proliferator activated receptor gamma	Homo sapiens	129-138
33599853-3	2021	In this study, we aimed to investigate the cytotoxic and anti-proliferative effects of bexarotene in C6 glioma cells through the PPARgamma/NF-kappaB pathway.	Bexarotene	87-97	nuclear factor kappa B subunit 1	Homo sapiens	139-148
33599853-7	2021	We found that bexarotene treatment decreased NF-kappaB and TAS levels and increased PPARgamma and 8-OHdG levels in C6 cells.	Bexarotene	14-24	nuclear factor kappa B subunit 1	Homo sapiens	45-54
33599853-7	2021	We found that bexarotene treatment decreased NF-kappaB and TAS levels and increased PPARgamma and 8-OHdG levels in C6 cells.	Bexarotene	14-24	peroxisome proliferator activated receptor gamma	Homo sapiens	84-93
33599853-8	2021	Bexarotene enhanced PPARgamma expression in a dose-dependent manner when compared to the control group (P < 0.01).	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	20-29
33599853-9	2021	Furthermore, we determined that bexarotene-induced apoptotic C6 cells enhanced through Annexin V-FITC/PI staining and caspase-3/-7 activation analyses since phosphatidylserine level on the outer surface of the cell membrane and caspase-3/-7 activities were increased in the cells treated with bexarotene.	Bexarotene	32-42	annexin A5	Homo sapiens	87-96
33599853-9	2021	Furthermore, we determined that bexarotene-induced apoptotic C6 cells enhanced through Annexin V-FITC/PI staining and caspase-3/-7 activation analyses since phosphatidylserine level on the outer surface of the cell membrane and caspase-3/-7 activities were increased in the cells treated with bexarotene.	Bexarotene	32-42	caspase 3	Homo sapiens	118-130
33599853-9	2021	Furthermore, we determined that bexarotene-induced apoptotic C6 cells enhanced through Annexin V-FITC/PI staining and caspase-3/-7 activation analyses since phosphatidylserine level on the outer surface of the cell membrane and caspase-3/-7 activities were increased in the cells treated with bexarotene.	Bexarotene	32-42	caspase 3	Homo sapiens	228-240
33599853-10	2021	In conclusion, bexarotene treatment in C6 glioma cells could modulate apoptosis profile, DNA damage, ROS production, and reduction of TAS levels through inhibition of NF-kappaB by enhancing PPARgamma expression.	Bexarotene	15-25	nuclear factor kappa B subunit 1	Homo sapiens	167-176
33599853-10	2021	In conclusion, bexarotene treatment in C6 glioma cells could modulate apoptosis profile, DNA damage, ROS production, and reduction of TAS levels through inhibition of NF-kappaB by enhancing PPARgamma expression.	Bexarotene	15-25	peroxisome proliferator activated receptor gamma	Homo sapiens	190-199
33527324-7	2021	Activation of RXR by Bexarotene significantly blocked expansion of phenotypic HSCs and HPCs and expressed increased functional HPCs as assessed by colony formation induced by UM171 and SR1.	Bexarotene	21-31	retinoid X receptor alpha	Homo sapiens	14-17
32916173-0	2020	Bexarotene promotes microglia/macrophages - Specific brain - Derived Neurotrophic factor expression and axon sprouting after traumatic brain injury.	Bexarotene	0-10	brain derived neurotrophic factor	Mus musculus	53-88
32594555-5	2021	Current treatment recommendations for FMF reserve use of a systemic retinoid, often bexarotene (activates retinoid X receptor (RXR)), for advanced/aggressive disease following insufficient response to light therapy, while acitretin (activates retinoic acid receptor (RAR)) is rarely mentioned as a therapeutic option.	Bexarotene	84-94	retinoid X receptor alpha	Homo sapiens	106-125
32594555-5	2021	Current treatment recommendations for FMF reserve use of a systemic retinoid, often bexarotene (activates retinoid X receptor (RXR)), for advanced/aggressive disease following insufficient response to light therapy, while acitretin (activates retinoic acid receptor (RAR)) is rarely mentioned as a therapeutic option.	Bexarotene	84-94	retinoid X receptor alpha	Homo sapiens	127-130
32916173-10	2020	Bexarotene also increased microglia/macrophages-specific brain derived neurotrophic factor (BDNF) expression after TBI.	Bexarotene	0-10	brain derived neurotrophic factor	Mus musculus	92-96
32916173-5	2020	Bexarotene, an agonist of retinoid X receptor (RXR), can activate RXR/PPARgamma heterodimers.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	70-79
32916173-15	2020	In conclusion, bexarotene promotes axon sprouting, increases microglia/macrophages-specific BDNF expression, and induces microglia/macrophages from a pro-inflammatory state towards an anti-inflammatory one after TBI at least partially in a PPARgamma-dependent manner.	Bexarotene	15-25	brain derived neurotrophic factor	Mus musculus	92-96
32916173-6	2020	The aim of the present study was to identify the effect of bexarotene on BDNF in microglia/macrophages and axon sprouting after TBI in mice.	Bexarotene	59-69	brain derived neurotrophic factor	Mus musculus	73-77
32916173-15	2020	In conclusion, bexarotene promotes axon sprouting, increases microglia/macrophages-specific BDNF expression, and induces microglia/macrophages from a pro-inflammatory state towards an anti-inflammatory one after TBI at least partially in a PPARgamma-dependent manner.	Bexarotene	15-25	peroxisome proliferator activated receptor gamma	Mus musculus	240-249
32916173-9	2020	We found that bexarotene promoted axon regeneration indicated by increased growth associated protein 43 (GAP43) expression, myelin basic protein (MBP) expression, and biotinylated dextran amine (BDA)+ axon sprouting.	Bexarotene	14-24	growth associated protein 43	Mus musculus	75-103
32916173-9	2020	We found that bexarotene promoted axon regeneration indicated by increased growth associated protein 43 (GAP43) expression, myelin basic protein (MBP) expression, and biotinylated dextran amine (BDA)+ axon sprouting.	Bexarotene	14-24	growth associated protein 43	Mus musculus	105-110
32916173-9	2020	We found that bexarotene promoted axon regeneration indicated by increased growth associated protein 43 (GAP43) expression, myelin basic protein (MBP) expression, and biotinylated dextran amine (BDA)+ axon sprouting.	Bexarotene	14-24	myelin basic protein	Mus musculus	124-144
32916173-9	2020	We found that bexarotene promoted axon regeneration indicated by increased growth associated protein 43 (GAP43) expression, myelin basic protein (MBP) expression, and biotinylated dextran amine (BDA)+ axon sprouting.	Bexarotene	14-24	myelin basic protein	Mus musculus	146-149
32916173-10	2020	Bexarotene also increased microglia/macrophages-specific brain derived neurotrophic factor (BDNF) expression after TBI.	Bexarotene	0-10	brain derived neurotrophic factor	Mus musculus	57-90
32170675-4	2020	In this study, we investigated effect of Bex on depression-like behaviour in mice induced by lipopolysaccharide (LPS) or corticosterone (CORT).	Bexarotene	41-44	cortistatin	Mus musculus	137-141
32422522-1	2020	Several steroids (abiraterone, prednisone, testosterone, cholesterol) and the BCL-2 inhibitor bexarotene were used as starting materials to synthesize iperazinyl-spacered rhodamine B conjugates.	Bexarotene	94-104	BCL2 apoptosis regulator	Homo sapiens	78-83
33009242-7	2020	In this study, we examined whether the PPARgamma agonist rosiglitazone and retinoid X receptor (RXR) agonist bexarotene could increase NIS expression and exhibit anticancer activity in human thyroid cancer cells.	Bexarotene	109-119	retinoid X receptor alpha	Homo sapiens	75-94
33009242-7	2020	In this study, we examined whether the PPARgamma agonist rosiglitazone and retinoid X receptor (RXR) agonist bexarotene could increase NIS expression and exhibit anticancer activity in human thyroid cancer cells.	Bexarotene	109-119	retinoid X receptor alpha	Homo sapiens	96-99
33009242-7	2020	In this study, we examined whether the PPARgamma agonist rosiglitazone and retinoid X receptor (RXR) agonist bexarotene could increase NIS expression and exhibit anticancer activity in human thyroid cancer cells.	Bexarotene	109-119	solute carrier family 5 member 5	Homo sapiens	135-138
33009242-15	2020	In addition, bexarotene potentiated the effects of rosiglitazone on cell growth and NIS protein expression.	Bexarotene	13-23	solute carrier family 5 member 5	Homo sapiens	84-87
32170675-5	2020	Our results showed that treatment with Bex for 15 days significantly improved LPS-induced depression-like behaviour in social interaction test and CORT-induced depression-like behaviour in forced swimming test and tail suspension test in mice.	Bexarotene	39-42	cortistatin	Mus musculus	147-151
32170675-6	2020	We found that the Bex treatment depressed the increase in the number of activated microglia and astrocytes in the frontal cortex, and the increase in the levels of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in LPS-injected mice.	Bexarotene	18-21	tumor necrosis factor	Mus musculus	187-196
32170675-6	2020	We found that the Bex treatment depressed the increase in the number of activated microglia and astrocytes in the frontal cortex, and the increase in the levels of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in LPS-injected mice.	Bexarotene	18-21	interleukin 1 alpha	Mus musculus	198-206
32170675-6	2020	We found that the Bex treatment depressed the increase in the number of activated microglia and astrocytes in the frontal cortex, and the increase in the levels of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 in LPS-injected mice.	Bexarotene	18-21	interleukin 6	Mus musculus	211-215
32170675-7	2020	Furthermore, Bex treatment also rescued the decrease in the expression of BDNF, and inhibition of CREB/BDNF/ERK pathway, and improved the expression of synaptic related protein in CORT-induced mice.	Bexarotene	13-16	brain derived neurotrophic factor	Mus musculus	74-78
32170675-7	2020	Furthermore, Bex treatment also rescued the decrease in the expression of BDNF, and inhibition of CREB/BDNF/ERK pathway, and improved the expression of synaptic related protein in CORT-induced mice.	Bexarotene	13-16	cAMP responsive element binding protein 1	Mus musculus	98-102
32170675-7	2020	Furthermore, Bex treatment also rescued the decrease in the expression of BDNF, and inhibition of CREB/BDNF/ERK pathway, and improved the expression of synaptic related protein in CORT-induced mice.	Bexarotene	13-16	brain derived neurotrophic factor	Mus musculus	103-107
32170675-7	2020	Furthermore, Bex treatment also rescued the decrease in the expression of BDNF, and inhibition of CREB/BDNF/ERK pathway, and improved the expression of synaptic related protein in CORT-induced mice.	Bexarotene	13-16	mitogen-activated protein kinase 1	Mus musculus	108-111
32170675-7	2020	Furthermore, Bex treatment also rescued the decrease in the expression of BDNF, and inhibition of CREB/BDNF/ERK pathway, and improved the expression of synaptic related protein in CORT-induced mice.	Bexarotene	13-16	cortistatin	Mus musculus	180-184
32472163-10	2020	Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity.	Bexarotene	10-14	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	127-132
32472163-10	2020	Moreover, Bexa blocked the sleep rebound period after total sleep deprivation, increased in the hypothalamus the expression of c-Fos, and decreased NeuN activity.	Bexarotene	10-14	RNA binding fox-1 homolog 3	Rattus norvegicus	148-152
32472163-14	2020	Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus.	Bexarotene	10-14	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	60-65
32472163-14	2020	Moreover, Bexa or UVI administration significantly affected c-Fos and NeuN expression in the hypothalamus.	Bexarotene	10-14	RNA binding fox-1 homolog 3	Rattus norvegicus	70-74
33099295-3	2020	Bexarotene has been found to improve neurological function in mice in an ApoE-dependent manner, but the detailed mechanism is not fully clear.	Bexarotene	0-10	apolipoprotein E	Mus musculus	73-77
32207181-1	2020	Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world.	Bexarotene	0-10	TSPY like 2	Homo sapiens	76-80
32207181-1	2020	Bexarotene is useful for both early and advanced cutaneous T-cell lymphoma (CTCL), and is sometimes applied to ultraviolet-tolerant early CTCL patients as one of the first-line therapies in the real world.	Bexarotene	0-10	TSPY like 2	Homo sapiens	138-142
32207181-3	2020	Development of an appropriate protocol for bexarotene that can induce a consistent response for CTCL without severe AE (SAE) is needed.	Bexarotene	43-53	TSPY like 2	Homo sapiens	96-100
32207181-10	2020	Our present study suggests that low-dose bexarotene plus NBUVB therapy is well-tolerated and could be one of the optimal therapies for advanced CTCL.	Bexarotene	41-51	TSPY like 2	Homo sapiens	144-148
32555436-2	2020	We have previously established that a rexinoid x receptor (RXR)-selective agonist, bexarotene, enhances the differentiation and fusion of myoblasts through a direct regulation of MyoD expression, coupled with an augmentation of myogenin protein.	Bexarotene	83-93	retinoid X receptor alpha	Homo sapiens	38-57
32555436-2	2020	We have previously established that a rexinoid x receptor (RXR)-selective agonist, bexarotene, enhances the differentiation and fusion of myoblasts through a direct regulation of MyoD expression, coupled with an augmentation of myogenin protein.	Bexarotene	83-93	retinoid X receptor alpha	Homo sapiens	59-62
32555436-2	2020	We have previously established that a rexinoid x receptor (RXR)-selective agonist, bexarotene, enhances the differentiation and fusion of myoblasts through a direct regulation of MyoD expression, coupled with an augmentation of myogenin protein.	Bexarotene	83-93	myogenic differentiation 1	Homo sapiens	179-183
32555436-2	2020	We have previously established that a rexinoid x receptor (RXR)-selective agonist, bexarotene, enhances the differentiation and fusion of myoblasts through a direct regulation of MyoD expression, coupled with an augmentation of myogenin protein.	Bexarotene	83-93	myogenin	Homo sapiens	228-236
32064346-4	2020	We then identified isotretinoin and bexarotene, two FDA-approved RXRA agonists, which exert cardioprotective effects.	Bexarotene	36-46	retinoid x receptor, gamma a	Danio rerio	65-69
31203573-0	2019	Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer"s Disease iPSC-Derived Neural Stem Cells.	Bexarotene	23-33	presenilin 1	Homo sapiens	56-68
30660765-5	2020	Bexarotene 50mg/kg/day inhibited CCI-induced MAPKs (p38MAPK, ERK1/2, and JNK) activation and upregulation of proinflammatory factors(IL-1beta, TNF-alpha and IL-6).	Bexarotene	0-10	mitogen activated protein kinase 3	Rattus norvegicus	61-67
30660765-5	2020	Bexarotene 50mg/kg/day inhibited CCI-induced MAPKs (p38MAPK, ERK1/2, and JNK) activation and upregulation of proinflammatory factors(IL-1beta, TNF-alpha and IL-6).	Bexarotene	0-10	mitogen-activated protein kinase 8	Rattus norvegicus	73-76
30660765-5	2020	Bexarotene 50mg/kg/day inhibited CCI-induced MAPKs (p38MAPK, ERK1/2, and JNK) activation and upregulation of proinflammatory factors(IL-1beta, TNF-alpha and IL-6).	Bexarotene	0-10	interleukin 1 beta	Rattus norvegicus	133-141
30660765-5	2020	Bexarotene 50mg/kg/day inhibited CCI-induced MAPKs (p38MAPK, ERK1/2, and JNK) activation and upregulation of proinflammatory factors(IL-1beta, TNF-alpha and IL-6).	Bexarotene	0-10	tumor necrosis factor	Rattus norvegicus	143-152
30660765-5	2020	Bexarotene 50mg/kg/day inhibited CCI-induced MAPKs (p38MAPK, ERK1/2, and JNK) activation and upregulation of proinflammatory factors(IL-1beta, TNF-alpha and IL-6).	Bexarotene	0-10	interleukin 6	Rattus norvegicus	157-161
30660765-7	2020	Furthermore, bexarotene treatment significantly upregulated MKP-1 in the spinal cord.	Bexarotene	13-23	dual specificity phosphatase 1	Rattus norvegicus	60-65
30660765-9	2020	These results indicated that bexarotene relieved CCI-induced neuroinflammation and neuropathic pain by targeting MKP-1.	Bexarotene	29-39	dual specificity phosphatase 1	Rattus norvegicus	113-118
31203573-10	2019	We show that treating these cells with autophagy-stimulating drug bexarotene restored autophagy and compensated mitochondrial anomalies in PS1 M146L NSCs, by enhancing the clearance of mitochondria.	Bexarotene	66-76	presenilin 1	Homo sapiens	139-142
31545398-10	2019	Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-13.	Bexarotene	0-10	matrix metallopeptidase 1	Homo sapiens	127-159
31545398-0	2019	Activation of RXR by bexarotene inhibits inflammatory conditions in human rheumatoid arthritis fibroblast-like synoviocytes.	Bexarotene	21-31	retinoid X receptor alpha	Homo sapiens	14-17
31545398-10	2019	Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-13.	Bexarotene	0-10	matrix metallopeptidase 3	Homo sapiens	161-166
31545398-5	2019	Bexarotene is a novel selective RXR ligand used in the treatment of T-cell lymphoma.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	32-35
31545398-6	2019	In the present study, bexarotene was used to investigate the involvement of RXR in tumor necrosis factor-alpha (TNF-alpha)-induced RA conditions in human FLS.	Bexarotene	22-32	retinoid X receptor alpha	Homo sapiens	76-79
31545398-10	2019	Bexarotene treatment exhibited a potential protective effect against cartilage degradation by downregulating the expression of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-13.	Bexarotene	0-10	matrix metallopeptidase 13	Homo sapiens	171-177
31545398-6	2019	In the present study, bexarotene was used to investigate the involvement of RXR in tumor necrosis factor-alpha (TNF-alpha)-induced RA conditions in human FLS.	Bexarotene	22-32	tumor necrosis factor	Homo sapiens	83-110
31545398-6	2019	In the present study, bexarotene was used to investigate the involvement of RXR in tumor necrosis factor-alpha (TNF-alpha)-induced RA conditions in human FLS.	Bexarotene	22-32	tumor necrosis factor	Homo sapiens	112-121
31545398-8	2019	The present study also demonstrated that bexarotene exerted an anti-inflammatory effect by downregulating expression of interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, and high mobility group box-1.	Bexarotene	41-51	interleukin 6	Homo sapiens	120-138
31545398-11	2019	In addition, the present results demonstrated that the effects of bexarotene were mediated through the p38 mitogen-activated protein kinase/nuclear factor-kappaB pathway, via inhibition of p38 protein and the inhibitor alpha of kappaB phosphorylation.	Bexarotene	66-76	mitogen-activated protein kinase 14	Homo sapiens	103-106
31545398-8	2019	The present study also demonstrated that bexarotene exerted an anti-inflammatory effect by downregulating expression of interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, and high mobility group box-1.	Bexarotene	41-51	C-X-C motif chemokine ligand 8	Homo sapiens	140-144
31545398-12	2019	Taken together, the present findings demonstrated the potential of RXR agonism using bexarotene as a treatment against the development and progression of RA.	Bexarotene	85-95	retinoid X receptor alpha	Homo sapiens	67-70
31545398-8	2019	The present study also demonstrated that bexarotene exerted an anti-inflammatory effect by downregulating expression of interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, and high mobility group box-1.	Bexarotene	41-51	C-C motif chemokine ligand 2	Homo sapiens	146-180
31596896-5	2019	RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.	Bexarotene	47-57	apolipoprotein E	Mus musculus	196-200
31545398-8	2019	The present study also demonstrated that bexarotene exerted an anti-inflammatory effect by downregulating expression of interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, and high mobility group box-1.	Bexarotene	41-51	high mobility group box 1	Homo sapiens	186-211
31545398-9	2019	Notably, bexarotene also rescued the TNF-alpha-induced downregulation of the anti-inflammatory cytokines IL-4 and transforming growth factor-beta1.	Bexarotene	9-19	tumor necrosis factor	Homo sapiens	37-46
31545398-9	2019	Notably, bexarotene also rescued the TNF-alpha-induced downregulation of the anti-inflammatory cytokines IL-4 and transforming growth factor-beta1.	Bexarotene	9-19	interleukin 4	Homo sapiens	105-109
31545398-9	2019	Notably, bexarotene also rescued the TNF-alpha-induced downregulation of the anti-inflammatory cytokines IL-4 and transforming growth factor-beta1.	Bexarotene	9-19	transforming growth factor beta 1	Homo sapiens	114-146
31596896-5	2019	RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.	Bexarotene	47-57	carbonic anhydrase 1	Mus musculus	226-229
31596896-5	2019	RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.	Bexarotene	47-57	apolipoprotein E	Mus musculus	276-280
31596896-5	2019	RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.	Bexarotene	47-57	RNA binding protein, fox-1 homolog (C. elegans) 3	Mus musculus	285-289
31596896-5	2019	RESULTS: In addition to cognitive improvement, bexarotene-treated 3xTg-AD mice were found to have 1) reductions of astrogliosis and reactive microglia both in cortex and hippocampus; 2) increased ApoE expression restricted to CA1; 3) increased number of cells co-labeled with ApoE and NeuN; 4) recovery of NeuN expression, suggesting neuronal protection; and, 5) recovery of basal synaptic transmission and synaptic plasticity.	Bexarotene	47-57	RNA binding protein, fox-1 homolog (C. elegans) 3	Mus musculus	306-310
31265900-3	2019	In this study, we investigated the effects of a potent retinoid X receptor (RXR) agonist, bexarotene, on estrogen synthesis and neuroprotective action in hippocampal slices.	Bexarotene	90-100	retinoid X receptor alpha	Homo sapiens	55-74
31265900-3	2019	In this study, we investigated the effects of a potent retinoid X receptor (RXR) agonist, bexarotene, on estrogen synthesis and neuroprotective action in hippocampal slices.	Bexarotene	90-100	retinoid X receptor alpha	Homo sapiens	76-79
31265900-4	2019	Treatment with bexarotene increased estradiol levels as well as estrogen-synthesizing enzymes and CYP19 expression in hippocampal slice cultures.	Bexarotene	15-25	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	98-103
31265900-7	2019	The RXR antagonists HX531 and UVI3003 and the CYP19 inhibitor letrozole abolished the neuroprotection elicited by bexarotene, indicating that estradiol produced by RXR stimulation protects neurons from ischemic insult.	Bexarotene	114-124	retinoid X receptor alpha	Homo sapiens	4-7
31265900-7	2019	The RXR antagonists HX531 and UVI3003 and the CYP19 inhibitor letrozole abolished the neuroprotection elicited by bexarotene, indicating that estradiol produced by RXR stimulation protects neurons from ischemic insult.	Bexarotene	114-124	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	46-51
31265900-7	2019	The RXR antagonists HX531 and UVI3003 and the CYP19 inhibitor letrozole abolished the neuroprotection elicited by bexarotene, indicating that estradiol produced by RXR stimulation protects neurons from ischemic insult.	Bexarotene	114-124	retinoid X receptor alpha	Homo sapiens	164-167
31265900-8	2019	The human brain-specific CYP19 promoter had 6 RXR half sites, and 2 of 6 half sites were responsible for CYP19 expression induced by bexarotene.	Bexarotene	133-143	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	25-30
31265900-8	2019	The human brain-specific CYP19 promoter had 6 RXR half sites, and 2 of 6 half sites were responsible for CYP19 expression induced by bexarotene.	Bexarotene	133-143	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	105-110
31265900-9	2019	Bexarotene increased the expression of catalase and glutathione peroxidase 1 and inhibited lipid peroxidation elicited by OGD/reoxygenation, suggesting that the antioxidative property of estrogen contributes to RXR-mediated neuroprotection.	Bexarotene	0-10	catalase	Homo sapiens	39-47
31265900-9	2019	Bexarotene increased the expression of catalase and glutathione peroxidase 1 and inhibited lipid peroxidation elicited by OGD/reoxygenation, suggesting that the antioxidative property of estrogen contributes to RXR-mediated neuroprotection.	Bexarotene	0-10	glutathione peroxidase 1	Homo sapiens	52-76
31265900-9	2019	Bexarotene increased the expression of catalase and glutathione peroxidase 1 and inhibited lipid peroxidation elicited by OGD/reoxygenation, suggesting that the antioxidative property of estrogen contributes to RXR-mediated neuroprotection.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	211-214
31055081-8	2019	Murine (m)BCEC isolated from 3xTg AD mice treated with Bex revealed elevated expression of APOE and ABCA1.	Bexarotene	55-58	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	100-105
31160175-1	2019	Several retinoid X receptor (RXR) ligands (rexinoids), such as bexarotene (1), exhibit teratogenicity, which is a serious impediment to their clinical application.	Bexarotene	63-73	retinoid x receptor, alpha b	Danio rerio	29-32
31010302-0	2019	Bexarotene Exerts Protective Effects Through Modulation of the Cerebral Vascular Smooth Muscle Cell Phenotypic Transformation by Regulating PPARgamma/FLAP/LTB4 After Subarachnoid Hemorrhage in Rats.	Bexarotene	0-10	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	140-149
31010302-0	2019	Bexarotene Exerts Protective Effects Through Modulation of the Cerebral Vascular Smooth Muscle Cell Phenotypic Transformation by Regulating PPARgamma/FLAP/LTB4 After Subarachnoid Hemorrhage in Rats.	Bexarotene	0-10	arachidonate 5-lipoxygenase activating protein	Rattus norvegicus	150-154
31010302-4	2019	Bexarotene reduced neurological impairment, improved cerebral cortical blood flow, inhibited VSMC phenotypic transformation and suppressed the expression of 5-lipoxygenase-activating protein (FLAP) and leukotriene B4 (LTB4), which was partly reversed by GW9662, an inhibitor of peroxisome proliferator-activated receptor gamma (PPARgamma).	Bexarotene	0-10	arachidonate 5-lipoxygenase activating protein	Rattus norvegicus	192-196
31010302-4	2019	Bexarotene reduced neurological impairment, improved cerebral cortical blood flow, inhibited VSMC phenotypic transformation and suppressed the expression of 5-lipoxygenase-activating protein (FLAP) and leukotriene B4 (LTB4), which was partly reversed by GW9662, an inhibitor of peroxisome proliferator-activated receptor gamma (PPARgamma).	Bexarotene	0-10	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	278-326
31010302-4	2019	Bexarotene reduced neurological impairment, improved cerebral cortical blood flow, inhibited VSMC phenotypic transformation and suppressed the expression of 5-lipoxygenase-activating protein (FLAP) and leukotriene B4 (LTB4), which was partly reversed by GW9662, an inhibitor of peroxisome proliferator-activated receptor gamma (PPARgamma).	Bexarotene	0-10	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	328-337
31010302-6	2019	Therefore, we conclude that bexarotene reduced neurological impairment, improved cerebral cortical blood flow and inhibited the VSMC phenotypic transformation after SAH, which was achieved by activating PPARgamma-mediated inhibition of FLAP/LTB4 in VSMCs.	Bexarotene	28-38	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	203-212
31010302-6	2019	Therefore, we conclude that bexarotene reduced neurological impairment, improved cerebral cortical blood flow and inhibited the VSMC phenotypic transformation after SAH, which was achieved by activating PPARgamma-mediated inhibition of FLAP/LTB4 in VSMCs.	Bexarotene	28-38	arachidonate 5-lipoxygenase activating protein	Rattus norvegicus	236-240
31055081-8	2019	Murine (m)BCEC isolated from 3xTg AD mice treated with Bex revealed elevated expression of APOE and ABCA1.	Bexarotene	55-58	apolipoprotein E	Mus musculus	91-95
31160175-1	2019	Several retinoid X receptor (RXR) ligands (rexinoids), such as bexarotene (1), exhibit teratogenicity, which is a serious impediment to their clinical application.	Bexarotene	63-73	retinoid x receptor, alpha b	Danio rerio	8-27
31298602-1	2019	Introduction: Retinoid X receptor (RXR) agonists have a limited role in cancer therapy with bexarotene and alitretinoin as approved drugs but their use is limited by adverse effects.	Bexarotene	92-102	retinoid X receptor alpha	Homo sapiens	14-33
31298602-1	2019	Introduction: Retinoid X receptor (RXR) agonists have a limited role in cancer therapy with bexarotene and alitretinoin as approved drugs but their use is limited by adverse effects.	Bexarotene	92-102	retinoid X receptor alpha	Homo sapiens	35-38
30903705-1	2019	OBJECTIVE: Central hypothyroidism (CH) is a well-known adverse effect of bexarotene treatment for cutaneous T-cell lymphoma (CTCL).	Bexarotene	73-83	TSPY like 2	Homo sapiens	125-129
30903705-4	2019	DESIGN AND PATIENTS: Sixty-six Japanese patients with CTCL were retrospectively investigated by evaluating thyroid function during the early phase of bexarotene therapy.	Bexarotene	150-160	TSPY like 2	Homo sapiens	54-58
30791908-0	2019	Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.	Bexarotene	37-47	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	81-90
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	forkhead box O1	Homo sapiens	56-61
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	forkhead box O3	Homo sapiens	63-69
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	forkhead box M1	Homo sapiens	125-130
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	aurora kinase B	Homo sapiens	132-147
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	aurora kinase B	Homo sapiens	149-154
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	vascular endothelial growth factor A	Homo sapiens	161-197
30978209-4	2019	RA and/or bexarotene increased the transcript levels of FOXO1, FOXO3A, and TRAIL receptors; reduced the transcript levels of FOXM1, Aurora kinase B (AURKB), and vascular endothelial growth factor A (VEGFA); and decreased the proliferation of OSCC-derived cell lines.	Bexarotene	10-20	vascular endothelial growth factor A	Homo sapiens	199-204
30978209-5	2019	Also, RA and/or bexarotene influenced the recruitment of FOXO3A and FOXM1 to target genes.	Bexarotene	16-26	forkhead box O3	Homo sapiens	57-63
30978209-5	2019	Also, RA and/or bexarotene influenced the recruitment of FOXO3A and FOXM1 to target genes.	Bexarotene	16-26	forkhead box M1	Homo sapiens	68-73
30978209-8	2019	This research suggests novel influences of the drugs RA and bexarotene on the expression of FOXM1 and FOXO3A in transcriptional regulatory pathways of human OSCC.	Bexarotene	60-70	forkhead box M1	Homo sapiens	92-97
30978209-8	2019	This research suggests novel influences of the drugs RA and bexarotene on the expression of FOXM1 and FOXO3A in transcriptional regulatory pathways of human OSCC.	Bexarotene	60-70	forkhead box O3	Homo sapiens	102-108
31141879-11	2019	In the three cell lines, Bexarotene-induced retinoid X receptor response element (RXRE)-luciferase reporter activation was induced only if the RXRa/LXRa heterodimer were co-expressed.	Bexarotene	25-35	retinoid X receptor alpha	Homo sapiens	44-63
31141879-11	2019	In the three cell lines, Bexarotene-induced retinoid X receptor response element (RXRE)-luciferase reporter activation was induced only if the RXRa/LXRa heterodimer were co-expressed.	Bexarotene	25-35	retinoid X receptor alpha	Homo sapiens	143-147
31141879-11	2019	In the three cell lines, Bexarotene-induced retinoid X receptor response element (RXRE)-luciferase reporter activation was induced only if the RXRa/LXRa heterodimer were co-expressed.	Bexarotene	25-35	nuclear receptor subfamily 1 group H member 3	Homo sapiens	148-152
29889596-2	2019	Early-stage mycosis fungoides (MF) has been effectively treated with bexarotene, an RXR-agonist, with overall response (OR) rates 54-67% and complete response (CR) rates 7-27%.	Bexarotene	69-79	retinoid X receptor alpha	Homo sapiens	84-87
30703361-6	2019	RXR protein levels in retina were downregulated in both human glaucoma and experimental RGC injury models while RXR agonist, bexarotene treatment resulted in upregulation of RXR expression particularly in the inner retinal layers.	Bexarotene	125-135	retinoid X receptor alpha	Homo sapiens	112-115
30703361-6	2019	RXR protein levels in retina were downregulated in both human glaucoma and experimental RGC injury models while RXR agonist, bexarotene treatment resulted in upregulation of RXR expression particularly in the inner retinal layers.	Bexarotene	125-135	retinoid X receptor alpha	Homo sapiens	112-115
30703361-9	2019	Overall, retinal RXR modulation by bexarotene significantly protected RGCs in vivo in both acute and chronic glaucoma models.	Bexarotene	35-45	retinoid X receptor alpha	Homo sapiens	17-20
30791908-0	2019	Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.	Bexarotene	37-47	sirtuin 6	Rattus norvegicus	91-96
30791908-0	2019	Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARgamma/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats.	Bexarotene	37-47	forkhead box O3	Rattus norvegicus	97-103
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	52-61
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	sirtuin 6	Rattus norvegicus	66-71
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	forkhead box O3	Rattus norvegicus	116-122
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	forkhead box O3	Rattus norvegicus	126-132
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	interleukin 6	Rattus norvegicus	135-139
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	interleukin 1 beta	Rattus norvegicus	141-149
30791908-11	2019	Mechanistically, bexarotene increased the levels of PPARgamma and SIRT6; decreased the expression of phosphorylated FoxO3a (p-FoxO3a), IL-6, IL-1beta, and TNF-a; and inhibited the microglia activation and neutrophils infiltration at 24 h after SAH.	Bexarotene	17-27	tumor necrosis factor	Rattus norvegicus	155-160
30791908-12	2019	Either UVI3003, OSS128167, or RXR siRNA abolished the neuroprotective effects of bexarotene and its regulation on protein levels of PPARgamma/SIRT6/p-FoxO3a after SAH.	Bexarotene	81-91	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	132-141
30791908-12	2019	Either UVI3003, OSS128167, or RXR siRNA abolished the neuroprotective effects of bexarotene and its regulation on protein levels of PPARgamma/SIRT6/p-FoxO3a after SAH.	Bexarotene	81-91	sirtuin 6	Rattus norvegicus	142-147
30791908-12	2019	Either UVI3003, OSS128167, or RXR siRNA abolished the neuroprotective effects of bexarotene and its regulation on protein levels of PPARgamma/SIRT6/p-FoxO3a after SAH.	Bexarotene	81-91	forkhead box O3	Rattus norvegicus	150-156
31359392-2	2019	These methods have been extensively applied beyond the present case study to generate several analogs of other potent RXR agonists (rexinoids), particularly the RXR agonist known as bexarotene (Bex), a Food and Drug Administration (FDA) approved drug for cutaneous T-cell lymphoma that is also often prescribed, off-label, for breast, lung, and other human cancers.	Bexarotene	182-192	retinoid X receptor alpha	Homo sapiens	118-121
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	retinoid X receptor alpha	Mus musculus	26-51
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	retinoid X receptor alpha	Mus musculus	53-61
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	apolipoprotein E	Mus musculus	109-113
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	115-120
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	ATP binding cassette subfamily G member 1	Mus musculus	126-131
29995422-1	2019	Bexarotene, an agonist of retinoid X receptor alpha (RXRalpha), has been shown to increase the expression of apoE, ABCA1, and ABCG1 by activating RXR/LXR and RXR/PPAR heterodimers, resulting in amyloid beta (Abeta)-protein clearance in the brain of an Alzheimer"s disease (AD) mouse model and reversal of mouse cognitive deficits.	Bexarotene	0-10	peroxisome proliferator activated receptor alpha	Mus musculus	162-166
30746761-4	2019	The docking studies indicated bexarotene as a lead compound that can activate various RXR receptor isoforms (alpha, beta, and gamma) and has a strong binding affinity to the receptor protein than retinoic acid, which is known as a natural endogenous RXR agonist.	Bexarotene	30-40	retinoid X receptor alpha	Homo sapiens	86-89
30746761-4	2019	The docking studies indicated bexarotene as a lead compound that can activate various RXR receptor isoforms (alpha, beta, and gamma) and has a strong binding affinity to the receptor protein than retinoic acid, which is known as a natural endogenous RXR agonist.	Bexarotene	30-40	retinoid X receptor alpha	Homo sapiens	250-253
30746761-5	2019	Dynamic simulation studies confirmed that the hydrogen bonding and hydrophobic interactions were highly stable in all the three isoforms of the RXR-bexarotene complex.	Bexarotene	148-158	retinoid X receptor alpha	Homo sapiens	144-147
30746761-6	2019	To further validate the significance of the RXR receptor in neurons, in vitro pharmacological treatment of neuronal SH-SY5Y cells with bexarotene was performed.	Bexarotene	135-145	retinoid X receptor alpha	Homo sapiens	44-47
30746761-7	2019	In vitro data from SH-SY5Y cells confirmed that bexarotene activated RXR-simulated neurite outgrowth significantly.	Bexarotene	48-58	retinoid X receptor alpha	Homo sapiens	69-72
31368868-0	2019	Inhibitory Mechanism of An Anticancer Drug, Bexarotene Against Amyloid beta Peptide Aggregation: Repurposing Via Neuroinformatics Approach.	Bexarotene	44-54	amyloid beta precursor protein	Homo sapiens	63-75
31368868-5	2019	Bexarotene is an anticancer drug that has been under consideration for its ability to suppress Abeta-peptide aggregation.	Bexarotene	0-10	amyloid beta precursor protein	Homo sapiens	95-100
31368868-9	2019	A deep structural analysis of Abeta upon binding with bexarotene revealed critical binding sites and structural twists involved in Abeta aggregation.	Bexarotene	54-64	amyloid beta precursor protein	Homo sapiens	30-35
31368868-10	2019	It is evident from the present that bexarotene could significantly restrain the process of primary nucleation of Abeta.	Bexarotene	36-46	amyloid beta precursor protein	Homo sapiens	113-118
31368868-11	2019	In addition, bexarotene showed a strong interaction with RAGE and BACE-1, suggesting them as plausible targets for the neuro-therapeutic action of bexarotene.	Bexarotene	13-23	advanced glycosylation end-product specific receptor	Homo sapiens	57-61
31368868-11	2019	In addition, bexarotene showed a strong interaction with RAGE and BACE-1, suggesting them as plausible targets for the neuro-therapeutic action of bexarotene.	Bexarotene	13-23	beta-secretase 1	Homo sapiens	66-72
31368868-11	2019	In addition, bexarotene showed a strong interaction with RAGE and BACE-1, suggesting them as plausible targets for the neuro-therapeutic action of bexarotene.	Bexarotene	147-157	advanced glycosylation end-product specific receptor	Homo sapiens	57-61
31368868-11	2019	In addition, bexarotene showed a strong interaction with RAGE and BACE-1, suggesting them as plausible targets for the neuro-therapeutic action of bexarotene.	Bexarotene	147-157	beta-secretase 1	Homo sapiens	66-72
31368868-12	2019	CONCLUSION: Hence, we could safely suggest that bexarotene is a potent drug candidate that could reduce Abeta- peptide aggregation by applying different mechanistic pathways.	Bexarotene	48-58	amyloid beta precursor protein	Homo sapiens	104-109
31359391-3	2019	The side-effect profile of Bex treatment includes hypothyroidism and hypertriglyceridemia arising from the inhibition or activation of additional nuclear receptors that partner with RXR.	Bexarotene	27-30	retinoid X receptor alpha	Homo sapiens	182-185
31359392-2	2019	These methods have been extensively applied beyond the present case study to generate several analogs of other potent RXR agonists (rexinoids), particularly the RXR agonist known as bexarotene (Bex), a Food and Drug Administration (FDA) approved drug for cutaneous T-cell lymphoma that is also often prescribed, off-label, for breast, lung, and other human cancers.	Bexarotene	182-192	retinoid X receptor alpha	Homo sapiens	161-164
31359392-2	2019	These methods have been extensively applied beyond the present case study to generate several analogs of other potent RXR agonists (rexinoids), particularly the RXR agonist known as bexarotene (Bex), a Food and Drug Administration (FDA) approved drug for cutaneous T-cell lymphoma that is also often prescribed, off-label, for breast, lung, and other human cancers.	Bexarotene	194-197	retinoid X receptor alpha	Homo sapiens	161-164
31359392-3	2019	Common side effects with Bex treatment include hypertriglyceridemia and hypothyroidism, because of off-target activation or inhibition of other nuclear receptor pathways impacted by RXR.	Bexarotene	25-28	retinoid X receptor alpha	Homo sapiens	182-185
31359392-5	2019	Several other potent RXR agonists, and their analogs, have been reported in the literature and rigorously evaluated (often in comparison to Bex) as potential cancer therapeutics with unique activity and side-effect profiles.	Bexarotene	140-143	retinoid X receptor alpha	Homo sapiens	21-24
30422238-3	2018	Objectives: To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.	Bexarotene	221-231	apolipoprotein E	Homo sapiens	72-86
30518623-0	2018	Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells.	Bexarotene	0-10	aurora kinase A	Mus musculus	34-39
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	14-24	aurora kinase A	Mus musculus	35-40
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	14-24	aurora kinase A	Mus musculus	353-358
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	14-24	aurora kinase A	Mus musculus	353-358
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	35-40
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	353-358
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	353-358
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	35-40
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	353-358
30518623-6	2018	We found that bexarotene decreased AURKA expression in VHL-deficient cells, thereby restoring the ability of these cells to ciliate in the absence of VHL Finally, bexarotene treatment reduced the propensity of subcutaneous lesions to develop into tumors in a mouse xenograft model of renal cell carcinoma (RCC), with a concomitant decrease in activated AURKA, highlighting the potential of bexarotene treatment as an intervention strategy in the clinic to manage renal cystogenesis associated with VHL deficiency and elevated AURKA expression.	Bexarotene	163-173	aurora kinase A	Mus musculus	353-358
30422238-0	2018	Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene.	Bexarotene	147-157	apolipoprotein A5	Homo sapiens	15-20
30422238-0	2018	Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene.	Bexarotene	147-157	apolipoprotein C3	Homo sapiens	25-30
30422238-1	2018	Importance: Hypertriglyceridemia is the most frequent and limiting adverse effect of bexarotene therapy in cutaneous T-cell lymphoma (CTCL).	Bexarotene	85-95	TSPY like 2	Homo sapiens	134-138
30422238-3	2018	Objectives: To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.	Bexarotene	164-174	apolipoprotein E	Homo sapiens	72-86
30422238-3	2018	Objectives: To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.	Bexarotene	164-174	apolipoprotein A5	Homo sapiens	93-98
30422238-3	2018	Objectives: To analyze the association between genetic polymorphisms of apolipoprotein genes APOA5, APOC3, and APOE and the severity of hypertriglyceridemia during bexarotene therapy and to optimize patient selection for bexarotene therapy based on adverse effect profile.	Bexarotene	164-174	apolipoprotein E	Homo sapiens	111-115
30422238-5	2018	One hundred twenty-five patients with a confirmed diagnosis of CTCL who had received bexarotene therapy for at least 3 months were enrolled.	Bexarotene	85-95	TSPY like 2	Homo sapiens	63-67
30422238-12	2018	After bexarotene treatment, carriers of at least 1 of the 2 minor alleles of APOA5 c.-1131T&gt;C and APOC3 c.*40C&gt;G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs 330.97 [169.03] mg/dL, respectively; P = .02).	Bexarotene	6-16	apolipoprotein A5	Homo sapiens	77-82
30422238-12	2018	After bexarotene treatment, carriers of at least 1 of the 2 minor alleles of APOA5 c.-1131T&gt;C and APOC3 c.*40C&gt;G showed lower levels of triglycerides than noncarriers (mean [SD], 241.59 [169.91] vs 330.97 [169.03] mg/dL, respectively; P = .02).	Bexarotene	6-16	apolipoprotein C3	Homo sapiens	101-106
30422238-13	2018	Conclusions and Relevance: These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile.	Bexarotene	170-180	apolipoprotein A5	Homo sapiens	72-77
30422238-13	2018	Conclusions and Relevance: These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile.	Bexarotene	170-180	apolipoprotein C3	Homo sapiens	82-87
30422238-13	2018	Conclusions and Relevance: These results indicate that the screening of APOA5 and APOC3 genotypes may be useful to estimate changes in triglyceride concentrations during bexarotene treatment in patients with CTCL and also to identify the best candidates for bexarotene therapy based on the expected adverse effect profile.	Bexarotene	170-180	TSPY like 2	Homo sapiens	208-212
30405170-5	2018	One of the agonists, possessing a rare non-acidic chemotype, revealed high selectivity on 12 nuclear receptors and comparable efficacy as bexarotene on induction of ATP-binding cassette transporter A1, angiopoietin like protein 4 and apolipoprotein E.	Bexarotene	138-148	ATP binding cassette subfamily A member 1	Homo sapiens	165-200
29637440-2	2018	Bexarotene is an RXR pharmacological agonist that is shown to be neuroprotective through its effects in promoting amyloid beta (Abeta) uptake by the glial cells in the brain.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	17-20
29637440-2	2018	Bexarotene is an RXR pharmacological agonist that is shown to be neuroprotective through its effects in promoting amyloid beta (Abeta) uptake by the glial cells in the brain.	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	128-133
29637440-3	2018	This study aimed to evaluate the dose-dependent effects of bexarotene on RXR expression in SH-SY5Y neuroblastoma cells and validate the drug effects in the brain in vivo.	Bexarotene	59-69	retinoid X receptor alpha	Homo sapiens	73-76
29637440-5	2018	Our study demonstrated that bexarotene promoted the expression of RXR alpha, beta and gamma isoforms at optimal concentrations in the cells and in the mice brain.	Bexarotene	28-38	retinoid X receptor alpha	Mus musculus	66-75
29637440-7	2018	Bexarotene treatment not only rescued the RXR expression loss caused by Abeta treatment (p < 0.05) but also protected the cells against Abeta-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05).	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	42-45
29637440-7	2018	Bexarotene treatment not only rescued the RXR expression loss caused by Abeta treatment (p < 0.05) but also protected the cells against Abeta-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05).	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	72-77
29637440-7	2018	Bexarotene treatment not only rescued the RXR expression loss caused by Abeta treatment (p < 0.05) but also protected the cells against Abeta-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05).	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	136-141
29637440-10	2018	The ER stress and BAD activation induced by high concentrations of bexarotene were rescued by the TrkB agonist, 7,8 dihydroxyflavone (p < 0.05) while TrkB inhibitor CTX-B treatment further exacerbated these effects.	Bexarotene	67-77	neurotrophic tyrosine kinase, receptor, type 2	Mus musculus	98-102
30405170-5	2018	One of the agonists, possessing a rare non-acidic chemotype, revealed high selectivity on 12 nuclear receptors and comparable efficacy as bexarotene on induction of ATP-binding cassette transporter A1, angiopoietin like protein 4 and apolipoprotein E.	Bexarotene	138-148	apolipoprotein E	Homo sapiens	234-250
30211407-9	2018	We have also shown that bexarotene tightly binds to both peroxisome proliferator-activated receptor gamma (PPAR-gamma) and retinoid X receptors (RXRs).	Bexarotene	24-34	peroxisome proliferator activated receptor gamma	Mus musculus	57-105
30211407-9	2018	We have also shown that bexarotene tightly binds to both peroxisome proliferator-activated receptor gamma (PPAR-gamma) and retinoid X receptors (RXRs).	Bexarotene	24-34	peroxisome proliferator activated receptor gamma	Mus musculus	107-117
29704526-2	2018	However, only one rexinoid, bexarotene (Targretin TM) has been successfully transitioned from the bench to the clinic and used to treat cutaneous T-cell lymphoma (CTCL).	Bexarotene	28-38	TSPY like 2	Homo sapiens	163-167
30294626-1	2018	This article presents the experimental data supporting analysis of differential gene expression of human cutaneous T cell lymphoma (CTCL) cell culture cells (Hut78) treated with bexarotene or a variety of rexinoids, in conjunction with "A Novel Gene Expression Analytics-based Approach to Structure Aided Design of Rexinoids for Development as Next-Generation Cancer Therapeutics" (Hanish et al.	Bexarotene	178-188	TSPY like 2	Homo sapiens	132-136
29886067-0	2018	Bexarotene protects against neurotoxicity partially through a PPARgamma-dependent mechanism in mice following traumatic brain injury.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	62-71
29886067-9	2018	These effects of bexarotene were partially abolished by T0070907, an antagonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	Bexarotene	17-27	peroxisome proliferator activated receptor gamma	Mus musculus	83-131
29886067-9	2018	These effects of bexarotene were partially abolished by T0070907, an antagonist of peroxisome proliferator-activated receptor gamma (PPARgamma).	Bexarotene	17-27	peroxisome proliferator activated receptor gamma	Mus musculus	133-142
29886067-10	2018	Additionally, bexarotene enhanced nuclear translocation and transcriptional activity of PPARgamma.	Bexarotene	14-24	peroxisome proliferator activated receptor gamma	Mus musculus	88-97
29886067-11	2018	These findings show that bexarotene inhibits neurotoxicity in mice after TBI, at least in part through a PPARgamma-dependent mechanism.	Bexarotene	25-35	peroxisome proliferator activated receptor gamma	Mus musculus	105-114
29688151-0	2018	Bexarotene attenuates early brain injury via inhibiting micoglia activation through PPARgamma after experimental subarachnoid hemorrhage.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	84-93
29688151-12	2018	The expression of PPARgamma was significantly increased with bexarotene treatment compared with vehicle-treated controls.	Bexarotene	61-71	peroxisome proliferator activated receptor gamma	Mus musculus	18-27
29717863-1	2018	Bexarotene is a pleiotropic molecule that has been proposed as an amyloid-beta (Abeta)-lowering drug for the treatment of Alzheimer"s disease (AD).	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	80-85
29717863-3	2018	However, whether bexarotene induces removal of Abeta plaques in mouse models of AD has been controversial.	Bexarotene	17-27	amyloid beta (A4) precursor protein	Mus musculus	47-52
29717863-6	2018	Bexarotene inhibited the intramembrane cleavage by gamma-secretase of the APP C-terminal fragment C99 to release Abeta in cell-free assays of the reconstituted enzyme in liposomes, but not in cells, and only at very high micromolar concentrations.	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	113-118
29717863-7	2018	Surprisingly, in vitro, bexarotene also inhibited the cleavage of Notch1, another major gamma-secretase substrate, demonstrating that its inhibition of gamma-secretase is not substrate specific and not mediated by acting via the cholesterol binding site of C99.	Bexarotene	24-34	notch 1	Mus musculus	66-72
29717863-8	2018	Our data suggest that bexarotene is a pleiotropic molecule that interfere with Abeta metabolism through multiple mechanisms.	Bexarotene	22-32	amyloid beta (A4) precursor protein	Mus musculus	79-84
29762675-10	2018	However, several transcription factors from multiple families (sox4, fosl2, mxd1, mafb, nfib) were all inhibited by UVI and potentiated by Bex and TBT.	Bexarotene	139-142	transcription factor Sox4	Xenopus laevis	63-67
29762675-10	2018	However, several transcription factors from multiple families (sox4, fosl2, mxd1, mafb, nfib) were all inhibited by UVI and potentiated by Bex and TBT.	Bexarotene	139-142	FOS-like antigen 2 L homeolog	Xenopus laevis	69-74
29762675-10	2018	However, several transcription factors from multiple families (sox4, fosl2, mxd1, mafb, nfib) were all inhibited by UVI and potentiated by Bex and TBT.	Bexarotene	139-142	MAX dimerization protein 1 L homeolog	Xenopus laevis	76-80
29762675-10	2018	However, several transcription factors from multiple families (sox4, fosl2, mxd1, mafb, nfib) were all inhibited by UVI and potentiated by Bex and TBT.	Bexarotene	139-142	v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B S homeolog	Xenopus laevis	82-86
29762675-10	2018	However, several transcription factors from multiple families (sox4, fosl2, mxd1, mafb, nfib) were all inhibited by UVI and potentiated by Bex and TBT.	Bexarotene	139-142	nuclear factor I B L homeolog	Xenopus laevis	88-92
29599065-1	2018	BACKGROUND: Bexarotene (Targretin ) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs).	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	71-90
29599065-1	2018	BACKGROUND: Bexarotene (Targretin ) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs).	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	92-95
29599065-1	2018	BACKGROUND: Bexarotene (Targretin ) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs).	Bexarotene	24-33	retinoid X receptor alpha	Homo sapiens	71-90
29599065-1	2018	BACKGROUND: Bexarotene (Targretin ) is currently the only FDA approved retinoid X receptor (RXR) -selective agonist for the treatment of cutaneous T-cell lymphomas (CTCLs).	Bexarotene	24-33	retinoid X receptor alpha	Homo sapiens	92-95
29127736-12	2018	Activation of the retinoid X receptor (RXR) agonist, bexarotene, potentiates the inhibitory effect of these ligands.	Bexarotene	53-63	retinoid X receptor alpha	Homo sapiens	18-37
29521139-2	2018	Bexarotene is a specific RXRs agonist which has been granted by FDA approval for the clinical treatment of cutaneous T cell lymphoma (CTCL).	Bexarotene	0-10	TSPY like 2	Homo sapiens	134-138
29642873-0	2018	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	0-10	solute carrier family 10 member 2	Homo sapiens	74-81
29642873-0	2018	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	82-91
29642873-0	2018	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	0-10	phosphatase and tensin homolog	Homo sapiens	92-96
29642873-0	2018	Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	0-10	mechanistic target of rapamycin kinase	Homo sapiens	97-101
29642873-8	2018	In addition, overexpressed slc10a2 in NSCLC cells can further suppress the proliferation and migration, and promote apoptosis under the treatment of bexarotene.	Bexarotene	149-159	solute carrier family 10 member 2	Homo sapiens	27-34
29642873-9	2018	On the contrary, the opposite results were obtained after slc10a2 gene was silenced in NSCLC cells treated with bexarotene.	Bexarotene	112-122	solute carrier family 10 member 2	Homo sapiens	58-65
29642873-12	2018	CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	39-49	solute carrier family 10 member 2	Homo sapiens	98-105
29642873-12	2018	CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	39-49	peroxisome proliferator activated receptor gamma	Homo sapiens	106-115
29642873-12	2018	CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	39-49	phosphatase and tensin homolog	Homo sapiens	116-120
29642873-12	2018	CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.	Bexarotene	39-49	mechanistic target of rapamycin kinase	Homo sapiens	121-125
29437960-5	2018	The RXR-specific agonist bexarotene inhibits HBV in HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (NTCP) (HepG2-NTCP), HepaRG cells, and primary Tupaia hepatocytes (PTHs); reducing RXRalpha expression significantly enhanced HBV infection in the cells.	Bexarotene	25-35	solute carrier family 10 member 1	Homo sapiens	79-125
29437960-5	2018	The RXR-specific agonist bexarotene inhibits HBV in HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (NTCP) (HepG2-NTCP), HepaRG cells, and primary Tupaia hepatocytes (PTHs); reducing RXRalpha expression significantly enhanced HBV infection in the cells.	Bexarotene	25-35	solute carrier family 10 member 1	Homo sapiens	127-131
29437960-5	2018	The RXR-specific agonist bexarotene inhibits HBV in HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (NTCP) (HepG2-NTCP), HepaRG cells, and primary Tupaia hepatocytes (PTHs); reducing RXRalpha expression significantly enhanced HBV infection in the cells.	Bexarotene	25-35	solute carrier family 10 member 1	Homo sapiens	140-144
29437960-5	2018	The RXR-specific agonist bexarotene inhibits HBV in HepG2 cells expressing the sodium taurocholate cotransporting polypeptide (NTCP) (HepG2-NTCP), HepaRG cells, and primary Tupaia hepatocytes (PTHs); reducing RXRalpha expression significantly enhanced HBV infection in the cells.	Bexarotene	25-35	retinoid X receptor alpha	Homo sapiens	209-217
29448961-11	2018	RESULTS: Bexarotene treatment enhanced cognition in APP/PS1 mice similar to previous findings.	Bexarotene	9-19	presenilin 1	Mus musculus	56-59
29287960-4	2018	Furthermore, the bexarotene derivatives also showed significant effects in inhibiting TNBC cell proliferation and migration, modulating cancer stem cell markers expressions, as well as limiting the epithelial-mesenchymal transition (EMT) activities of TNBC cell lines in terms of downregulating EMT marker and blocking nuclear translocation of beta-catenin.	Bexarotene	17-27	catenin beta 1	Homo sapiens	344-356
29127736-12	2018	Activation of the retinoid X receptor (RXR) agonist, bexarotene, potentiates the inhibitory effect of these ligands.	Bexarotene	53-63	retinoid X receptor alpha	Homo sapiens	39-42
28981706-2	2017	We have previously established that bexarotene, a clinically approved agonist of retinoid X receptor (RXR), promotes the specification and differentiation of skeletal muscle lineage.	Bexarotene	36-46	retinoid X receptor alpha	Homo sapiens	81-100
29188497-0	2018	Bexarotene, a Selective RXRalpha Agonist, Reverses Hypotension Associated with Inflammation and Tissue Injury in a Rat Model of Septic Shock.	Bexarotene	0-10	retinoid X receptor alpha	Rattus norvegicus	24-32
29188497-2	2018	The aim of this study was to investigate effects of bexarotene, a selective RXRalpha agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARalpha/beta/gamma-RXRalpha heterodimer formation in a rat model of septic shock.	Bexarotene	52-62	retinoid X receptor alpha	Rattus norvegicus	76-84
29188497-2	2018	The aim of this study was to investigate effects of bexarotene, a selective RXRalpha agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARalpha/beta/gamma-RXRalpha heterodimer formation in a rat model of septic shock.	Bexarotene	52-62	nitric oxide synthase 2	Rattus norvegicus	174-205
29188497-2	2018	The aim of this study was to investigate effects of bexarotene, a selective RXRalpha agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARalpha/beta/gamma-RXRalpha heterodimer formation in a rat model of septic shock.	Bexarotene	52-62	nitric oxide synthase 2	Rattus norvegicus	207-211
29188497-2	2018	The aim of this study was to investigate effects of bexarotene, a selective RXRalpha agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARalpha/beta/gamma-RXRalpha heterodimer formation in a rat model of septic shock.	Bexarotene	52-62	cytochrome P450, family 4, subfamily f, polypeptide 6	Rattus norvegicus	217-242
29188497-2	2018	The aim of this study was to investigate effects of bexarotene, a selective RXRalpha agonist, on the changes in renal, cardiac, hepatic, and pulmonary expression/activity of inducible nitric oxide synthase (iNOS) and cytochrome P450 (CYP) 4F6 in relation to PPARalpha/beta/gamma-RXRalpha heterodimer formation in a rat model of septic shock.	Bexarotene	52-62	retinoid X receptor alpha	Rattus norvegicus	279-287
29188497-9	2018	The results suggest that increased formation of PPARalpha/beta/gamma-RXRalpha heterodimers and CYP4F6 expression/activity in addition to decreased iNOS expression contributes to the beneficial effect of bexarotene to prevent the hypotension associated with inflammation and tissue injury during rat endotoxemia.	Bexarotene	203-213	retinoid X receptor alpha	Rattus norvegicus	69-77
29188497-9	2018	The results suggest that increased formation of PPARalpha/beta/gamma-RXRalpha heterodimers and CYP4F6 expression/activity in addition to decreased iNOS expression contributes to the beneficial effect of bexarotene to prevent the hypotension associated with inflammation and tissue injury during rat endotoxemia.	Bexarotene	203-213	cytochrome P450, family 4, subfamily f, polypeptide 6	Rattus norvegicus	95-101
29188497-9	2018	The results suggest that increased formation of PPARalpha/beta/gamma-RXRalpha heterodimers and CYP4F6 expression/activity in addition to decreased iNOS expression contributes to the beneficial effect of bexarotene to prevent the hypotension associated with inflammation and tissue injury during rat endotoxemia.	Bexarotene	203-213	nitric oxide synthase 2	Rattus norvegicus	147-151
29212711-0	2017	PPARdelta activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.	Bexarotene	24-34	peroxisome proliferator activator receptor delta	Mus musculus	0-9
29212711-9	2017	To determine the basis for PPARdelta neuroprotection, we evaluated metabolic function and noted markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010.	Bexarotene	171-181	peroxisome proliferator activator receptor delta	Mus musculus	27-36
28981706-2	2017	We have previously established that bexarotene, a clinically approved agonist of retinoid X receptor (RXR), promotes the specification and differentiation of skeletal muscle lineage.	Bexarotene	36-46	retinoid X receptor alpha	Homo sapiens	102-105
28689412-10	2017	We have demonstrated that bexarotene is not capable to reduce amyloid deposits due to weak binding to Abeta fibrils.	Bexarotene	26-36	amyloid beta (A4) precursor protein	Mus musculus	102-107
28483659-0	2017	The long non-coding RNA Neat1 is an important mediator of the therapeutic effect of bexarotene on traumatic brain injury in mice.	Bexarotene	84-94	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	24-29
28483659-2	2017	The present study aims to investigate the potential roles of the long noncoding RNA Neat1 in the neuroprotective effects of bexarotene.	Bexarotene	124-134	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	84-89
28483659-9	2017	RESULTS: Bexarotene prominently up-regulated the Neat1 level in an RXR-alpha-dependent manner.	Bexarotene	9-19	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	49-54
28483659-9	2017	RESULTS: Bexarotene prominently up-regulated the Neat1 level in an RXR-alpha-dependent manner.	Bexarotene	9-19	retinoid X receptor alpha	Mus musculus	67-76
28483659-15	2017	CONCLUSION: Bexarotene up-regulates the lncRNA Neat1, which inhibits apoptosis and inflammation, thereby resulting in better functional recovery in mice after TBI.	Bexarotene	12-22	nuclear paraspeckle assembly transcript 1 (non-protein coding)	Mus musculus	47-52
28687611-6	2017	The counter-regulation of phospholipids and Akt by RA was mimicked by knockdown of lysophosphatidylcholine acyltransferase-3 or the selective retinoid X receptor (RXR) agonist bexarotene and prevented by the selective RXR antagonist Hx531.	Bexarotene	176-186	thymoma viral proto-oncogene 1	Mus musculus	44-47
28689412-2	2017	It has been suggested that bexarotene stimulates expression of apolipoprotein E (ApoE) leading to intracellular clearance of amyloid beta (Abeta).	Bexarotene	27-37	apolipoprotein E	Mus musculus	63-79
28689412-2	2017	It has been suggested that bexarotene stimulates expression of apolipoprotein E (ApoE) leading to intracellular clearance of amyloid beta (Abeta).	Bexarotene	27-37	apolipoprotein E	Mus musculus	81-85
28689412-2	2017	It has been suggested that bexarotene stimulates expression of apolipoprotein E (ApoE) leading to intracellular clearance of amyloid beta (Abeta).	Bexarotene	27-37	amyloid beta (A4) precursor protein	Mus musculus	139-144
28689412-4	2017	Two interesting questions include whether bexarotene can destroy Abeta fibrils via direct interaction with them and how this compound impacts the lag phase in the fibril growth process.	Bexarotene	42-52	amyloid beta (A4) precursor protein	Mus musculus	65-70
28689412-13	2017	We have also shown that bexarotene has a low binding propensity to Abeta monomer and dimer.	Bexarotene	24-34	amyloid beta (A4) precursor protein	Mus musculus	67-72
28689412-6	2017	The impotence of bexarotene in destroying fibrils means that this compound is weakly bound to Abeta.	Bexarotene	17-27	amyloid beta (A4) precursor protein	Mus musculus	94-99
28748653-10	2017	Our report is the second to describe PT-CTCL demonstrating a long-term complete response to oral bexarotene.	Bexarotene	97-107	TSPY like 2	Homo sapiens	40-44
28748653-11	2017	Given its anti-carcinogenic properties and favorable toxicity profile, oral bexarotene represents an appealing treatment option for PT-CTCL refractory to skin-directed therapies.	Bexarotene	76-86	TSPY like 2	Homo sapiens	135-139
28469839-5	2017	Interestingly, bexarotene induces the early expression of a myogenic progenitor marker, Meox1, while the expression of many RA targets is also enhanced by bexarotene.	Bexarotene	15-25	mesenchyme homeobox 1	Homo sapiens	88-93
28770285-6	2017	For the therapy of higher stages, interferon alpha and the RXR-specific retinoid bexarotene are used as first-line medications.	Bexarotene	81-91	retinoid X receptor alpha	Homo sapiens	59-62
28319634-4	2017	This case illustrates the importance of surveillance for CD4 leukopenia in patients on long-term bexarotene therapy with routine complete blood cell counts (CBC) and T-cell counts as well as consideration of rotating patients off bexarotene therapy even in those who derive continuous benefit.	Bexarotene	97-107	CD4 molecule	Homo sapiens	57-60
27235741-0	2017	Bexarotene protects against traumatic brain injury in mice partially through apolipoprotein E.	Bexarotene	0-10	apolipoprotein E	Mus musculus	77-93
27235741-10	2017	Taken together, bexarotene inhibits the inflammatory response as well as cell apoptosis and improves the neurological function of mice after TBI partially through apolipoprotein E.	Bexarotene	16-26	apolipoprotein E	Mus musculus	163-179
28251414-1	2017	Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer"s disease is being investigated.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	30-49
28251414-1	2017	Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer"s disease is being investigated.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	51-54
28319634-0	2017	Late-onset bexarotene-induced CD4 lymphopenia in a cutaneous T-cell lymphoma patient.	Bexarotene	11-21	CD4 molecule	Homo sapiens	30-33
28319634-2	2017	We report a rare case of a patient with cutaneous T-cell lymphoma (CTCL) who developed profound CD4 lymphopenia in the setting of long-term bexarotene therapy.	Bexarotene	140-150	TSPY like 2	Homo sapiens	67-71
28319634-2	2017	We report a rare case of a patient with cutaneous T-cell lymphoma (CTCL) who developed profound CD4 lymphopenia in the setting of long-term bexarotene therapy.	Bexarotene	140-150	CD4 molecule	Homo sapiens	96-99
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	apolipoprotein E	Homo sapiens	44-49
28319634-3	2017	Bexarotene is a third-generation retinoid that inhibits epithelial cell proliferation and is approved for treatment of advanced CTCL (stages IIB-IVB) in adult patients who have failed at least 1 prior systemic therapy.	Bexarotene	0-10	TSPY like 2	Homo sapiens	128-132
27543197-0	2017	Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.	Bexarotene	57-67	retinoid X receptor alpha	Homo sapiens	29-48
27543197-1	2017	Safety, tolerability, pharmacokinetics and efficacy of bexarotene, a novel retinoid X receptor (RXR)-selective retinoid, were evaluated in Japanese patients with stage IIB-IVB and relapsed/refractory stage IB-IIA cutaneous T-cell lymphomas (CTCL).	Bexarotene	55-65	retinoid X receptor alpha	Homo sapiens	75-94
28641286-13	2017	CONCLUSIONS: Bexarotene sensitizes blood platelets for thrombin and/or CRP induced activation and apoptosis.	Bexarotene	13-23	coagulation factor II	Mus musculus	55-63
28641286-13	2017	CONCLUSIONS: Bexarotene sensitizes blood platelets for thrombin and/or CRP induced activation and apoptosis.	Bexarotene	13-23	C-reactive protein, pentraxin-related	Mus musculus	71-74
27320328-8	2017	However, the mechanism of action of bexarotene and similar rexinoids remains controversial, particularly in the context of human APOE.	Bexarotene	36-46	apolipoprotein E	Homo sapiens	129-133
27592633-0	2016	Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).	Bexarotene	199-209	retinoid X receptor alpha	Homo sapiens	60-79
27592633-0	2016	Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).	Bexarotene	199-209	retinoid X receptor alpha	Homo sapiens	81-84
28641286-7	2017	The present study explored whether treatment of platelets with bexarotene modifies platelet activation and apoptosis following exposure to thrombin or CRP.	Bexarotene	63-73	coagulation factor II	Mus musculus	139-147
28641286-7	2017	The present study explored whether treatment of platelets with bexarotene modifies platelet activation and apoptosis following exposure to thrombin or CRP.	Bexarotene	63-73	C-reactive protein, pentraxin-related	Mus musculus	151-154
27842487-7	2017	Administration of bexarotene facilitates intracellular Abeta clearance via RXR regulated apolipoprotein E (ApoE) production.	Bexarotene	18-28	amyloid beta (A4) precursor protein	Mus musculus	55-60
27842487-7	2017	Administration of bexarotene facilitates intracellular Abeta clearance via RXR regulated apolipoprotein E (ApoE) production.	Bexarotene	18-28	apolipoprotein E	Mus musculus	89-105
27842487-7	2017	Administration of bexarotene facilitates intracellular Abeta clearance via RXR regulated apolipoprotein E (ApoE) production.	Bexarotene	18-28	apolipoprotein E	Mus musculus	107-111
27842487-8	2017	OBJECTIVE: To the best of our knowledge, this is the first structural attempt to find binding interactions of the drug bexarotene with monomeric Abeta peptide.	Bexarotene	119-129	amyloid beta (A4) precursor protein	Mus musculus	145-150
27842487-10	2017	RESULTS: We found in our study the basic amino acids His13 and Lys 16 of Abeta peptide to be crucial for the interaction with bexarotene.	Bexarotene	126-136	amyloid beta (A4) precursor protein	Mus musculus	73-78
27842487-11	2017	CONCLUSION: We speculate that direct binding of bexarotene to free Abeta peptide may lessen the concentration of free Abeta peptides in the brain and hamper the propensity of the peptide"s clumping and aggregating behavior.	Bexarotene	48-58	amyloid beta (A4) precursor protein	Mus musculus	67-72
27842487-11	2017	CONCLUSION: We speculate that direct binding of bexarotene to free Abeta peptide may lessen the concentration of free Abeta peptides in the brain and hamper the propensity of the peptide"s clumping and aggregating behavior.	Bexarotene	48-58	amyloid beta (A4) precursor protein	Mus musculus	118-123
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	retinoid X receptor alpha	Homo sapiens	115-134
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	retinoid X receptor alpha	Homo sapiens	136-139
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	ATP binding cassette subfamily A member 1	Homo sapiens	172-177
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	apolipoprotein E	Homo sapiens	250-255
27567858-2	2016	Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Abeta42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits.	Bexarotene	149-159	apolipoprotein E	Homo sapiens	250-255
26569440-6	2016	In the bexarotene group an increase in mean plasma osteocalcin level and mean plasma TRACP5b level was detected.	Bexarotene	7-17	bone gamma-carboxyglutamate protein	Rattus norvegicus	51-62
29067298-0	2016	A randomized controlled study to evaluate the effect of bexarotene on amyloid-beta and apolipoprotein E metabolism in healthy subjects.	Bexarotene	56-66	apolipoprotein E	Homo sapiens	87-103
29067298-1	2016	INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Abeta metabolism in normal healthy individuals with the APOE epsilon3/epsilon3 genotype.	Bexarotene	84-94	apolipoprotein E	Homo sapiens	146-162
29067298-1	2016	INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Abeta metabolism in normal healthy individuals with the APOE epsilon3/epsilon3 genotype.	Bexarotene	84-94	apolipoprotein E	Homo sapiens	164-168
29067298-1	2016	INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Abeta metabolism in normal healthy individuals with the APOE epsilon3/epsilon3 genotype.	Bexarotene	84-94	apolipoprotein E	Homo sapiens	244-248
29067298-1	2016	INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Abeta metabolism in normal healthy individuals with the APOE epsilon3/epsilon3 genotype.	Bexarotene	96-105	apolipoprotein E	Homo sapiens	146-162
29067298-1	2016	INTRODUCTION: We conducted a phase Ib proof of mechanism trial to determine whether bexarotene (Targretin) increases central nervous system (CNS) apolipoprotein E (apoE) levels and alters Abeta metabolism in normal healthy individuals with the APOE epsilon3/epsilon3 genotype.	Bexarotene	96-105	apolipoprotein E	Homo sapiens	164-168
29067298-2	2016	METHODS: We used stable isotope labeling kinetics (SILK-ApoE and SILK-Abeta) to measure the effect of bexarotene on the turnover rate of apoE and Abeta peptides and stable isotope spike absolute quantitation (SISAQ) to quantitate their concentrations in the cerebrospinal fluid (CSF).	Bexarotene	102-112	apolipoprotein E	Homo sapiens	137-141
29067298-6	2016	Bexarotene increased CSF apoE by 25% but had no effect on metabolism of Abeta peptides.	Bexarotene	0-10	apolipoprotein E	Homo sapiens	25-29
24732904-1	2016	Bexarotene, a synthetic retinoid licensed for the treatment of refractory cutaneous T-cell lymphoma (CTCL), has been used clinically in Poland since 2007 in 21 patients.	Bexarotene	0-10	TSPY like 2	Homo sapiens	101-105
24732904-11	2016	Based on the results of our analysis, bexarotene is a valuable tool in the treatment of refractory early-stage CTCL.	Bexarotene	38-48	TSPY like 2	Homo sapiens	111-115
27624652-4	2016	Following thromboembolic stroke bexarotene enhanced autophagy in the ischemic brain concomitantly with a reduction in lesion volume and amelioration of behavioral deficits in aged transgenic mice expressing the human P301L-Tau mutation.	Bexarotene	32-42	microtubule associated protein tau	Homo sapiens	223-226
27624652-5	2016	In in vitro studies bexarotene increased the expression of autophagy markers and reduced autophagic flux in neuronal cells expressing P301L-Tau.	Bexarotene	20-30	microtubule associated protein tau	Homo sapiens	140-143
27624652-6	2016	Bexarotene also restored mitochondrial respiration deficits in P301L-Tau neurons.	Bexarotene	0-10	microtubule associated protein tau	Homo sapiens	69-72
27297672-7	2016	Treatment of APOE4 mice with bexarotene for 7 days increased apoE4 protein levels but was not sufficient to reduce TBI-induced Abeta40 Thus, rapid clearance of TBI-induced Abeta40 occurs in mice but these pathways are impaired in APOE4 carriers.	Bexarotene	29-39	apolipoprotein E	Homo sapiens	13-18
27297672-7	2016	Treatment of APOE4 mice with bexarotene for 7 days increased apoE4 protein levels but was not sufficient to reduce TBI-induced Abeta40 Thus, rapid clearance of TBI-induced Abeta40 occurs in mice but these pathways are impaired in APOE4 carriers.	Bexarotene	29-39	apolipoprotein E	Homo sapiens	61-66
27297672-7	2016	Treatment of APOE4 mice with bexarotene for 7 days increased apoE4 protein levels but was not sufficient to reduce TBI-induced Abeta40 Thus, rapid clearance of TBI-induced Abeta40 occurs in mice but these pathways are impaired in APOE4 carriers.	Bexarotene	29-39	apolipoprotein E	Homo sapiens	230-235
26957434-4	2016	Bexarotene treatment reduced nestin expression, while significantly increasing glial fibrillary acidic protein (GFAP) expression.	Bexarotene	0-10	glial fibrillary acidic protein	Mus musculus	79-110
26957434-4	2016	Bexarotene treatment reduced nestin expression, while significantly increasing glial fibrillary acidic protein (GFAP) expression.	Bexarotene	0-10	glial fibrillary acidic protein	Mus musculus	112-116
26957434-8	2016	However, transglutaminase 2 (TG2) induction, an adverse effect of ATRA, was much weaker in bexarotene treated primary GBM cells.	Bexarotene	91-101	transglutaminase 2, C polypeptide	Mus musculus	9-27
26957434-8	2016	However, transglutaminase 2 (TG2) induction, an adverse effect of ATRA, was much weaker in bexarotene treated primary GBM cells.	Bexarotene	91-101	transglutaminase 2, C polypeptide	Mus musculus	29-32
26957434-9	2016	Consistently, the TG2 enzymatic activity was negligibly affected by bexarotene treatment.	Bexarotene	68-78	transglutaminase 2, C polypeptide	Mus musculus	18-21
27051978-1	2016	Bexarotene, a selective agonist for Retinoid X receptors (RXR) improves cognitive deficits and amyloid-beta (Abeta) clearance in mice.	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	109-114
27051978-2	2016	Here we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on APOE isoform and Abeta deposition.	Bexarotene	33-43	apolipoprotein E	Mus musculus	89-93
27051978-2	2016	Here we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on APOE isoform and Abeta deposition.	Bexarotene	33-43	amyloid beta (A4) precursor protein	Mus musculus	106-111
26688581-0	2016	Rescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1.	Bexarotene	32-42	low density lipoprotein receptor-related protein 1	Mus musculus	92-96
26811014-4	2016	Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat.	Bexarotene	102-112	TSPY like 2	Homo sapiens	68-72
26688581-2	2016	Bexarotene, a retinoid X receptor (RXR) agonist, has been reported to have potential beneficial effects on cognition by increasing brain apoE levels and lipidation.	Bexarotene	0-10	apolipoprotein E	Mus musculus	137-141
26688581-4	2016	Upon bexarotene treatment, levels of brain apoE and ATP-binding cassette sub-family A member 1 (ABCA1) were significantly increased in both mice.	Bexarotene	5-15	apolipoprotein E	Mus musculus	43-47
26688581-4	2016	Upon bexarotene treatment, levels of brain apoE and ATP-binding cassette sub-family A member 1 (ABCA1) were significantly increased in both mice.	Bexarotene	5-15	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	52-94
26688581-4	2016	Upon bexarotene treatment, levels of brain apoE and ATP-binding cassette sub-family A member 1 (ABCA1) were significantly increased in both mice.	Bexarotene	5-15	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	96-101
26688581-5	2016	While levels of PSD95, glutamate receptor 1 (GluR1), and N-methyl-d-aspartate receptor NR1 subunit (NR1), which are key postsynaptic proteins that regulate synaptic plasticity, were decreased with aging, they were restored by bexarotene treatment in the brains of control but not nLrp1(-/-) mice.	Bexarotene	226-236	discs large MAGUK scaffold protein 4	Mus musculus	16-21
26688581-5	2016	While levels of PSD95, glutamate receptor 1 (GluR1), and N-methyl-d-aspartate receptor NR1 subunit (NR1), which are key postsynaptic proteins that regulate synaptic plasticity, were decreased with aging, they were restored by bexarotene treatment in the brains of control but not nLrp1(-/-) mice.	Bexarotene	226-236	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	57-103
26688581-6	2016	These results indicate that the beneficial effects of bexarotene on synaptic integrity depend on the presence of neuronal LRP1.	Bexarotene	54-64	low density lipoprotein receptor-related protein 1	Mus musculus	122-126
26688581-8	2016	Taken together, our results demonstrate that apoE-targeted treatment through the RXR pathway has a potential beneficial effect on synapses during aging; however, the therapeutic application of bexarotene requires extreme caution due to its toxic side effects.	Bexarotene	193-203	apolipoprotein E	Mus musculus	45-49
26376806-7	2016	Studying the effect of the nuclear retinoid X receptor agonist, bexarotene, on NEP and IDE expression, we have found that both enzymes can be up-regulated by this compound but this mechanism is not APP-isoform specific and does not involve AICD but, on the contrary, affects HDAC1 occupancy on the NEP gene promoter.	Bexarotene	64-74	membrane metalloendopeptidase	Homo sapiens	79-82
26175148-5	2016	We have previously shown that bexarotene reduces Abeta levels in AD mouse models and we have hypothesized that this effect requires ABCA1-mediated lipidation of ApoE.	Bexarotene	30-40	apolipoprotein E	Mus musculus	161-165
26175148-8	2016	Bexarotene reduced levels of soluble Abeta 1-40 and 1-42 in the hippocampus of ABCA1 WT but not ABCA1 KO APP/PS1 mice.	Bexarotene	0-10	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	79-84
26175148-13	2016	Importantly, bexarotene ameliorated deficits in novel object recognition in ABCA1 WT but not ABCA1 KO APP/PS1 mice.	Bexarotene	13-23	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	76-81
26175148-14	2016	These data indicate that ABCA1-induced lipidation of ApoE is necessary for the ability of bexarotene to clear hippocampal soluble Abeta and ameliorate cognitive deficits.	Bexarotene	90-100	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	25-30
26175148-14	2016	These data indicate that ABCA1-induced lipidation of ApoE is necessary for the ability of bexarotene to clear hippocampal soluble Abeta and ameliorate cognitive deficits.	Bexarotene	90-100	apolipoprotein E	Mus musculus	53-57
26175148-14	2016	These data indicate that ABCA1-induced lipidation of ApoE is necessary for the ability of bexarotene to clear hippocampal soluble Abeta and ameliorate cognitive deficits.	Bexarotene	90-100	amyloid beta (A4) precursor protein	Mus musculus	130-135
26175148-0	2016	ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.	Bexarotene	23-33	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	0-5
26175148-0	2016	ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.	Bexarotene	23-33	presenilin 1	Mus musculus	105-108
26175148-4	2016	ApoE and ABCA1 are induced by the action of the RXR agonist, bexarotene.	Bexarotene	61-71	apolipoprotein E	Mus musculus	0-4
26175148-4	2016	ApoE and ABCA1 are induced by the action of the RXR agonist, bexarotene.	Bexarotene	61-71	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	9-14
26175148-5	2016	We have previously shown that bexarotene reduces Abeta levels in AD mouse models and we have hypothesized that this effect requires ABCA1-mediated lipidation of ApoE.	Bexarotene	30-40	amyloid beta (A4) precursor protein	Mus musculus	49-54
26175148-5	2016	We have previously shown that bexarotene reduces Abeta levels in AD mouse models and we have hypothesized that this effect requires ABCA1-mediated lipidation of ApoE.	Bexarotene	30-40	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	132-137
26376806-7	2016	Studying the effect of the nuclear retinoid X receptor agonist, bexarotene, on NEP and IDE expression, we have found that both enzymes can be up-regulated by this compound but this mechanism is not APP-isoform specific and does not involve AICD but, on the contrary, affects HDAC1 occupancy on the NEP gene promoter.	Bexarotene	64-74	insulin degrading enzyme	Homo sapiens	87-90
26376806-7	2016	Studying the effect of the nuclear retinoid X receptor agonist, bexarotene, on NEP and IDE expression, we have found that both enzymes can be up-regulated by this compound but this mechanism is not APP-isoform specific and does not involve AICD but, on the contrary, affects HDAC1 occupancy on the NEP gene promoter.	Bexarotene	64-74	histone deacetylase 1	Homo sapiens	275-280
26376806-7	2016	Studying the effect of the nuclear retinoid X receptor agonist, bexarotene, on NEP and IDE expression, we have found that both enzymes can be up-regulated by this compound but this mechanism is not APP-isoform specific and does not involve AICD but, on the contrary, affects HDAC1 occupancy on the NEP gene promoter.	Bexarotene	64-74	membrane metalloendopeptidase	Homo sapiens	298-301
26822146-0	2016	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer"s disease.	Bexarotene	60-70	xin actin binding repeat containing 1	Homo sapiens	71-74
26668312-4	2016	Whereas bexarotene regulates fundamental biological processes through retinoid X receptor (RXR)-mediated gene expression, molecular pathways underlying its positive effects on myogenesis remain unclear.	Bexarotene	8-18	retinoid X receptor alpha	Homo sapiens	70-89
26668312-4	2016	Whereas bexarotene regulates fundamental biological processes through retinoid X receptor (RXR)-mediated gene expression, molecular pathways underlying its positive effects on myogenesis remain unclear.	Bexarotene	8-18	retinoid X receptor alpha	Homo sapiens	91-94
26668312-6	2016	We show that bexarotene promotes myoblast differentiation and fusion through the activation of RXR and the regulation of Akt/PKB isoform-specific expression.	Bexarotene	13-23	retinoid X receptor alpha	Homo sapiens	95-98
26668312-6	2016	We show that bexarotene promotes myoblast differentiation and fusion through the activation of RXR and the regulation of Akt/PKB isoform-specific expression.	Bexarotene	13-23	AKT serine/threonine kinase 1	Homo sapiens	121-128
26352085-1	2016	BACKGROUND: Studies have suggested that triglyceride to HDL-cholesterol ratio (TRG/HDL) is a surrogate marker of insulin resistance (IR), but information regarding its use in pediatric patients is limited.	Bexarotene	79-82	insulin	Homo sapiens	113-120
26822146-1	2016	BACKGROUND: We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on brain amyloid measured by amyloid imaging in patients with Alzheimer"s disease (AD) in a proof-of-concept trial.	Bexarotene	72-82	retinoid X receptor alpha	Homo sapiens	59-62
26822146-14	2016	The data suggest that bexarotene reduced brain amyloid and increased serum Abeta1-42 in ApoE4 noncarriers.	Bexarotene	22-32	apolipoprotein E	Homo sapiens	88-93
26025659-1	2016	Bexarotene has been reported to reduce brain amyloid-beta (Abeta) levels and to improve cognitive function in transgenic mouse models of Alzheimer"s disease (AD).	Bexarotene	0-10	amyloid beta (A4) precursor protein	Mus musculus	59-64
26332008-2	2016	Bexarotene gel is a topical retinoid used in the treatment of CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	62-66
26444777-2	2016	Targretin  is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux.	Bexarotene	0-9	retinoid X receptor alpha	Homo sapiens	16-35
26444777-2	2016	Targretin  is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux.	Bexarotene	0-9	retinoid X receptor alpha	Homo sapiens	37-40
26444777-3	2016	After 6 months of treatment with Targretin  300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% .	Bexarotene	33-42	microtubule associated protein tau	Homo sapiens	93-96
27978526-1	2016	BACKGROUND/AIMS: The retinoid X receptor agonist bexarotene is utilized for the treatment of cutaneous T-cell lymphoma and is effective in several further malignancies.	Bexarotene	49-59	retinoid X receptor alpha	Homo sapiens	21-40
27978526-9	2016	RESULTS: A 48 hours exposure of human erythrocytes to bexarotene (&gt;= 0.4 microg/ml) significantly increased the percentage of annexin-V-binding cells without significantly modifying forward scatter.	Bexarotene	54-64	annexin A5	Homo sapiens	129-138
27978526-12	2016	The effect of bexarotene on annexin-V-binding was significantly blunted by removal of extracellular Ca2+ and by addition of D4476 (10 microM), but not by addition of staurosporine (1 microM), SB203580 (2 microM), or zVAD (10 microM).	Bexarotene	14-24	annexin A5	Homo sapiens	28-37
26806040-0	2016	Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors.	Bexarotene	70-80	retinoid X receptor alpha	Homo sapiens	42-61
26806040-2	2016	As one of the novel synthetic analogs of retinoids, bexarotene selectively binds to and activates the retinoid X receptor (RXRs) subfamilies, exerting a prophylactic and therapeutic effect on a large series of tumors in vitro and in vivo covering cutaneous lesions, lung and breast cancers, nervous system diseases etc.	Bexarotene	52-62	retinoid X receptor alpha	Homo sapiens	102-121
26025659-4	2016	Rats were tested for the ability of bexarotene to prevent changes induced by an Abeta challenge in the form intracerebroventricular (i.c.v) administration of 7PA2 conditioned medium (7PA2 CM) which contains high levels of Abeta species.	Bexarotene	36-46	amyloid beta precursor protein	Rattus norvegicus	80-85
25328014-11	2015	Moreover, knocking down the expression of Src effectively reduced the sensitivity of SK-BR-3 cells to the inhibitory effects of UAB30 and Targretin on invasiveness.	Bexarotene	138-147	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	42-45
25328014-12	2015	Taken together, our results demonstrate that UAB30 and Targretin each inhibit invasion and migration by targeting Src in human breast cancer cells.	Bexarotene	55-64	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	114-117
25328014-0	2015	Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.	Bexarotene	69-78	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	0-3
25328014-0	2015	Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.	Bexarotene	69-78	retinoid X receptor alpha	Homo sapiens	39-42
26546745-0	2015	Activation of RXR/PPARgamma underlies neuroprotection by bexarotene in ischemic stroke.	Bexarotene	57-67	peroxisome proliferator activated receptor gamma	Mus musculus	18-27
25328014-1	2015	9-cis-UAB30 (UAB30) and Targretin are well-known retinoid X receptor (RXR) agonists.	Bexarotene	24-33	retinoid X receptor alpha	Homo sapiens	49-68
25328014-1	2015	9-cis-UAB30 (UAB30) and Targretin are well-known retinoid X receptor (RXR) agonists.	Bexarotene	24-33	retinoid X receptor alpha	Homo sapiens	70-73
25328014-3	2015	However, whether the anti-mammary cancer effects of UAB30 or Targretin originate from the activation of RXR is unclear.	Bexarotene	61-70	retinoid X receptor alpha	Homo sapiens	104-107
25328014-4	2015	In the present study, we hypothesized that UAB30 and Targretin not only affect RXR, but likely influence one or more off-target proteins.	Bexarotene	53-62	retinoid X receptor alpha	Homo sapiens	79-82
25328014-6	2015	In vitro kinase assay data revealed that UAB30 or Targretin interacted with Src and attenuated its kinase activity.	Bexarotene	50-59	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	76-79
25328014-9	2015	We show that activity and expression of MMP-9 were decreased by UAB30 or Targretin.	Bexarotene	73-82	matrix metallopeptidase 9	Homo sapiens	40-45
26546745-6	2015	The amelioration of histological outcome, as well as the ability of bexarotene to revert middle cerebral artery occlusion (MCAo)-induced spleen atrophy, was antagonised by BR1211, a pan-RXR antagonist, or by the selective peroxisome proliferator-activated receptor (PPAR)gamma antagonist bisphenol A diglycidyl ether (BADGE), highlighting the involvement of the RXR/PPARgamma heterodimer in the beneficial effects exerted by the drug.	Bexarotene	68-78	peroxisome proliferator activated receptor gamma	Mus musculus	266-276
26546745-6	2015	The amelioration of histological outcome, as well as the ability of bexarotene to revert middle cerebral artery occlusion (MCAo)-induced spleen atrophy, was antagonised by BR1211, a pan-RXR antagonist, or by the selective peroxisome proliferator-activated receptor (PPAR)gamma antagonist bisphenol A diglycidyl ether (BADGE), highlighting the involvement of the RXR/PPARgamma heterodimer in the beneficial effects exerted by the drug.	Bexarotene	68-78	peroxisome proliferator activated receptor gamma	Mus musculus	366-375
26490873-6	2015	Although our data demonstrated that bexarotene was ineffective in neuroprotection in rats in vivo, the results revealed that bexarotene has the capacity to coregulate subsets of Nurr1 target genes including the receptor tyrosine kinase subunit Ret.	Bexarotene	125-135	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	178-183
26687705-1	2015	CONTEXT: Bexarotene is a retinoid X receptor agonist, which is currently used for the treatment of cutaneous T-cell lymphoma (CTCL).	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	25-44
26687705-1	2015	CONTEXT: Bexarotene is a retinoid X receptor agonist, which is currently used for the treatment of cutaneous T-cell lymphoma (CTCL).	Bexarotene	9-19	TSPY like 2	Homo sapiens	126-130
26687705-7	2015	Bexarotene was discontinued due to poor response of CTCL, 3 months after which her HDL-C levels returned to baseline of 80 to 90 mg/dL (2.07-2.33 mmol/L).	Bexarotene	0-10	TSPY like 2	Homo sapiens	52-56
26490873-6	2015	Although our data demonstrated that bexarotene was ineffective in neuroprotection in rats in vivo, the results revealed that bexarotene has the capacity to coregulate subsets of Nurr1 target genes including the receptor tyrosine kinase subunit Ret.	Bexarotene	125-135	ret proto-oncogene	Rattus norvegicus	244-247
26490873-7	2015	Moreover, bexarotene was able to restore dysfunctional Ret-dependent neurotrophic signaling in alpha-synuclein-overexpressing mouse DA neurons.	Bexarotene	10-20	ret proto-oncogene	Mus musculus	55-58
26490873-7	2015	Moreover, bexarotene was able to restore dysfunctional Ret-dependent neurotrophic signaling in alpha-synuclein-overexpressing mouse DA neurons.	Bexarotene	10-20	synuclein, alpha	Mus musculus	95-110
26490873-11	2015	Moreover, given the protective role of Nurr1, this study also investigated how Nurr1 could be pharmacologically targeted via bexarotene, a ligand of Nurr1"s heterodimerization partner retinoid X receptor (RXR).	Bexarotene	125-135	nuclear receptor subfamily 4, group A, member 2	Mus musculus	79-84
26490873-11	2015	Moreover, given the protective role of Nurr1, this study also investigated how Nurr1 could be pharmacologically targeted via bexarotene, a ligand of Nurr1"s heterodimerization partner retinoid X receptor (RXR).	Bexarotene	125-135	nuclear receptor subfamily 4, group A, member 2	Mus musculus	79-84
25602514-0	2015	Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions.	Bexarotene	47-57	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	65-79
26071899-0	2015	RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.	Bexarotene	77-87	triggering receptor expressed on myeloid cells 2	Mus musculus	56-61
26071899-1	2015	We have recently demonstrated that short term bexarotene treatment of APP/PS1 mice significantly improves their cognitive performance.	Bexarotene	46-56	presenilin 1	Mus musculus	74-77
26071899-8	2015	The results of our study demonstrate that in AD model mice expressing human APP, gene networks up-regulated in response to RXR activation by the specific, small molecule, ligand bexarotene may influence diverse regulatory pathways that are considered critical for cognitive performance, inflammatory response and Abeta clearance, and may provide an explanation of the bexarotene therapeutic effect at the molecular level.	Bexarotene	178-188	retinoid X receptor alpha	Homo sapiens	123-126
26071899-8	2015	The results of our study demonstrate that in AD model mice expressing human APP, gene networks up-regulated in response to RXR activation by the specific, small molecule, ligand bexarotene may influence diverse regulatory pathways that are considered critical for cognitive performance, inflammatory response and Abeta clearance, and may provide an explanation of the bexarotene therapeutic effect at the molecular level.	Bexarotene	368-378	retinoid X receptor alpha	Homo sapiens	123-126
26012882-2	2015	All-trans-retinoic acid, the natural ligand for RARs, is used therapeutically for the treatment of acute promyelocytic leukemia (APL), whereas the synthetic rexinoid bexarotene (a representative member of the aromatic retinoids or arotinoids) is approved for the treatment of cutaneous T-cell lymphoma (CTCL).	Bexarotene	166-176	TSPY like 2	Homo sapiens	303-307
25826424-6	2015	Here we provide evidence that retinoids, including Bexarotene, selectively induce CTCL lineages to increase integrin beta7 expression and function prior to growth arrest and apoptosis.	Bexarotene	51-61	TSPY like 2	Homo sapiens	82-86
25826424-6	2015	Here we provide evidence that retinoids, including Bexarotene, selectively induce CTCL lineages to increase integrin beta7 expression and function prior to growth arrest and apoptosis.	Bexarotene	51-61	integrin subunit beta 7	Homo sapiens	108-122
26085639-6	2015	We report that the omega-3 fatty acid docosahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Abeta, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD.	Bexarotene	86-96	nuclear receptor subfamily 1, group H, member 3	Mus musculus	107-110
26085639-6	2015	We report that the omega-3 fatty acid docosahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Abeta, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD.	Bexarotene	86-96	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	141-146
26085639-6	2015	We report that the omega-3 fatty acid docosahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of Abca1 and ApoE, reduces soluble forms of Abeta, and abrogates release of pro-inflammatory cytokines and mediators both in vitro and in a mouse model of AD.	Bexarotene	86-96	apolipoprotein E	Mus musculus	151-155
25630951-0	2015	Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-/-) mice and angiogenesis.	Bexarotene	24-34	apolipoprotein E	Mus musculus	112-116
25833198-0	2015	Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.	Bexarotene	18-28	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	68-100
26190974-0	2015	Neuroprotective Effect of Bexarotene in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.	Bexarotene	26-36	superoxide dismutase 1, soluble	Mus musculus	44-48
26190974-4	2015	In this study, we analyze the potential therapeutic effect of Bxt in the SOD1(G93A) mouse model of ALS.	Bexarotene	62-65	superoxide dismutase 1, soluble	Mus musculus	73-77
26190974-9	2015	Bxt treatment contributed to preserve the MN homeostasis in the SOD1(G93A) mice.	Bexarotene	0-3	superoxide dismutase 1, soluble	Mus musculus	64-68
26190974-13	2015	Overall, these neuroprotective effects suggest that treatment with Bxt could be useful in ALS, particularly in those cases related to SOD1 mutations.	Bexarotene	67-70	superoxide dismutase 1, soluble	Mus musculus	134-138
25602514-0	2015	Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions.	Bexarotene	47-57	peroxisome proliferator activated receptor alpha	Mus musculus	187-196
25602514-0	2015	Combined sub-optimal doses of rosuvastatin and bexarotene impair angiotensin II-induced arterial mononuclear cell adhesion through inhibition of Nox5 signaling pathways and increased RXR/PPARalpha and RXR/PPARgamma interactions.	Bexarotene	47-57	peroxisome proliferator activated receptor gamma	Mus musculus	205-214
25602514-5	2015	Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 muM), which did not influence Ang-II-induced MC recruitment when either stimulus was studied alone, significantly reduced this response.	Bexarotene	44-47	latexin	Homo sapiens	53-56
25602514-5	2015	Surprisingly, a combination of Rosu (10 nM)+Bex (0.3 muM), which did not influence Ang-II-induced MC recruitment when either stimulus was studied alone, significantly reduced this response.	Bexarotene	44-47	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	83-89
25602514-8	2015	In vivo, combined but not single administration of Rosu (1.25 mg/kg/day) and Bex (10 mg/kg/day) significantly diminished Ang-II-induced arteriolar leukocyte adhesion in the cremasteric microcirculation of C57BL/6 mice and atherosclerotic lesion formation in apoE(-/-) mice subjected to an atherogenic diet.	Bexarotene	77-80	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	121-127
26451138-0	2015	Identification of Bexarotene as a PPARgamma Antagonist with HDX.	Bexarotene	18-28	peroxisome proliferator activated receptor gamma	Homo sapiens	34-43
25844636-2	2015	The retinoid X receptor agonist bexarotene suppresses MMP-9 expression in endothelial cells and displays neuroprotective effects.	Bexarotene	32-42	matrix metallopeptidase 9	Rattus norvegicus	54-59
25844636-9	2015	RESULTS: After 24 h, 48 h, and 72 h post-I/R, several effects were observed with bexarotene administration: (i) brain water content and BBB permeability were significantly reduced; (ii) MMP-9 mRNA and protein expression as well as activity were significantly decreased; (iii) claudin-5 and occludin expression were significantly increased; and (iv) apoE expression was significantly increased.	Bexarotene	81-91	matrix metallopeptidase 9	Rattus norvegicus	186-191
25844636-9	2015	RESULTS: After 24 h, 48 h, and 72 h post-I/R, several effects were observed with bexarotene administration: (i) brain water content and BBB permeability were significantly reduced; (ii) MMP-9 mRNA and protein expression as well as activity were significantly decreased; (iii) claudin-5 and occludin expression were significantly increased; and (iv) apoE expression was significantly increased.	Bexarotene	81-91	claudin 5	Rattus norvegicus	276-285
25844636-9	2015	RESULTS: After 24 h, 48 h, and 72 h post-I/R, several effects were observed with bexarotene administration: (i) brain water content and BBB permeability were significantly reduced; (ii) MMP-9 mRNA and protein expression as well as activity were significantly decreased; (iii) claudin-5 and occludin expression were significantly increased; and (iv) apoE expression was significantly increased.	Bexarotene	81-91	occludin	Rattus norvegicus	290-298
25844636-9	2015	RESULTS: After 24 h, 48 h, and 72 h post-I/R, several effects were observed with bexarotene administration: (i) brain water content and BBB permeability were significantly reduced; (ii) MMP-9 mRNA and protein expression as well as activity were significantly decreased; (iii) claudin-5 and occludin expression were significantly increased; and (iv) apoE expression was significantly increased.	Bexarotene	81-91	apolipoprotein E	Rattus norvegicus	349-353
25844636-11	2015	This effect may be due in part to bexarotene"s upregulation of apoE expression, which has been previously shown to reduce BBB permeability through suppressing MMP-9-mediated degradation of the tight junction proteins claudin-5 and occludin.	Bexarotene	34-44	apolipoprotein E	Rattus norvegicus	63-67
25844636-11	2015	This effect may be due in part to bexarotene"s upregulation of apoE expression, which has been previously shown to reduce BBB permeability through suppressing MMP-9-mediated degradation of the tight junction proteins claudin-5 and occludin.	Bexarotene	34-44	matrix metallopeptidase 9	Rattus norvegicus	159-164
25844636-11	2015	This effect may be due in part to bexarotene"s upregulation of apoE expression, which has been previously shown to reduce BBB permeability through suppressing MMP-9-mediated degradation of the tight junction proteins claudin-5 and occludin.	Bexarotene	34-44	claudin 5	Rattus norvegicus	217-226
25844636-11	2015	This effect may be due in part to bexarotene"s upregulation of apoE expression, which has been previously shown to reduce BBB permeability through suppressing MMP-9-mediated degradation of the tight junction proteins claudin-5 and occludin.	Bexarotene	34-44	occludin	Rattus norvegicus	231-239
26402114-4	2015	In animal models of AD, the anticancer drug bexarotene (a retinoid X receptor agonist) has been found to restore cognitive functions and decrease the brain amyloid burden by regulating cholesterol homeostasis.	Bexarotene	44-54	retinoid X receptor alpha	Homo sapiens	58-77
26402114-8	2015	Our results demonstrated that bexarotene induces the expression of ABCA1 but not ApoE.	Bexarotene	30-40	ATP binding cassette subfamily A member 1	Homo sapiens	67-72
26402114-10	2015	Regarding the transport of Abeta peptides, bexarotene increases the expression of ABCB1, which in turn decreases Abeta apical-to-basolateral transport.	Bexarotene	43-53	ATP binding cassette subfamily B member 1	Homo sapiens	82-87
25434990-2	2015	Despite the fact that the RXR-based drug Targretin (bexarotene) is currently used for treating human cutaneous T-cell lymphoma and the fact that RXRalpha ligands (rexinoids) show beneficial effects in the treatment of cancer and diseases, the therapeutic potential of RXRalpha remains unexplored.	Bexarotene	41-50	retinoid X receptor alpha	Homo sapiens	26-29
25434990-2	2015	Despite the fact that the RXR-based drug Targretin (bexarotene) is currently used for treating human cutaneous T-cell lymphoma and the fact that RXRalpha ligands (rexinoids) show beneficial effects in the treatment of cancer and diseases, the therapeutic potential of RXRalpha remains unexplored.	Bexarotene	52-62	retinoid X receptor alpha	Homo sapiens	26-29
25777514-4	2015	Bexarotene (BEXA), an RXR agonist that increases ApoE expression and microglia phagocytosis has been proposed as a promising therapy for AD, resolving both the amyloid pathology and memory loss.	Bexarotene	0-10	apolipoprotein E	Mus musculus	49-53
25777514-4	2015	Bexarotene (BEXA), an RXR agonist that increases ApoE expression and microglia phagocytosis has been proposed as a promising therapy for AD, resolving both the amyloid pathology and memory loss.	Bexarotene	12-16	apolipoprotein E	Mus musculus	49-53
26451138-1	2015	The retinoid x receptors (RXRs) are the pharmacological target of Bexarotene, an antineoplastic agent indicated for the treatment of cutaneous T cell lymphoma (CTCL).	Bexarotene	66-76	TSPY like 2	Homo sapiens	160-164
26451138-3	2015	Here we have applied hydrogen/deuterium exchange (HDX) mass spectrometry to characterize the effects of Bexarotene on the conformational plasticity of the intact RXRalpha:PPARgamma heterodimer.	Bexarotene	104-114	retinoid X receptor alpha	Homo sapiens	162-170
26451138-3	2015	Here we have applied hydrogen/deuterium exchange (HDX) mass spectrometry to characterize the effects of Bexarotene on the conformational plasticity of the intact RXRalpha:PPARgamma heterodimer.	Bexarotene	104-114	peroxisome proliferator activated receptor gamma	Homo sapiens	171-180
26451138-4	2015	Interestingly, addition of Bexarotene to PPARgamma in the absence of RXRalpha induced protection from solvent exchange, suggesting direct receptor binding.	Bexarotene	27-37	peroxisome proliferator activated receptor gamma	Homo sapiens	41-50
26451138-6	2015	Furthermore, Bexarotene functioned as a PPARgamma antagonist able to alter rosiglitazone induced transactivation in a cell based promoter:reporter transactivation assay.	Bexarotene	13-23	peroxisome proliferator activated receptor gamma	Homo sapiens	40-49
32262006-0	2014	Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system.	Bexarotene	16-26	albumin	Homo sapiens	41-54
32262006-2	2014	This study exploited a folate-decorated delivery of bexarotene-loaded bovine serum albumin nanoparticles, which could solubilize the poorly water-soluble drug and overcome the nonspecific targeting disadvantage.	Bexarotene	52-62	albumin	Homo sapiens	77-90
32262006-3	2014	Bexarotene-loaded bovine serum albumin nanoparticles (BEX-BSANPs) were optimized by a desolvation technique, subsequently conjugated with folate by carbodiimide reaction.	Bexarotene	0-10	albumin	Homo sapiens	25-38
32262006-4	2014	The resultant folate-modified bexarotene-loaded bovine serum albumin nanoparticles (FA-BEX-BSANPs) showed a spherical shape, with a diameter of 195.3 +- 5.6 nm, a zeta potential of -33.64 +- 1.97 mV, and 71.28 +- 1.93 mug folate was coupled per mg BSA.	Bexarotene	30-40	albumin	Homo sapiens	55-68
24723466-2	2014	Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA.	Bexarotene	169-179	retinoid X receptor alpha	Mus musculus	72-76
25169989-10	2014	Bexarotene had a greater effect on calponin reduction, MCP-1 inhibition, and p38 MAP kinase inhibition than any individual agonist.	Bexarotene	0-10	C-C motif chemokine ligand 2	Rattus norvegicus	55-60
25169989-10	2014	Bexarotene had a greater effect on calponin reduction, MCP-1 inhibition, and p38 MAP kinase inhibition than any individual agonist.	Bexarotene	0-10	mitogen activated protein kinase 14	Rattus norvegicus	77-80
25169989-11	2014	PPARgamma knockout cells demonstrated blunted responses to bexarotene, indicating that PPARgamma is necessary for the effects of bexarotene.	Bexarotene	59-69	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
25169989-11	2014	PPARgamma knockout cells demonstrated blunted responses to bexarotene, indicating that PPARgamma is necessary for the effects of bexarotene.	Bexarotene	59-69	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	87-96
25169989-11	2014	PPARgamma knockout cells demonstrated blunted responses to bexarotene, indicating that PPARgamma is necessary for the effects of bexarotene.	Bexarotene	129-139	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-9
25169989-11	2014	PPARgamma knockout cells demonstrated blunted responses to bexarotene, indicating that PPARgamma is necessary for the effects of bexarotene.	Bexarotene	129-139	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	87-96
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	retinoid X receptor alpha	Homo sapiens	70-73
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	amyloid beta (A4) precursor protein	Mus musculus	128-133
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	apolipoprotein E	Mus musculus	218-234
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	apolipoprotein E	Mus musculus	236-240
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	256-261
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	ATP binding cassette subfamily G member 1	Mus musculus	262-267
25217640-1	2014	Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-beta (Abeta) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation.	Bexarotene	31-41	apolipoprotein E	Mus musculus	276-280
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	retinoid X receptor alpha	Homo sapiens	24-27
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	89-94
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	apolipoprotein E	Homo sapiens	96-101
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	apolipoprotein E	Homo sapiens	142-147
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	amyloid beta (A4) precursor protein	Mus musculus	148-153
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	amyloid beta (A4) precursor protein	Mus musculus	181-186
25217640-6	2014	In E4FAD-HP, short-term RXR agonist treatment (Bex or LG100268; 5.75-6 months) increased ABCA1, apoE4 lipoprotein-association/lipidation, and apoE4/Abeta complex, decreased soluble Abeta, and increased PSD95.	Bexarotene	47-50	discs large MAGUK scaffold protein 4	Mus musculus	202-207
25169989-6	2014	Compared with dimethylsulfoxide, bexarotene blocked angiotensin II-induced SM contractile gene induction (calponin and smooth muscle-alpha-actin) and protein synthesis ([(3)H]leucine incorporation).	Bexarotene	33-43	angiotensinogen	Rattus norvegicus	52-66
25169989-6	2014	Compared with dimethylsulfoxide, bexarotene blocked angiotensin II-induced SM contractile gene induction (calponin and smooth muscle-alpha-actin) and protein synthesis ([(3)H]leucine incorporation).	Bexarotene	33-43	actin alpha 2, smooth muscle	Rattus norvegicus	119-144
25169989-7	2014	Bexarotene also decreased angiotensin II-mediated inflammation, as measured by decreased expression of monocyte chemoattractant protein-1 (MCP-1).	Bexarotene	0-10	angiotensinogen	Rattus norvegicus	26-40
25169989-7	2014	Bexarotene also decreased angiotensin II-mediated inflammation, as measured by decreased expression of monocyte chemoattractant protein-1 (MCP-1).	Bexarotene	0-10	C-C motif chemokine ligand 2	Rattus norvegicus	103-137
25169989-7	2014	Bexarotene also decreased angiotensin II-mediated inflammation, as measured by decreased expression of monocyte chemoattractant protein-1 (MCP-1).	Bexarotene	0-10	C-C motif chemokine ligand 2	Rattus norvegicus	139-144
25169989-8	2014	Activation of p38 mitogen-activated protein (MAP) kinase but not extracellular signal-related kinase (ERK) or protein kinase B (Akt) was also blunted by bexarotene.	Bexarotene	153-163	mitogen activated protein kinase 14	Rattus norvegicus	14-17
25172665-3	2014	Here, we provide evidence that an RXRalpha-specific ligand, bexarotene, dose-dependently inhibits the mRNA expression of ARE-driven genes.	Bexarotene	60-70	retinoid X receptor alpha	Homo sapiens	34-42
25172665-4	2014	Knock-down of RXRalpha by siRNA abolished the inhibitory effect of bexarotene.	Bexarotene	67-77	retinoid X receptor alpha	Homo sapiens	14-22
25172665-5	2014	Conversely, the over-expression of RXRalpha enhanced the inhibition by bexarotene, indicating that the effect is mediated by RXRalpha.	Bexarotene	71-81	retinoid X receptor alpha	Homo sapiens	35-43
25172665-5	2014	Conversely, the over-expression of RXRalpha enhanced the inhibition by bexarotene, indicating that the effect is mediated by RXRalpha.	Bexarotene	71-81	retinoid X receptor alpha	Homo sapiens	125-133
25172665-6	2014	The inhibition by bexarotene was also found in the non-small-cell lung cancer cell line A549, which carries a dysfunctional somatic mutation of Kelch-like ECH-associated protein 1 (KEAP1), suggesting that KEAP1 is not involved.	Bexarotene	18-28	kelch like ECH associated protein 1	Homo sapiens	144-179
25172665-6	2014	The inhibition by bexarotene was also found in the non-small-cell lung cancer cell line A549, which carries a dysfunctional somatic mutation of Kelch-like ECH-associated protein 1 (KEAP1), suggesting that KEAP1 is not involved.	Bexarotene	18-28	kelch like ECH associated protein 1	Homo sapiens	181-186
25172665-6	2014	The inhibition by bexarotene was also found in the non-small-cell lung cancer cell line A549, which carries a dysfunctional somatic mutation of Kelch-like ECH-associated protein 1 (KEAP1), suggesting that KEAP1 is not involved.	Bexarotene	18-28	kelch like ECH associated protein 1	Homo sapiens	205-210
24664180-5	2014	Moreover, these authors demonstrated that bexarotene, a retinoid X receptor (RXR) agonist, exerts major effects on Abeta levels, mainly through increased apolipoprotein E (ApoE) expression.	Bexarotene	42-52	retinoid X receptor alpha	Homo sapiens	56-75
24664180-5	2014	Moreover, these authors demonstrated that bexarotene, a retinoid X receptor (RXR) agonist, exerts major effects on Abeta levels, mainly through increased apolipoprotein E (ApoE) expression.	Bexarotene	42-52	retinoid X receptor alpha	Homo sapiens	77-80
24664180-5	2014	Moreover, these authors demonstrated that bexarotene, a retinoid X receptor (RXR) agonist, exerts major effects on Abeta levels, mainly through increased apolipoprotein E (ApoE) expression.	Bexarotene	42-52	amyloid beta (A4) precursor protein	Mus musculus	115-120
24664180-5	2014	Moreover, these authors demonstrated that bexarotene, a retinoid X receptor (RXR) agonist, exerts major effects on Abeta levels, mainly through increased apolipoprotein E (ApoE) expression.	Bexarotene	42-52	apolipoprotein E	Homo sapiens	154-170
24664180-5	2014	Moreover, these authors demonstrated that bexarotene, a retinoid X receptor (RXR) agonist, exerts major effects on Abeta levels, mainly through increased apolipoprotein E (ApoE) expression.	Bexarotene	42-52	apolipoprotein E	Homo sapiens	172-176
24664180-7	2014	Most of these explanations have been solely based on the ability of bexarotene to reduce Abeta levels and not on the mechanisms that lead to such a reduction.	Bexarotene	68-78	amyloid beta (A4) precursor protein	Mus musculus	89-94
24767949-3	2014	We find that oral treatment with bexarotene over 1 week acutely reduced spike discharges in both models and seizures in the Kv1.1 null mouse model without major alterations in the background frequency of brain rhythms.	Bexarotene	33-43	potassium voltage-gated channel, shaker-related subfamily, member 1	Mus musculus	124-129
24603314-2	2014	This study aimed to examine the effects of RXRalpha agonist bexarotene on pathological left ventricular hypertrophy (LVH) in a spontaneously hypertensive rat (SHR) model and the underlying mechanism.	Bexarotene	60-70	retinoid X receptor alpha	Rattus norvegicus	43-51
24603314-10	2014	Immunoblot with heart tissue homogenates from SHRs revealed that bexarotene activated the LKB1/AMPK signaling pathway and inhibited p70S6K.	Bexarotene	65-75	serine/threonine kinase 11	Rattus norvegicus	90-94
24603314-10	2014	Immunoblot with heart tissue homogenates from SHRs revealed that bexarotene activated the LKB1/AMPK signaling pathway and inhibited p70S6K.	Bexarotene	65-75	protein kinase AMP-activated catalytic subunit alpha 2	Rattus norvegicus	95-99
24603314-10	2014	Immunoblot with heart tissue homogenates from SHRs revealed that bexarotene activated the LKB1/AMPK signaling pathway and inhibited p70S6K.	Bexarotene	65-75	ribosomal protein S6 kinase B1	Rattus norvegicus	132-138
24723466-2	2014	Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA.	Bexarotene	169-179	cathepsin G	Mus musculus	133-137
24723466-2	2014	Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA.	Bexarotene	169-179	promyelocytic leukemia	Mus musculus	138-141
24723466-2	2014	Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA.	Bexarotene	169-179	retinoic acid receptor, alpha	Mus musculus	142-146
24723466-2	2014	Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA.	Bexarotene	169-179	retinoid X receptor alpha	Mus musculus	194-198
24801499-6	2014	On the basis of the X-ray crystal structures of these new rexinoids and bexarotene (Targretin) bound to hRXRalpha-LBD, we reveal that each rexinoid, which induced hyperlipidemia, had methyl groups that interacted with helix 7 residues of the LBD.	Bexarotene	72-82	retinoid X receptor alpha	Homo sapiens	104-113
23968145-1	2014	BACKGROUND: Topical bexarotene 1% gel is currently FDA-approved for early stage (IA and IB) persistent or refractory cutaneous T-cell lymphoma (CTCL).	Bexarotene	20-30	TSPY like 2	Homo sapiens	144-148
25000142-8	2014	Bexarotene, an amphipathic drug currently considered as a potential candidate medication for the treatment of neurodegenerative diseases, competed with cholesterol for binding to Abeta and prevented oligomeric channel formation.	Bexarotene	0-10	amyloid beta precursor protein	Homo sapiens	179-184
23843199-9	2014	The drug bexarotene showed the highest G score (-13.32) with hRXRbeta.	Bexarotene	9-19	retinoid X receptor beta	Homo sapiens	61-69
24801499-6	2014	On the basis of the X-ray crystal structures of these new rexinoids and bexarotene (Targretin) bound to hRXRalpha-LBD, we reveal that each rexinoid, which induced hyperlipidemia, had methyl groups that interacted with helix 7 residues of the LBD.	Bexarotene	84-93	retinoid X receptor alpha	Homo sapiens	104-113
24599963-7	2014	These effects on modulating apoE are comparable with the effects recently reported for the RXR agonist bexarotene.	Bexarotene	103-113	apolipoprotein E	Mus musculus	28-32
24872469-0	2014	A CD30(-) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate.	Bexarotene	78-88	TNF receptor superfamily member 8	Homo sapiens	2-6
24872469-4	2014	Here, we report a 61-year-old man presenting with tumoral ulcer on the plantar area of the foot who was diagnosed cutaneous CD30(-) large cell transformed MF and treated with systemic methotraxate and bexarotene therapy.	Bexarotene	201-211	TNF receptor superfamily member 8	Homo sapiens	124-128
24849361-0	2014	Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.	Bexarotene	68-78	apolipoprotein E	Homo sapiens	12-17
24849361-4	2014	In the present study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apoE, ABCA1, and ABCG1 in young, naive apoE3- and apoE4-targeted replacement mice and assessed the extent to which this reverses the apoE4-driven pathological phenotype.	Bexarotene	69-79	apolipoprotein E	Mus musculus	110-114
24849361-4	2014	In the present study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apoE, ABCA1, and ABCG1 in young, naive apoE3- and apoE4-targeted replacement mice and assessed the extent to which this reverses the apoE4-driven pathological phenotype.	Bexarotene	69-79	ATP binding cassette subfamily G member 1	Mus musculus	127-132
24849361-5	2014	This investigation reveled that bexarotene increases the mRNA and protein levels of ABCA1 and ABCG1 in hippocampal neurons, but has no effect on the corresponding levels of apoE.	Bexarotene	32-42	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	84-89
24849361-5	2014	This investigation reveled that bexarotene increases the mRNA and protein levels of ABCA1 and ABCG1 in hippocampal neurons, but has no effect on the corresponding levels of apoE.	Bexarotene	32-42	ATP binding cassette subfamily G member 1	Mus musculus	94-99
24849361-7	2014	Furthermore, bexarotene reversed the apoE4-driven accumulation of Abeta42 and hyperphosphorylated tau in hippocampal neurons, as well as the apoE4-induced reduction in the levels of the presynaptic marker vesicular glutamatergic transporter 1 (VGluT1).	Bexarotene	13-23	apolipoprotein E	Homo sapiens	37-42
24849361-7	2014	Furthermore, bexarotene reversed the apoE4-driven accumulation of Abeta42 and hyperphosphorylated tau in hippocampal neurons, as well as the apoE4-induced reduction in the levels of the presynaptic marker vesicular glutamatergic transporter 1 (VGluT1).	Bexarotene	13-23	solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7	Mus musculus	244-250
24849361-8	2014	In conclusion, the results show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neuronal impairments in vivo and suggest that this is due to reversal of the lipidation deficiency of apoE4.	Bexarotene	82-92	apolipoprotein E	Homo sapiens	50-55
24849361-8	2014	In conclusion, the results show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neuronal impairments in vivo and suggest that this is due to reversal of the lipidation deficiency of apoE4.	Bexarotene	82-92	retinoid X receptor alpha	Homo sapiens	70-73
24849361-8	2014	In conclusion, the results show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neuronal impairments in vivo and suggest that this is due to reversal of the lipidation deficiency of apoE4.	Bexarotene	82-92	apolipoprotein E	Homo sapiens	106-111
24849361-8	2014	In conclusion, the results show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neuronal impairments in vivo and suggest that this is due to reversal of the lipidation deficiency of apoE4.	Bexarotene	82-92	apolipoprotein E	Homo sapiens	106-111
24599963-9	2014	Both bexarotene and 9-cis-RA promote the lipidation status of apoE, in which 9-cis-RA promotes a stronger effect and exhibits less cytotoxicity compared with bexarotene.	Bexarotene	158-168	apolipoprotein E	Mus musculus	62-66
24599963-10	2014	Importantly, we showed that oral administration of bexarotene and 9-cis-RA significantly increases apoE, ABCA1, and ABCG1 levels in mouse brains.	Bexarotene	51-61	apolipoprotein E	Mus musculus	99-103
24599963-10	2014	Importantly, we showed that oral administration of bexarotene and 9-cis-RA significantly increases apoE, ABCA1, and ABCG1 levels in mouse brains.	Bexarotene	51-61	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	105-110
24599963-10	2014	Importantly, we showed that oral administration of bexarotene and 9-cis-RA significantly increases apoE, ABCA1, and ABCG1 levels in mouse brains.	Bexarotene	51-61	ATP binding cassette subfamily G member 1	Mus musculus	116-121
24616413-4	2014	Bexarotene also differently affects the gene expression of deiodinases 1 and 2 as well as the peripheral clearance of thyroxine.	Bexarotene	0-10	iodothyronine deiodinase 2	Homo sapiens	59-78
25164224-13	2014	CONCLUSION: Bexarotene treatment could attenuate arteriosclerosis progression in STZ induced diabetic apoE(-/-) mice, the underlying mechanism might be related to suppressing oxidative stress and decreasing blood glucose level and improving lipids metabolism.	Bexarotene	12-22	apolipoprotein E	Mus musculus	102-106
24599963-9	2014	Both bexarotene and 9-cis-RA promote the lipidation status of apoE, in which 9-cis-RA promotes a stronger effect and exhibits less cytotoxicity compared with bexarotene.	Bexarotene	5-15	apolipoprotein E	Mus musculus	62-66
24666648-0	2014	Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).	Bexarotene	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	51-55
24666648-0	2014	Bexarotene prodrugs: targeting through cleavage by NQO1 (DT-diaphorase).	Bexarotene	0-10	NAD(P)H quinone dehydrogenase 1	Homo sapiens	57-70
24666648-1	2014	Bexarotene, a retinoid X receptor (RXR) agonist, is being tested as a potential disease modifying treatment for neurodegenerative conditions.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	14-33
24666648-1	2014	Bexarotene, a retinoid X receptor (RXR) agonist, is being tested as a potential disease modifying treatment for neurodegenerative conditions.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	35-38
24666648-2	2014	To limit the peripheral exposure of bexarotene and release it only in the affected areas of the brain, we designed a prodrug strategy based on the enzyme NAD(P)H/quinone oxidoreductase (NQO1) that is elevated in neurodegenerative diseases.	Bexarotene	36-46	NAD(P)H quinone dehydrogenase 1	Homo sapiens	186-190
24666648-3	2014	A series of indolequinones (known substrates of NQO1) was synthesized and coupled to bexarotene.	Bexarotene	85-95	NAD(P)H quinone dehydrogenase 1	Homo sapiens	48-52
24456080-4	2014	RXR agonist bexarotene (Targretin ) is used for the treatment of cutaneous T-cell lymphoma in clinical practice.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	0-3
24456080-4	2014	RXR agonist bexarotene (Targretin ) is used for the treatment of cutaneous T-cell lymphoma in clinical practice.	Bexarotene	24-33	retinoid X receptor alpha	Homo sapiens	0-3
24944741-1	2014	Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer"s disease that have been the subject of recent controversy.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	28-47
24944741-1	2014	Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer"s disease that have been the subject of recent controversy.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	49-52
24944741-1	2014	Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer"s disease that have been the subject of recent controversy.	Bexarotene	12-21	retinoid X receptor alpha	Homo sapiens	28-47
24944741-1	2014	Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer"s disease that have been the subject of recent controversy.	Bexarotene	12-21	retinoid X receptor alpha	Homo sapiens	49-52
23837676-1	2013	BACKGROUND: Bexarotene was approved for cutaneous T-cell lymphoma (CTCL) in 1999.	Bexarotene	12-22	TSPY like 2	Homo sapiens	67-71
24285015-2	2014	Approximately 50% of CTCL patients respond to bexarotene (Bex).	Bexarotene	46-56	TSPY like 2	Homo sapiens	21-25
24285015-2	2014	Approximately 50% of CTCL patients respond to bexarotene (Bex).	Bexarotene	58-61	TSPY like 2	Homo sapiens	21-25
24434091-0	2013	The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.	Bexarotene	32-42	retinoid X receptor alpha	Homo sapiens	4-23
24434091-2	2013	The antitumor agent bexarotene via nuclear retinoid X receptor (RXR) activation might modulate numerous metabolic pathways involved in the pathogenesis of schizophrenia and schizoaffective disorder.	Bexarotene	20-30	retinoid X receptor alpha	Homo sapiens	43-62
24434091-2	2013	The antitumor agent bexarotene via nuclear retinoid X receptor (RXR) activation might modulate numerous metabolic pathways involved in the pathogenesis of schizophrenia and schizoaffective disorder.	Bexarotene	20-30	retinoid X receptor alpha	Homo sapiens	64-67
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	148-158	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	98-103
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	148-158	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	220-225
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	160-169	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	98-103
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	160-169	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	220-225
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	176-183	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	98-103
24117438-3	2013	Using bioluminescence resonance energy transfer (BRET) assays to directly monitor interactions of Nurr1 with other NucHRs, we found the cancer drug bexarotene (Targretin, also LGD1069) displayed biased interactions with Nurr1-RXR heterodimers compared with RXR-RXR homodimers.	Bexarotene	176-183	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	220-225
24136145-1	2013	BACKGROUND: Both gemcitabine and bexarotene are established single agents for the treatment of cutaneous T-cell lymphoma (CTCL).	Bexarotene	33-43	TSPY like 2	Homo sapiens	122-126
29261220-4	2014	This alternative myelin-centered perspective is used herein to help explain key disconnects in the existing treatment literature by focusing on recent reports on brain effects of bexarotene, the only marketed retinoid X receptor (RXR) agonist.	Bexarotene	179-189	retinoid X receptor alpha	Homo sapiens	209-228
29261220-4	2014	This alternative myelin-centered perspective is used herein to help explain key disconnects in the existing treatment literature by focusing on recent reports on brain effects of bexarotene, the only marketed retinoid X receptor (RXR) agonist.	Bexarotene	179-189	retinoid X receptor alpha	Homo sapiens	230-233
24080207-6	2013	Tumors exposed to raloxifene, bexarotene and/or the combination showed significant suppression of proliferating cell nuclear antigen, cyclin D1, and beta-catenin with an increased apoptotic cells (3-fold) and p21 expression (3.8-fold) as compared tumors of rats fed control diet.	Bexarotene	30-40	proliferating cell nuclear antigen	Rattus norvegicus	98-132
24080207-6	2013	Tumors exposed to raloxifene, bexarotene and/or the combination showed significant suppression of proliferating cell nuclear antigen, cyclin D1, and beta-catenin with an increased apoptotic cells (3-fold) and p21 expression (3.8-fold) as compared tumors of rats fed control diet.	Bexarotene	30-40	cyclin D1	Rattus norvegicus	134-143
24080207-6	2013	Tumors exposed to raloxifene, bexarotene and/or the combination showed significant suppression of proliferating cell nuclear antigen, cyclin D1, and beta-catenin with an increased apoptotic cells (3-fold) and p21 expression (3.8-fold) as compared tumors of rats fed control diet.	Bexarotene	30-40	catenin beta 1	Rattus norvegicus	149-161
24080207-6	2013	Tumors exposed to raloxifene, bexarotene and/or the combination showed significant suppression of proliferating cell nuclear antigen, cyclin D1, and beta-catenin with an increased apoptotic cells (3-fold) and p21 expression (3.8-fold) as compared tumors of rats fed control diet.	Bexarotene	30-40	KRAS proto-oncogene, GTPase	Rattus norvegicus	209-212
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	77-87	apolipoprotein E	Mus musculus	229-233
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	77-87	amyloid beta (A4) precursor protein	Mus musculus	265-270
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	77-87	amyloid beta (A4) precursor protein	Mus musculus	304-309
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	89-98	apolipoprotein E	Mus musculus	229-233
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	89-98	amyloid beta (A4) precursor protein	Mus musculus	265-270
24047423-4	2013	Landreth"s group in three murine models of AD has shown that the RXR agonist bexarotene (Targretin), Food and Drug Administration (FDA) approved and used since 1999 for the treatment of cutaneous T cell lymphoma, promotes a fast ApoE-dependent clearance of soluble Abeta peptides from the brain, reduces Abeta plaques, and stimulates the reversal of cognitive, social, and olfactory deficits.	Bexarotene	89-98	amyloid beta (A4) precursor protein	Mus musculus	304-309
24229456-3	2013	Apolipoprotein E4 is the strongest genetic risk factor for AD and bexarotene appeared to exert spectacular effects on AD pathology when tested in APP/PS1 transgenic mice.	Bexarotene	66-76	presenilin 1	Mus musculus	150-153
23837676-2	2013	Apart from the two first clinical trials published ten years ago, very few data were published on the long-term use of bexarotene in CTCL patients.	Bexarotene	119-129	TSPY like 2	Homo sapiens	133-137
23837676-3	2013	OBJECTIVES: We performed a retrospective review of CTCL patients treated with bexarotene at a single skin Cancer department between 2002 and 2012.	Bexarotene	78-88	TSPY like 2	Homo sapiens	51-55
23837676-4	2013	We aimed to determine retrospectively the long-term tolerability and outcome of bexarotene in a cohort of CTCL patients and to compare these results with data from the literature.	Bexarotene	80-90	TSPY like 2	Homo sapiens	106-110
23837676-10	2013	CONCLUSIONS: This study with a very long observation time confirms that bexarotene is well tolerated by CTCL patients during long-term use.	Bexarotene	72-82	TSPY like 2	Homo sapiens	104-108
23429500-1	2013	By the application of the invariom formalism, which provides aspherical atomic scattering factors, the electron densities of the RXR-selective retinoid agonists bexarotene (1a) and disila-bexarotene (1b) were derived from their known low resolution (d = 0.76 A) crystal structures.	Bexarotene	161-171	retinoid X receptor alpha	Homo sapiens	129-132
23764200-4	2013	Drugs that activate RXRs, including bexarotene, can increase APOE and ABCA1 production, and have been shown to decrease the Abeta burden and improve cognition in mouse models of Abeta amyloidosis.	Bexarotene	36-46	apolipoprotein E	Mus musculus	61-65
23764200-4	2013	Drugs that activate RXRs, including bexarotene, can increase APOE and ABCA1 production, and have been shown to decrease the Abeta burden and improve cognition in mouse models of Abeta amyloidosis.	Bexarotene	36-46	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	70-75
23764200-6	2013	FINDINGS: In efforts to clarify these behavioral findings, mutant APP/PS1 mice were acutely dosed with bexarotene.	Bexarotene	103-113	presenilin 1	Mus musculus	70-73
23764200-7	2013	While ABCA1 was upregulated in mutant APP/PS1 mice treated with bexarotene, this drug failed to attenuate Abeta plaques or cognitive deficits in these mice.	Bexarotene	64-74	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	6-11
23704552-2	2013	(Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer"s disease (AD) that treatment of APP/PS1DeltaE9 mice with bexarotene decreased Abeta pathology and ameliorated memory deficits.	Bexarotene	170-180	amyloid beta (A4) precursor protein	Mus musculus	191-196
23704555-2	2013	(Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces beta-amyloid (Abeta) levels and plaque burden in two mouse models of Abeta deposition in Alzheimer"s disease (AD).	Bexarotene	82-92	amyloid beta (A4) precursor protein	Mus musculus	123-128
23704555-2	2013	(Reports, 23 March 2012, p. 1503; published online 9 February 2012) reported that bexarotene rapidly reduces beta-amyloid (Abeta) levels and plaque burden in two mouse models of Abeta deposition in Alzheimer"s disease (AD).	Bexarotene	82-92	amyloid beta (A4) precursor protein	Mus musculus	178-183
23601557-11	2013	Administration of the RXR agonist bexarotene increased ISF apoE levels while ISF Abeta levels were decreased.	Bexarotene	34-44	apolipoprotein E	Mus musculus	59-63
22917895-1	2013	BACKGROUND: Bexarotene is the only Food and Drug Administration-approved retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) and is associated with a relatively high frequency of adverse effects.	Bexarotene	12-22	TSPY like 2	Homo sapiens	130-134
23430755-6	2013	By double labeling of senescent cells, first by SA-beta-Gal and then by antibodies against genes related to cellular senescence, we found that p21, p16, and RARbeta, but not p53, were upregulated by bexarotene in mammary tumors and in breast cancer cell lines, suggesting involvement of multiple signaling pathways in mediating the senescence program of rexinoids.	Bexarotene	199-209	H3 histone pseudogene 16	Homo sapiens	143-146
23430755-6	2013	By double labeling of senescent cells, first by SA-beta-Gal and then by antibodies against genes related to cellular senescence, we found that p21, p16, and RARbeta, but not p53, were upregulated by bexarotene in mammary tumors and in breast cancer cell lines, suggesting involvement of multiple signaling pathways in mediating the senescence program of rexinoids.	Bexarotene	199-209	cyclin dependent kinase inhibitor 2A	Homo sapiens	148-151
23430755-6	2013	By double labeling of senescent cells, first by SA-beta-Gal and then by antibodies against genes related to cellular senescence, we found that p21, p16, and RARbeta, but not p53, were upregulated by bexarotene in mammary tumors and in breast cancer cell lines, suggesting involvement of multiple signaling pathways in mediating the senescence program of rexinoids.	Bexarotene	199-209	retinoic acid receptor beta	Homo sapiens	157-164
23430755-6	2013	By double labeling of senescent cells, first by SA-beta-Gal and then by antibodies against genes related to cellular senescence, we found that p21, p16, and RARbeta, but not p53, were upregulated by bexarotene in mammary tumors and in breast cancer cell lines, suggesting involvement of multiple signaling pathways in mediating the senescence program of rexinoids.	Bexarotene	199-209	tumor protein p53	Homo sapiens	174-177
23557425-6	2013	Bexarotene is the first retinoid approved by the US FDA for CTCL therapy.	Bexarotene	0-10	TSPY like 2	Homo sapiens	60-64
22949521-6	2012	The interaction of RFC3 with RXRalpha depends on 9-cis-RA and bexarotene, but not on all-trans-RA or an RA receptor (RAR)-selective ligand.	Bexarotene	62-72	replication factor C subunit 3	Homo sapiens	19-23
24278042-4	2013	Orally administrated bexarotene, the first synthetic selective RXR retinoid, was revealed to be active against the cutaneous manifestation of CTCL.	Bexarotene	21-31	retinoid X receptor alpha	Homo sapiens	63-66
24278042-4	2013	Orally administrated bexarotene, the first synthetic selective RXR retinoid, was revealed to be active against the cutaneous manifestation of CTCL.	Bexarotene	21-31	TSPY like 2	Homo sapiens	142-146
22963233-12	2013	CONCLUSION:  Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose.	Bexarotene	37-47	TSPY like 2	Homo sapiens	66-70
23149703-0	2012	Combination treatment in CTCL: the current role of bexarotene.	Bexarotene	51-61	TSPY like 2	Homo sapiens	25-29
22949521-6	2012	The interaction of RFC3 with RXRalpha depends on 9-cis-RA and bexarotene, but not on all-trans-RA or an RA receptor (RAR)-selective ligand.	Bexarotene	62-72	retinoid X receptor alpha	Homo sapiens	29-37
22661092-4	2012	Interestingly, under physiological flow conditions, TNF-alpha-induced endothelial adhesion of human mononuclear cells was concentration-dependently inhibited by preincubation of the human umbilical arterial endothelial cells with RXR agonists such as bexarotene or 9-cis-retinoid acid.	Bexarotene	251-261	tumor necrosis factor	Homo sapiens	52-61
22926341-1	2012	In pursuit of effective therapeutic agents for the estrogen receptor (ER)-negative breast cancer, we previously showed that bexarotene reduced mammary tumor development by 75% in ErbB2 mice.	Bexarotene	124-134	estrogen receptor 1 (alpha)	Mus musculus	51-68
22926341-1	2012	In pursuit of effective therapeutic agents for the estrogen receptor (ER)-negative breast cancer, we previously showed that bexarotene reduced mammary tumor development by 75% in ErbB2 mice.	Bexarotene	124-134	estrogen receptor 1 (alpha)	Mus musculus	70-72
22926341-1	2012	In pursuit of effective therapeutic agents for the estrogen receptor (ER)-negative breast cancer, we previously showed that bexarotene reduced mammary tumor development by 75% in ErbB2 mice.	Bexarotene	124-134	erb-b2 receptor tyrosine kinase 2	Mus musculus	179-184
22927238-2	2012	Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors.	Bexarotene	79-89	retinoid X receptor alpha	Homo sapiens	185-188
22239668-0	2012	Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.	Bexarotene	25-35	retinoid X receptor alpha	Homo sapiens	169-188
22239668-1	2012	The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs).	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	4-23
22239668-1	2012	The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs).	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	25-28
22661092-4	2012	Interestingly, under physiological flow conditions, TNF-alpha-induced endothelial adhesion of human mononuclear cells was concentration-dependently inhibited by preincubation of the human umbilical arterial endothelial cells with RXR agonists such as bexarotene or 9-cis-retinoid acid.	Bexarotene	251-261	retinoid X receptor alpha	Homo sapiens	230-233
22661092-10	2012	In vivo, bexarotene dose-dependently inhibited TNF-alpha-induced leukocyte adhesion to the murine cremasteric arterioles and decreased VCAM-1 and ICAM-1 expression.	Bexarotene	9-19	tumor necrosis factor	Mus musculus	47-56
22661092-10	2012	In vivo, bexarotene dose-dependently inhibited TNF-alpha-induced leukocyte adhesion to the murine cremasteric arterioles and decreased VCAM-1 and ICAM-1 expression.	Bexarotene	9-19	vascular cell adhesion molecule 1	Mus musculus	135-141
22661092-10	2012	In vivo, bexarotene dose-dependently inhibited TNF-alpha-induced leukocyte adhesion to the murine cremasteric arterioles and decreased VCAM-1 and ICAM-1 expression.	Bexarotene	9-19	intercellular adhesion molecule 1	Mus musculus	146-152
22678563-1	2012	Bexarotene is an oral retinoid shown to be active against the cutaneous manifestations of cutaneous T-cell lym-phoma (CTCL).	Bexarotene	0-10	TSPY like 2	Homo sapiens	118-122
22678563-3	2012	We present here data on 37 Finnish patients with CTCL treated with bexarotene during the last 10 years.	Bexarotene	67-77	TSPY like 2	Homo sapiens	49-53
22307264-7	2012	Finally, based on the hypothesis             that Targretin may decrease the expression of COX-2, the effects of Targretin             and COX inhibitors were compared in these models.	Bexarotene	50-59	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	91-96
22057854-1	2012	PURPOSE: This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin( )) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy.	Bexarotene	68-78	retinoid X receptor alpha	Homo sapiens	40-59
22323736-3	2012	Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble Abeta within hours in an apoE-dependent manner.	Bexarotene	39-49	amyloid beta (A4) precursor protein	Mus musculus	115-120
22323736-3	2012	Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced clearance of soluble Abeta within hours in an apoE-dependent manner.	Bexarotene	39-49	apolipoprotein E	Mus musculus	140-144
22057854-1	2012	PURPOSE: This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin( )) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy.	Bexarotene	80-89	retinoid X receptor alpha	Homo sapiens	40-59
22431924-0	2012	Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.	Bexarotene	50-60	APC, WNT signaling pathway regulator	Mus musculus	88-91
22057855-1	2012	PURPOSE: Bexarotene (Targretin( ) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	49-68
22057855-1	2012	PURPOSE: Bexarotene (Targretin( ) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism.	Bexarotene	9-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
22057855-1	2012	PURPOSE: Bexarotene (Targretin( ) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	49-68
22057855-1	2012	PURPOSE: Bexarotene (Targretin( ) capsules) is a retinoid-X-receptor agonist and an inducer of CYP3A4-mediated metabolism.	Bexarotene	21-30	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-101
22057855-10	2012	The likely mechanism for this interaction is through induction of CYP3A4 by bexarotene given the role of this enzyme in the metabolism of atorvastatin.	Bexarotene	76-86	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72
22053058-6	2012	Bexarotene also induced mRNA and protein levels for peroxisome proliferator-activated receptor (PPAR) gamma, whereas selective knockdown of PPARgamma attenuated the induction of both lipid droplets and adipocyte differentiation-related protein.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	52-107
22053058-10	2012	It is noteworthy that combining low doses of bexarotene with the PPARgamma agonist rosiglitazone provides effective growth suppression of mammary epithelial cells, potentially dissociating systemic adverse effects associated with standard bexarotene treatment from the antiproliferative effects on mammary epithelium.	Bexarotene	239-249	peroxisome proliferator activated receptor gamma	Homo sapiens	65-74
22431924-3	2012	Experiments were designed to assess the chemopreventive efficacy of the selective RXR agonist bexarotene for the suppression of intestinal tumorigenesis in Apc(Min/+) mice.	Bexarotene	94-104	APC, WNT signaling pathway regulator	Mus musculus	156-159
22431924-9	2012	Intestinal tumors of bexarotene-fed mice showed significantly reduced expression of proliferating cell nuclear antigen (60%, P &lt; .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-alpha messenger RNA and uptake of oleate (34%, P &lt; .01).	Bexarotene	21-31	proliferating cell nuclear antigen	Mus musculus	84-118
22431924-9	2012	Intestinal tumors of bexarotene-fed mice showed significantly reduced expression of proliferating cell nuclear antigen (60%, P &lt; .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-alpha messenger RNA and uptake of oleate (34%, P &lt; .01).	Bexarotene	21-31	cyclin D1	Mus musculus	140-149
22431924-9	2012	Intestinal tumors of bexarotene-fed mice showed significantly reduced expression of proliferating cell nuclear antigen (60%, P &lt; .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-alpha messenger RNA and uptake of oleate (34%, P &lt; .01).	Bexarotene	21-31	prostaglandin-endoperoxide synthase 2	Mus musculus	155-171
22431924-9	2012	Intestinal tumors of bexarotene-fed mice showed significantly reduced expression of proliferating cell nuclear antigen (60%, P &lt; .0001), cyclin D1, and cyclooxygenase 2 and increased RXR-alpha messenger RNA and uptake of oleate (34%, P &lt; .01).	Bexarotene	21-31	retinoid X receptor alpha	Mus musculus	186-195
22142826-0	2012	Bexarotene via CBP/p300 induces suppression of NF-kappaB-dependent cell growth and invasion in thyroid cancer.	Bexarotene	0-10	CREB binding protein	Homo sapiens	15-23
22142826-0	2012	Bexarotene via CBP/p300 induces suppression of NF-kappaB-dependent cell growth and invasion in thyroid cancer.	Bexarotene	0-10	nuclear factor kappa B subunit 1	Homo sapiens	47-56
22142826-9	2012	We show that bexarotene inhibits the transactivation potential of NF-kappaB in an RXR-dependent manner through decreased promoter permissiveness without interfering with NF-kappaB nuclear translocation and binding to its responsive elements.	Bexarotene	13-23	nuclear factor kappa B subunit 1	Homo sapiens	66-75
22142826-9	2012	We show that bexarotene inhibits the transactivation potential of NF-kappaB in an RXR-dependent manner through decreased promoter permissiveness without interfering with NF-kappaB nuclear translocation and binding to its responsive elements.	Bexarotene	13-23	retinoid X receptor alpha	Homo sapiens	82-85
21547336-1	2011	Bexarotene (Targretin( )), was registered for the treatment of cutaneous T-cell lymphoma (CTCL) in 2002, and has been reported to induce a 45% overall response.	Bexarotene	0-10	TSPY like 2	Homo sapiens	90-94
21764128-0	2011	Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.	Bexarotene	94-104	TNF receptor superfamily member 8	Homo sapiens	18-22
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	27-36
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	37-40
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	45-48
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	45-48
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	45-48
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	176-185
22223330-4	2012	Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists.	Bexarotene	0-10	vitamin D receptor	Homo sapiens	196-199
22223330-5	2012	When the potencies of honokiol and bexarotene were compared, honokiol was able to serve as a subsidiary agonist in the activation of RXR heterodimers in a similar manner to bexarotene.	Bexarotene	35-45	retinoid X receptor alpha	Homo sapiens	133-136
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	retinoid X receptor alpha	Homo sapiens	14-33
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	retinoid X receptor alpha	Homo sapiens	35-38
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	peroxisome proliferator activated receptor delta	Homo sapiens	41-51
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	angiopoietin like 4	Homo sapiens	101-108
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	lipoprotein lipase	Homo sapiens	134-137
23056264-6	2012	Activation of retinoic X receptor (RXR), PPAR delta functional partner, using bexarotene upregulated Angptl4 expression and inhibited LPL activity in a PPAR delta dependent fashion.	Bexarotene	78-88	peroxisome proliferator activated receptor delta	Homo sapiens	152-162
23056264-7	2012	Silencing of Angptl4 blocked the effect of GW501516 and bexarotene on LPL activity.	Bexarotene	56-66	angiopoietin like 4	Homo sapiens	13-20
23056264-7	2012	Silencing of Angptl4 blocked the effect of GW501516 and bexarotene on LPL activity.	Bexarotene	56-66	lipoprotein lipase	Homo sapiens	70-73
21547336-1	2011	Bexarotene (Targretin( )), was registered for the treatment of cutaneous T-cell lymphoma (CTCL) in 2002, and has been reported to induce a 45% overall response.	Bexarotene	12-21	TSPY like 2	Homo sapiens	90-94
21547336-3	2011	This study explored the usefulness of a novel cancer-associated gene, NAV3 and corresponding chromosome 12 copy numbers as possible biomarkers to monitor the therapeutic response to bexarotene in 21 Finnish patients with CTCL.	Bexarotene	182-192	neuron navigator 3	Homo sapiens	70-74
21547336-3	2011	This study explored the usefulness of a novel cancer-associated gene, NAV3 and corresponding chromosome 12 copy numbers as possible biomarkers to monitor the therapeutic response to bexarotene in 21 Finnish patients with CTCL.	Bexarotene	182-192	TSPY like 2	Homo sapiens	221-225
20821348-4	2011	Previously we discovered that DEC2 (differentially expressed in chondrocytes-2), a helix-loop-helix transcription repressor, was induced by bexarotene in human mammary epithelial cells.	Bexarotene	140-150	basic helix-loop-helix family member e41	Homo sapiens	36-78
21585279-0	2011	Successful treatment of angioimmunoblastic T-cell lymphoma with the retinoid X receptor agonist, bexarotene.	Bexarotene	97-107	retinoid X receptor alpha	Homo sapiens	68-87
20821348-0	2011	The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.	Bexarotene	13-23	cyclin D1	Homo sapiens	34-43
20821348-0	2011	The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor.	Bexarotene	13-23	basic helix-loop-helix family member e41	Homo sapiens	74-78
20821348-5	2011	Therefore, we hypothesized that bexarotene represses the transcription of cyclin D1 through induction of DEC2.	Bexarotene	32-42	cyclin D1	Homo sapiens	74-83
20821348-1	2011	Bexarotene is an RXR-selective vitamin A analog that has been shown to prevent ER-negative mammary tumorigenesis in animal models.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	17-20
20821348-2	2011	While investigating the mechanism by which bexarotene prevents ER-negative breast cancer development, we found that the expression of cyclin D1, a critical cell cycle promoter, was repressed by bexarotene in vitro and in vivo.	Bexarotene	43-53	cyclin D1	Homo sapiens	134-143
20821348-5	2011	Therefore, we hypothesized that bexarotene represses the transcription of cyclin D1 through induction of DEC2.	Bexarotene	32-42	basic helix-loop-helix family member e41	Homo sapiens	105-109
20821348-2	2011	While investigating the mechanism by which bexarotene prevents ER-negative breast cancer development, we found that the expression of cyclin D1, a critical cell cycle promoter, was repressed by bexarotene in vitro and in vivo.	Bexarotene	194-204	cyclin D1	Homo sapiens	134-143
20821348-4	2011	Previously we discovered that DEC2 (differentially expressed in chondrocytes-2), a helix-loop-helix transcription repressor, was induced by bexarotene in human mammary epithelial cells.	Bexarotene	140-150	basic helix-loop-helix family member e41	Homo sapiens	30-34
20821348-6	2011	Luciferase reporter studies demonstrated that either bexarotene treatment or forced expression of DEC2 can repress the transcription of a cyclin D1 promoter reporter by affecting the basal transcriptional activity.	Bexarotene	53-63	cyclin D1	Homo sapiens	138-147
20821348-7	2011	Results from chromatin immunoprecipitation experiments showed that bexarotene treatment causes the recruitment of DEC2 and HDAC1 (histone deacetylase 1) to the cyclin D1 promoter.	Bexarotene	67-77	basic helix-loop-helix family member e41	Homo sapiens	114-118
20821348-7	2011	Results from chromatin immunoprecipitation experiments showed that bexarotene treatment causes the recruitment of DEC2 and HDAC1 (histone deacetylase 1) to the cyclin D1 promoter.	Bexarotene	67-77	histone deacetylase 1	Homo sapiens	123-128
20821348-7	2011	Results from chromatin immunoprecipitation experiments showed that bexarotene treatment causes the recruitment of DEC2 and HDAC1 (histone deacetylase 1) to the cyclin D1 promoter.	Bexarotene	67-77	histone deacetylase 1	Homo sapiens	130-151
20821348-7	2011	Results from chromatin immunoprecipitation experiments showed that bexarotene treatment causes the recruitment of DEC2 and HDAC1 (histone deacetylase 1) to the cyclin D1 promoter.	Bexarotene	67-77	cyclin D1	Homo sapiens	160-169
20821348-9	2011	Trichostatin A, a HDAC inhibitor, reverses the cyclin D1 repression by bexarotene, suggesting that repression of cyclin D1 involves histone deacetylation.	Bexarotene	71-81	cyclin D1	Homo sapiens	47-56
21726055-1	2011	Twofold sila-substitution (C/Si exchange) of the clinically used RXR-selective retinoid agonist bexarotene leads to disila-bexarotene, which displays pharmacological potency similar to that of the parent carbon compound, as shown in a HeLa-cell-based RXR assay.	Bexarotene	96-106	retinoid X receptor alpha	Homo sapiens	65-68
20821348-9	2011	Trichostatin A, a HDAC inhibitor, reverses the cyclin D1 repression by bexarotene, suggesting that repression of cyclin D1 involves histone deacetylation.	Bexarotene	71-81	cyclin D1	Homo sapiens	113-122
21726055-1	2011	Twofold sila-substitution (C/Si exchange) of the clinically used RXR-selective retinoid agonist bexarotene leads to disila-bexarotene, which displays pharmacological potency similar to that of the parent carbon compound, as shown in a HeLa-cell-based RXR assay.	Bexarotene	96-106	retinoid X receptor alpha	Homo sapiens	251-254
20821348-12	2011	These results suggest that bexarotene down-regulates cyclin D1 through induction of DEC2, followed by recruitment of HDAC1 to the cyclin D1 promoter causing transcriptional repression.	Bexarotene	27-37	cyclin D1	Homo sapiens	53-62
20821348-12	2011	These results suggest that bexarotene down-regulates cyclin D1 through induction of DEC2, followed by recruitment of HDAC1 to the cyclin D1 promoter causing transcriptional repression.	Bexarotene	27-37	basic helix-loop-helix family member e41	Homo sapiens	84-88
20821348-12	2011	These results suggest that bexarotene down-regulates cyclin D1 through induction of DEC2, followed by recruitment of HDAC1 to the cyclin D1 promoter causing transcriptional repression.	Bexarotene	27-37	histone deacetylase 1	Homo sapiens	117-122
20821348-12	2011	These results suggest that bexarotene down-regulates cyclin D1 through induction of DEC2, followed by recruitment of HDAC1 to the cyclin D1 promoter causing transcriptional repression.	Bexarotene	27-37	cyclin D1	Homo sapiens	130-139
21649908-1	2011	BACKGROUND: LGD1069 (Targretin ) is a selective retinoid X receptor (RXR) ligand, which is used in patients for cutaneous T-cell lymphoma.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	48-67
21622945-10	2011	TBT and bexarotene, but not rosiglitazone, also induced the expression of TGM2 (an RXR target) and ABCA1 (a liver X receptor target).	Bexarotene	8-18	transglutaminase 2	Homo sapiens	74-78
21622945-10	2011	TBT and bexarotene, but not rosiglitazone, also induced the expression of TGM2 (an RXR target) and ABCA1 (a liver X receptor target).	Bexarotene	8-18	retinoid X receptor alpha	Homo sapiens	83-86
21622945-10	2011	TBT and bexarotene, but not rosiglitazone, also induced the expression of TGM2 (an RXR target) and ABCA1 (a liver X receptor target).	Bexarotene	8-18	ATP binding cassette subfamily A member 1	Homo sapiens	99-104
21649908-1	2011	BACKGROUND: LGD1069 (Targretin ) is a selective retinoid X receptor (RXR) ligand, which is used in patients for cutaneous T-cell lymphoma.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	69-72
20849457-0	2010	A transient epidermolysis bullosa simplex-like phenotype associated with bexarotene treatment in a G138E KRT5 heterozygote.	Bexarotene	73-83	keratin 5	Homo sapiens	105-109
21737656-5	2011	Four such single nucleotide polymorphisms (SNPs) reside on the region upstream of solute carrier family 10, member 2 (SLC10A2), and one SNP is located close to lymphocyte cytosolic protein 1 (LCP1), whose expression correlated with the activity of bexarotene in tumor cells.	Bexarotene	248-258	lymphocyte cytosolic protein 1	Homo sapiens	160-190
21461579-5	2011	The RXR family plays a role in cell differentiation and proliferation and is known to be the target of bexarotene, which is used in the treatment of CTCL.	Bexarotene	103-113	retinoid X receptor alpha	Homo sapiens	4-7
21461579-5	2011	The RXR family plays a role in cell differentiation and proliferation and is known to be the target of bexarotene, which is used in the treatment of CTCL.	Bexarotene	103-113	TSPY like 2	Homo sapiens	149-153
21185985-5	2010	Among synthetic retinoids, isotretinoin, acitretin, tazarotene and adapalene are ligands of the RAR, bexarotene is the first rexinoid (ligand of the RXR), alitretinoin the first panagonist (RAR+ RXR).	Bexarotene	101-111	retinoid X receptor alpha	Homo sapiens	149-152
21185985-5	2010	Among synthetic retinoids, isotretinoin, acitretin, tazarotene and adapalene are ligands of the RAR, bexarotene is the first rexinoid (ligand of the RXR), alitretinoin the first panagonist (RAR+ RXR).	Bexarotene	101-111	retinoid X receptor alpha	Homo sapiens	195-198
21636543-3	2011	Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer cells derived from transgenic mice and in two clinical studies in lung cancer (including wild-type EGFR tumors, with or without KRAS mutations), as reported in this issue of the journal by Dragnev and colleagues (beginning on page 818).	Bexarotene	24-34	cyclin D1	Mus musculus	57-66
21636543-3	2011	Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer cells derived from transgenic mice and in two clinical studies in lung cancer (including wild-type EGFR tumors, with or without KRAS mutations), as reported in this issue of the journal by Dragnev and colleagues (beginning on page 818).	Bexarotene	24-34	epidermal growth factor receptor	Mus musculus	99-103
21636543-3	2011	Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer cells derived from transgenic mice and in two clinical studies in lung cancer (including wild-type EGFR tumors, with or without KRAS mutations), as reported in this issue of the journal by Dragnev and colleagues (beginning on page 818).	Bexarotene	24-34	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	132-136
21636543-3	2011	Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer cells derived from transgenic mice and in two clinical studies in lung cancer (including wild-type EGFR tumors, with or without KRAS mutations), as reported in this issue of the journal by Dragnev and colleagues (beginning on page 818).	Bexarotene	24-34	epidermal growth factor receptor	Mus musculus	255-259
21636543-3	2011	Combining erlotinib and bexarotene, however, to cotarget cyclin D1 via the retinoid X receptor and EGFR was active preclinically in KRAS-driven lung cancer cells derived from transgenic mice and in two clinical studies in lung cancer (including wild-type EGFR tumors, with or without KRAS mutations), as reported in this issue of the journal by Dragnev and colleagues (beginning on page 818).	Bexarotene	24-34	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	284-288
21636548-1	2011	The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation.	Bexarotene	13-23	cyclin D1	Homo sapiens	34-43
21636548-11	2011	In conclusion, bexarotene plus erlotinib was active in KRAS-driven lung cancer cells, was biologically active in early-stage mutant KRAS NSCLC, and was clinically active in advanced, chemotherapy-refractory mutant KRAS tumors in this study and previous trials.	Bexarotene	15-25	KRAS proto-oncogene, GTPase	Homo sapiens	55-59
21636548-11	2011	In conclusion, bexarotene plus erlotinib was active in KRAS-driven lung cancer cells, was biologically active in early-stage mutant KRAS NSCLC, and was clinically active in advanced, chemotherapy-refractory mutant KRAS tumors in this study and previous trials.	Bexarotene	15-25	KRAS proto-oncogene, GTPase	Homo sapiens	132-136
21636548-11	2011	In conclusion, bexarotene plus erlotinib was active in KRAS-driven lung cancer cells, was biologically active in early-stage mutant KRAS NSCLC, and was clinically active in advanced, chemotherapy-refractory mutant KRAS tumors in this study and previous trials.	Bexarotene	15-25	KRAS proto-oncogene, GTPase	Homo sapiens	132-136
21931572-3	2011	The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 receptor and enhance the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	19-29	interleukin 2 receptor subunit beta	Homo sapiens	192-205
21931572-3	2011	The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 receptor and enhance the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	142-152	interleukin 2 receptor subunit beta	Homo sapiens	192-205
19603308-6	2010	Bexarotene may be used alone or in association with interferon alfa, interferon gamma, extracorporeal photophoresis and PUVA.	Bexarotene	0-10	interferon gamma	Homo sapiens	69-85
19845753-0	2010	About the cutaneous targets of bexarotene in CTCL patients.	Bexarotene	31-41	TSPY like 2	Homo sapiens	45-49
19845753-7	2010	The main bexarotene"s target thus remains T-cells by inducing their apoptosis, a mechanism that is different from the other retinoids used in CTCL.	Bexarotene	9-19	TSPY like 2	Homo sapiens	142-146
19845755-3	2010	Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	49-52
19845755-3	2010	Bexarotene, the first synthetic highly selective RXR retinoid, was approved for the treatment of all stages of CTCL in patients refractory to at least one systemic therapy.	Bexarotene	0-10	TSPY like 2	Homo sapiens	111-115
19845755-4	2010	Recently, six cases in which the initiation of bexarotene therapy for CTCL was associated with the progression of internal disease despite improvement of cutaneous signs and symptoms were reported.	Bexarotene	47-57	TSPY like 2	Homo sapiens	70-74
19777233-3	2010	Bexarotene is a selective RXR agonist, which exerts its effects in blocking cell cycle progression, inducing apoptosis and differentiation, preventing multidrug resistance, and inhibiting angiogenesis and metastasis, making it a promising chemopreventive agent against cancer.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	26-29
20484880-2	2010	METHODS: A retrospective study on patients with cutaneous T-cell lymphoma (CTCL) treated with bexarotene was performed to see if bexarotene could act on the dominant T-cell clones.	Bexarotene	94-104	TSPY like 2	Homo sapiens	75-79
20484880-10	2010	CONCLUSION: This is the first study on the evolution of the T-cell clone in blood and skin in CTCL patients during bexarotene therapy.	Bexarotene	115-125	TSPY like 2	Homo sapiens	94-98
19682769-2	2009	Bexarotene, a retinoid X receptor is a selective retinoid, induces T-cell apoptosis.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	14-33
19592467-0	2009	Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.	Bexarotene	9-19	nuclear receptor subfamily 1, group H, member 3	Mus musculus	116-119
19592467-4	2009	METHODS AND RESULTS: Using wild-type and LXR alpha/beta-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers.	Bexarotene	90-100	nuclear receptor subfamily 1, group H, member 3	Mus musculus	41-50
19592467-4	2009	METHODS AND RESULTS: Using wild-type and LXR alpha/beta-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers.	Bexarotene	90-100	nuclear receptor subfamily 1, group H, member 3	Mus musculus	41-44
19592467-4	2009	METHODS AND RESULTS: Using wild-type and LXR alpha/beta-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers.	Bexarotene	90-100	nuclear receptor subfamily 1, group H, member 3	Mus musculus	152-155
19592467-4	2009	METHODS AND RESULTS: Using wild-type and LXR alpha/beta-deficient mice, we show here that bexarotene induces hypertriglyceridemia and activates hepatic LXR-target genes of lipogenesis in an LXR-dependent manner, hence exerting a permissive effect on RXR/LXR heterodimers.	Bexarotene	90-100	nuclear receptor subfamily 1, group H, member 3	Mus musculus	152-155
19592467-5	2009	Interestingly, RNA analysis and Chromatin Immunoprecipitation assays performed in the liver reveal that the in vivo permissive effect of bexarotene on the RXR/LXR heterodimer is restricted to lipogenic genes without modulation of genes controlling cholesterol homeostasis.	Bexarotene	137-147	nuclear receptor subfamily 1, group H, member 3	Mus musculus	159-162
19592467-6	2009	CONCLUSIONS: These findings demonstrate that the hypertriglyceridemic action of bexarotene occurs via the RXR/LXR heterodimer and show that RXR heterodimers can act with a selective permissivity on target genes of specific metabolic pathways in the liver.	Bexarotene	80-90	nuclear receptor subfamily 1, group H, member 3	Mus musculus	110-113
19222457-1	2009	BACKGROUND: Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL).	Bexarotene	12-22	TSPY like 2	Homo sapiens	145-149
19544141-0	2009	Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis.	Bexarotene	88-98	TNF receptor superfamily member 8	Homo sapiens	40-44
19222457-1	2009	BACKGROUND: Bexarotene (Targretin) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL).	Bexarotene	24-33	TSPY like 2	Homo sapiens	145-149
19222457-2	2009	OBJECTIVES: To summarize our experience with bexarotene for patients with CTCL with the aim of assessing efficacy and safety.	Bexarotene	45-55	TSPY like 2	Homo sapiens	74-78
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	23-33	insulin like growth factor binding protein 6	Homo sapiens	249-256
19147676-10	2009	In conclusion, bexarotene causes combined dyslipidemia as reflected by increased TG, VLDL-C, and LDL-C and decreased HDL-C, which is the result of an increased VLDL-TG production that causes an increase of the endogenous CETP activity.	Bexarotene	15-25	CD320 antigen	Mus musculus	85-89
19147676-10	2009	In conclusion, bexarotene causes combined dyslipidemia as reflected by increased TG, VLDL-C, and LDL-C and decreased HDL-C, which is the result of an increased VLDL-TG production that causes an increase of the endogenous CETP activity.	Bexarotene	15-25	CD320 antigen	Mus musculus	160-164
19147676-10	2009	In conclusion, bexarotene causes combined dyslipidemia as reflected by increased TG, VLDL-C, and LDL-C and decreased HDL-C, which is the result of an increased VLDL-TG production that causes an increase of the endogenous CETP activity.	Bexarotene	15-25	cholesteryl ester transfer protein	Homo sapiens	221-225
19147676-0	2009	Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.	Bexarotene	0-10	cholesteryl ester transfer protein	Homo sapiens	89-123
19147676-4	2009	Bexarotene increased plasma triglyceride (TG; +150%), primarily associated with very low-density lipoprotein (VLDL), and raised plasma total cholesterol (+50%).	Bexarotene	0-10	CD320 antigen	Mus musculus	110-114
19147676-5	2009	However, whereas bexarotene increased VLDL-cholesterol (C) and low-density lipoprotein (LDL)-C (+63%), it decreased high-density lipoprotein (HDL)-C (-30%) and tended to decrease apoAI (-18%) concomitant with an increase in endogenous CETP activity (+44%).	Bexarotene	17-27	CD320 antigen	Mus musculus	38-42
19147676-5	2009	However, whereas bexarotene increased VLDL-cholesterol (C) and low-density lipoprotein (LDL)-C (+63%), it decreased high-density lipoprotein (HDL)-C (-30%) and tended to decrease apoAI (-18%) concomitant with an increase in endogenous CETP activity (+44%).	Bexarotene	17-27	cholesteryl ester transfer protein	Homo sapiens	235-239
19147676-6	2009	To evaluate the cause of the bexarotene-induced hypertriglyceridemia and the role of CETP in the bexarotene-induced shift in cholesterol distribution, E3L and E3L.CETP mice were treated with bexarotene through dietary supplementation [0.03% (wt/wt)].	Bexarotene	97-107	cholesteryl ester transfer protein	Homo sapiens	163-167
19147676-6	2009	To evaluate the cause of the bexarotene-induced hypertriglyceridemia and the role of CETP in the bexarotene-induced shift in cholesterol distribution, E3L and E3L.CETP mice were treated with bexarotene through dietary supplementation [0.03% (wt/wt)].	Bexarotene	97-107	cholesteryl ester transfer protein	Homo sapiens	163-167
19147676-7	2009	Bexarotene increased VLDL-associated TG in both E3L (+47%) and E3L.CETP (+29%) mice by increasing VLDL-TG production (+68%).	Bexarotene	0-10	CD320 antigen	Mus musculus	21-25
19147676-7	2009	Bexarotene increased VLDL-associated TG in both E3L (+47%) and E3L.CETP (+29%) mice by increasing VLDL-TG production (+68%).	Bexarotene	0-10	cholesteryl ester transfer protein	Homo sapiens	67-71
19147676-7	2009	Bexarotene increased VLDL-associated TG in both E3L (+47%) and E3L.CETP (+29%) mice by increasing VLDL-TG production (+68%).	Bexarotene	0-10	CD320 antigen	Mus musculus	98-102
19147676-8	2009	Bexarotene did not affect the total cholesterol levels or distribution in E3L mice but increased VLDL-C (+11%) and decreased HDL-C (-56%) as well as apoAI (-31%) in E3L.CETP mice, concomitant with increased endogenous CETP activity (+41%).	Bexarotene	0-10	CD320 antigen	Mus musculus	97-101
19147676-9	2009	This increased CETP activity by bexarotene-treatment is likely due to the increase in VLDL-TG, a CETP substrate that drives CETP activity.	Bexarotene	32-42	cholesteryl ester transfer protein	Homo sapiens	15-19
19147676-9	2009	This increased CETP activity by bexarotene-treatment is likely due to the increase in VLDL-TG, a CETP substrate that drives CETP activity.	Bexarotene	32-42	CD320 antigen	Mus musculus	86-90
19147676-9	2009	This increased CETP activity by bexarotene-treatment is likely due to the increase in VLDL-TG, a CETP substrate that drives CETP activity.	Bexarotene	32-42	cholesteryl ester transfer protein	Homo sapiens	97-101
19147676-9	2009	This increased CETP activity by bexarotene-treatment is likely due to the increase in VLDL-TG, a CETP substrate that drives CETP activity.	Bexarotene	32-42	cholesteryl ester transfer protein	Homo sapiens	97-101
19067706-0	2009	Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.	Bexarotene	0-10	tumor protein p53	Homo sapiens	25-28
19067706-0	2009	Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma.	Bexarotene	0-10	tumor protein p73	Homo sapiens	29-32
19067706-10	2009	Bexarotene upregulated and activated Bax in sensitive lines, although not enough to signal significant apoptosis.	Bexarotene	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	37-40
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	tumor protein p53	Homo sapiens	43-46
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	tumor protein p53	Homo sapiens	108-111
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	tumor protein p73	Homo sapiens	156-159
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	tumor protein p53	Homo sapiens	108-111
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	tumor protein p73	Homo sapiens	219-222
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	H3 histone pseudogene 16	Homo sapiens	256-259
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	BCL2 associated X, apoptosis regulator	Homo sapiens	261-264
19067706-13	2009	We further found that bexarotene activates p53 by phosphorylation at Ser15, which influences the binding of p53 to promoters for cell cycle arrest, induces p73 upregulation, and, in concordance, also modulates some p53/p73 downstream target genes, such as p21, Bax, survivin and cdc2.	Bexarotene	22-32	cyclin dependent kinase 1	Homo sapiens	279-283
19067706-14	2009	Bexarotene-mediated ataxia telangiectasia mutated protein (ATM) activation in all studied lines suggests that ATM is likely to be the p53/p73 upstream activator.	Bexarotene	0-10	ATM serine/threonine kinase	Homo sapiens	59-62
19067706-14	2009	Bexarotene-mediated ataxia telangiectasia mutated protein (ATM) activation in all studied lines suggests that ATM is likely to be the p53/p73 upstream activator.	Bexarotene	0-10	ATM serine/threonine kinase	Homo sapiens	110-113
19067706-14	2009	Bexarotene-mediated ataxia telangiectasia mutated protein (ATM) activation in all studied lines suggests that ATM is likely to be the p53/p73 upstream activator.	Bexarotene	0-10	tumor protein p53	Homo sapiens	134-137
19067706-14	2009	Bexarotene-mediated ataxia telangiectasia mutated protein (ATM) activation in all studied lines suggests that ATM is likely to be the p53/p73 upstream activator.	Bexarotene	0-10	tumor protein p73	Homo sapiens	138-141
19067706-15	2009	CONCLUSIONS: Our data indicate for the first time that bexarotene exerts its effect in CTCL mainly by triggering the p53/p73-dependent cell cycle inhibition pathway, probably by upstream ATM activation.	Bexarotene	55-65	tumor protein p53	Homo sapiens	117-120
19067706-15	2009	CONCLUSIONS: Our data indicate for the first time that bexarotene exerts its effect in CTCL mainly by triggering the p53/p73-dependent cell cycle inhibition pathway, probably by upstream ATM activation.	Bexarotene	55-65	tumor protein p73	Homo sapiens	121-124
19067706-15	2009	CONCLUSIONS: Our data indicate for the first time that bexarotene exerts its effect in CTCL mainly by triggering the p53/p73-dependent cell cycle inhibition pathway, probably by upstream ATM activation.	Bexarotene	55-65	ATM serine/threonine kinase	Homo sapiens	187-190
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	23-33	insulin like growth factor binding protein 6	Homo sapiens	258-302
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	23-33	retinoic acid receptor beta	Homo sapiens	305-312
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	23-33	cyclin D1	Homo sapiens	317-326
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	35-44	insulin like growth factor binding protein 6	Homo sapiens	249-256
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	35-44	insulin like growth factor binding protein 6	Homo sapiens	258-302
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	35-44	retinoic acid receptor beta	Homo sapiens	305-312
18957410-1	2009	The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation of both estrogen receptor-negative and estrogen receptor-positive breast cancer in preclinical models and controls the expression of growth-regulatory biomarkers, such as IGFBP-6 (insulin-like growth factor-binding protein 6), RARbeta, or cyclin D1.	Bexarotene	35-44	cyclin D1	Homo sapiens	317-326
18957410-3	2009	In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300.	Bexarotene	34-44	retinoid X receptor alpha	Homo sapiens	107-115
18957410-3	2009	In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300.	Bexarotene	34-44	retinoic acid receptor beta	Homo sapiens	117-124
18957410-3	2009	In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300.	Bexarotene	34-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	126-130
18957410-3	2009	In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300.	Bexarotene	34-44	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	132-136
18957410-3	2009	In chromatin binding experiments, bexarotene increased the occupancy of the identified enhancer element by RXRalpha, RARbeta, cJun, cFos, and p300.	Bexarotene	34-44	E1A binding protein p300	Homo sapiens	142-146
18957410-4	2009	In normal mammary epithelial cells and T47D breast cancer cells, small interfering RNA-mediated knockdown of all RXR isoforms or RARbeta, but not RARalpha or RARgamma alone, blocked the induction of IGFBP-6 by bexarotene.	Bexarotene	210-220	retinoid X receptor alpha	Homo sapiens	113-116
18957410-4	2009	In normal mammary epithelial cells and T47D breast cancer cells, small interfering RNA-mediated knockdown of all RXR isoforms or RARbeta, but not RARalpha or RARgamma alone, blocked the induction of IGFBP-6 by bexarotene.	Bexarotene	210-220	insulin like growth factor binding protein 6	Homo sapiens	199-206
18773928-8	2008	Of all dual treatments, those with the RXR agonist Bexarotene, resulted in the highest level of phosphorylated Smad2, a 7-fold increase over TGFbeta2 alone.	Bexarotene	51-61	SMAD family member 2	Mus musculus	111-116
19016373-3	2009	OBJECTIVE: To evaluate the efficacy and safety of an oral bexarotene and methotrexate combination for the treatment of refractory CTCL.	Bexarotene	58-68	TSPY like 2	Homo sapiens	130-134
19016373-4	2009	METHOD: A retrospective study was carried out of 12 patients with refractory stage CTCL treated with an oral combination of bexarotene and methotrexate from 2000 to 2007.	Bexarotene	124-134	TSPY like 2	Homo sapiens	83-87
19016373-5	2009	RESULTS: Twelve patients with CTCL stage IA-IIB disease who received a combination of bexarotene and methotrexate were identified.	Bexarotene	86-96	TSPY like 2	Homo sapiens	30-34
19016373-13	2009	CONCLUSION: An oral bexarotene and methotrexate combination may be a promising future alternative to monotherapy for the treatment of CTCL, but further studies are required.	Bexarotene	20-30	TSPY like 2	Homo sapiens	134-138
18773928-8	2008	Of all dual treatments, those with the RXR agonist Bexarotene, resulted in the highest level of phosphorylated Smad2, a 7-fold increase over TGFbeta2 alone.	Bexarotene	51-61	transforming growth factor, beta 2	Mus musculus	141-149
18489056-5	2008	We hypothesize that combination of the high-dose fenofibrate (400 mg) with the retinoid X receptor ligand bexarotene and vorinostat might have induced an increased rate of apoptosis in lymphoma cells in our patient resulting in an extensive release of lymphoma antigens.	Bexarotene	106-116	retinoid X receptor alpha	Homo sapiens	79-98
19074853-11	2008	Treatment with the retinoid X receptor agonist bexarotene induced UBE1L and reduced cyclin D1 immunoblot expression.	Bexarotene	47-57	retinoid X receptor alpha	Homo sapiens	19-38
19074853-11	2008	Treatment with the retinoid X receptor agonist bexarotene induced UBE1L and reduced cyclin D1 immunoblot expression.	Bexarotene	47-57	ubiquitin like modifier activating enzyme 7	Homo sapiens	66-71
19074853-11	2008	Treatment with the retinoid X receptor agonist bexarotene induced UBE1L and reduced cyclin D1 immunoblot expression.	Bexarotene	47-57	cyclin D1	Homo sapiens	84-93
18559673-0	2008	Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.	Bexarotene	36-46	retinoid X receptor alpha	Homo sapiens	81-90
18559673-1	2008	The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL).	Bexarotene	18-28	TSPY like 2	Homo sapiens	101-105
18559673-1	2008	The oral rexinoid bexarotene (Targretin) is widely used for treatment of cutaneous T-cell lymphomas (CTCL).	Bexarotene	30-39	TSPY like 2	Homo sapiens	101-105
18559673-8	2008	We assessed RXR-alpha and RXR-beta expression by Western blot analysis and found that resistant cells had significantly decreased RXR-alpha expression compared with pretherapy bexarotene-sensitive cells.	Bexarotene	176-186	retinoid X receptor beta	Homo sapiens	26-34
18559673-9	2008	Our findings indicate that reduced expression of the RXR-alpha receptor subunit may represent a mechanism for resistance to bexarotene in T-cell malignancies.	Bexarotene	124-134	retinoid X receptor alpha	Homo sapiens	53-62
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	30-40	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	30-40	retinoid X receptor alpha	Homo sapiens	151-154
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	42-49	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	42-49	retinoid X receptor alpha	Homo sapiens	151-154
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	50-59	nuclear receptor subfamily 1 group I member 2	Homo sapiens	143-146
18544536-6	2008	Interestingly, two rexinoids, bexarotene (LGD1069/Targretin) and LG100268, caused a rapid and sustained decrease in the protein levels of both SXR and RXR.	Bexarotene	50-59	retinoid X receptor alpha	Homo sapiens	151-154
19074853-13	2008	Increased UBE1L with reduced cyclin D1 and Ki-67 expression occurred in human lung cancer when a therapeutic bexarotene intratumoral level was achieved.	Bexarotene	109-119	ubiquitin like modifier activating enzyme 7	Homo sapiens	10-15
19074853-13	2008	Increased UBE1L with reduced cyclin D1 and Ki-67 expression occurred in human lung cancer when a therapeutic bexarotene intratumoral level was achieved.	Bexarotene	109-119	cyclin D1	Homo sapiens	29-38
18615708-0	2008	CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.	Bexarotene	57-67	CD8a molecule	Homo sapiens	0-3
18615708-2	2008	Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	54-58
18615708-3	2008	Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.	Bexarotene	86-96	CD8a molecule	Homo sapiens	37-40
18615708-3	2008	Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.	Bexarotene	86-96	TSPY like 2	Homo sapiens	42-46
18429646-1	2008	BACKGROUND: The new rexinoid bexarotene is a retinoid X receptor antagonist and immune response modifier.	Bexarotene	29-39	retinoid X receptor alpha	Homo sapiens	45-64
17986279-1	2008	OBJECTIVE: To evaluate the effects of pretreatment with the retinoid X receptor (RXR) agonist bexarotene on the efficacy of radioiodine therapy for metastases of differentiated thyroid carcinoma (DTC) with limited uptake of radioiodine (I-131).	Bexarotene	94-104	retinoid X receptor alpha	Homo sapiens	60-79
17986279-1	2008	OBJECTIVE: To evaluate the effects of pretreatment with the retinoid X receptor (RXR) agonist bexarotene on the efficacy of radioiodine therapy for metastases of differentiated thyroid carcinoma (DTC) with limited uptake of radioiodine (I-131).	Bexarotene	94-104	retinoid X receptor alpha	Homo sapiens	81-84
17849452-6	2008	The expression of 26 genes was decreased in lung tumors, whereas only two genes, Apolipoprotein D and CYP26b, had their mRNA expression increased by bexarotene.	Bexarotene	149-159	apolipoprotein D	Mus musculus	81-97
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	caspase 3	Mus musculus	44-53
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	DNA methyltransferase 3A	Mus musculus	55-62
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	64-67
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	baculoviral IAP repeat-containing 5	Mus musculus	73-81
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	cyclin E1	Mus musculus	116-125
17849452-8	2008	Bexarotene decreased the mRNA expression of Caspase-3, Dnmt-3a, EP3, and survivin, as well as the expression of the Cyclin E1, estrogen receptor-alpha, and iNOS genes.	Bexarotene	0-10	estrogen receptor 1 (alpha)	Mus musculus	127-150
17849452-9	2008	Bexarotene had a greater effect in decreasing the expression of Caspase-3, Cyclin E1, Dnmt-3a, EP3, iNOS, and survivin, when administered to mice with established tumors than when administered to mice while tumors were emerging.	Bexarotene	0-10	caspase 3	Mus musculus	64-73
17849452-9	2008	Bexarotene had a greater effect in decreasing the expression of Caspase-3, Cyclin E1, Dnmt-3a, EP3, iNOS, and survivin, when administered to mice with established tumors than when administered to mice while tumors were emerging.	Bexarotene	0-10	cyclin E1	Mus musculus	75-84
17849452-9	2008	Bexarotene had a greater effect in decreasing the expression of Caspase-3, Cyclin E1, Dnmt-3a, EP3, iNOS, and survivin, when administered to mice with established tumors than when administered to mice while tumors were emerging.	Bexarotene	0-10	DNA methyltransferase 3A	Mus musculus	86-93
17849452-9	2008	Bexarotene had a greater effect in decreasing the expression of Caspase-3, Cyclin E1, Dnmt-3a, EP3, iNOS, and survivin, when administered to mice with established tumors than when administered to mice while tumors were emerging.	Bexarotene	0-10	prostaglandin E receptor 3 (subtype EP3)	Mus musculus	95-98
17849452-9	2008	Bexarotene had a greater effect in decreasing the expression of Caspase-3, Cyclin E1, Dnmt-3a, EP3, iNOS, and survivin, when administered to mice with established tumors than when administered to mice while tumors were emerging.	Bexarotene	0-10	baculoviral IAP repeat-containing 5	Mus musculus	110-118
18335654-3	2008	Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	28-47
18335654-3	2008	Bexarotene gel is a topical retinoid X receptor (RXR) agonist with activity on the follicular unit that has not been previously reported in the management of FME The case of a 73-year-old male with FMF that responded to bexarotene gel is presented.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	49-52
18560232-2	2008	Rosiglitazone, a PPAR-gamma ligand, is approved for treatment of insulin-resistant diabetes, and bexarotene, a RXR ligand, is approved for treatment of cutaneous T-cell lymphoma.	Bexarotene	97-107	retinoid X receptor alpha	Homo sapiens	111-114
17553039-4	2007	Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced-stage CTCL and in the U.S.A. for refractory CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	140-144
18181037-0	2008	Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.	Bexarotene	103-113	retinoid X receptor alpha	Homo sapiens	75-94
18405181-0	2008	Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.	Bexarotene	10-20	TNF receptor superfamily member 8	Homo sapiens	47-51
18405184-0	2008	Treatment of Sezary syndrome with bexarotene after IFNalpha and methotrexate failure.	Bexarotene	34-44	interferon alpha 1	Homo sapiens	51-59
18405187-0	2008	Bexarotene monotherapy for epidermotropic CD8+ CTCL.	Bexarotene	0-10	CD8a molecule	Homo sapiens	42-45
18405187-0	2008	Bexarotene monotherapy for epidermotropic CD8+ CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	47-51
18278999-1	2007	The retinoid X receptor-selective ligands has been used for advanced stages of cutaneous T-cell lymphoma refractory to previous systemic therapy, being bexarotene the first drug in this group approved in Europe.	Bexarotene	152-162	retinoid X receptor alpha	Homo sapiens	4-23
17553039-4	2007	Bexarotene, a novel rexinoid, is an oral, noncytotoxic drug that has been approved in Europe for the treatment of refractory advanced-stage CTCL and in the U.S.A. for refractory CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	178-182
17553039-5	2007	We provide guidance on the use of bexarotene in the management of CTCL, based on data from phase II/III clinical trials and the authors" clinical experience, and suggest how the potential of the drug can be maximized.	Bexarotene	34-44	TSPY like 2	Homo sapiens	66-70
17553039-6	2007	The clinical trial results with bexarotene are reviewed, especially in comparison with interferon-alpha, which is the other commonly used noncytotoxic systemic therapy for CTCL.	Bexarotene	32-42	TSPY like 2	Homo sapiens	172-176
17553039-7	2007	A treatment algorithm for bexarotene in refractory CTCL is suggested.	Bexarotene	26-36	TSPY like 2	Homo sapiens	51-55
17553039-10	2007	We conclude that bexarotene is effective in the management of CTCL, and has the advantage of oral administration.	Bexarotene	17-27	TSPY like 2	Homo sapiens	62-66
17925686-2	2007	The purpose of our study was to evaluate the efficacy and safety of bexarotene, an RXR receptor-selective retinoid, in the treatment of folliculotropic lymphoma after 3 months and 6 months of therapy.	Bexarotene	68-78	retinoid X receptor alpha	Homo sapiens	83-86
17546636-0	2007	Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.	Bexarotene	0-10	C-C motif chemokine receptor 4	Homo sapiens	79-99
17546636-0	2007	Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.	Bexarotene	0-10	C-C motif chemokine ligand 17	Homo sapiens	149-155
17546636-9	2007	After treatment with bexarotene for 36-96 hr, a 28% reduction in CCR4 expression was noted (P &lt; 0.05) among the malignant population with an associated 9% decrease in chemotaxis to TARC (P &lt; 0.05).	Bexarotene	21-31	C-C motif chemokine receptor 4	Homo sapiens	65-69
17546636-9	2007	After treatment with bexarotene for 36-96 hr, a 28% reduction in CCR4 expression was noted (P &lt; 0.05) among the malignant population with an associated 9% decrease in chemotaxis to TARC (P &lt; 0.05).	Bexarotene	21-31	C-C motif chemokine ligand 17	Homo sapiens	184-188
17546636-10	2007	Our results show that bexarotene may inhibit malignant cell trafficking to the skin through an ability to suppress CCR4 expression among Sezary syndrome lymphocytes.	Bexarotene	22-32	C-C motif chemokine receptor 4	Homo sapiens	115-119
17440015-1	2007	OBJECTIVE: Therapy with the retinoid X receptor agonist bexarotene is associated with hypothyroidism caused by decreased pituitary TSH secretion.	Bexarotene	56-66	retinoid X receptor alpha	Homo sapiens	28-47
17515523-0	2007	Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome.	Bexarotene	50-59	CD4 molecule	Homo sapiens	82-85
17763605-6	2007	Bexarotene is indicated in CTCL patients who are refractory to at least one prior systemic therapy.	Bexarotene	0-10	TSPY like 2	Homo sapiens	27-31
17483357-0	2007	Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	45-64
17366595-1	2007	BACKGROUND: Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T-cell lymphoma (CTCL).	Bexarotene	12-22	TSPY like 2	Homo sapiens	135-139
17483357-0	2007	Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.	Bexarotene	12-19	retinoid X receptor alpha	Homo sapiens	45-64
17483357-0	2007	Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	45-64
17008586-5	2006	Bexarotene protects from atherosclerosis development in mice, at least in part by improving the circulating cholesterol distribution profile likely via a marked decrease of dietary cholesterol absorption caused by modulation of intestinal expression of genes recently identified as major players in this process, Niemann-Pick-C1-Like1 (NPC1L1) and CD13.	Bexarotene	0-10	NPC1 like intracellular cholesterol transporter 1	Mus musculus	313-334
17487744-0	2007	Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines.	Bexarotene	24-34	TNF superfamily member 10	Homo sapiens	74-79
17487744-4	2007	The leukemic cell lines KG1a (apoptosis-resistant) and ML-1 (apoptosis-sensitive) were treated with the RXR-specific retinoid bexarotene, TRAIL, or both, and apoptosis was determined.	Bexarotene	126-136	retinoid X receptor alpha	Homo sapiens	104-107
17487744-5	2007	In KG1a cells, bexarotene downregulated FLIP(Long) and activated caspase-8, thereby allowing for TRAIL-triggered apoptosis.	Bexarotene	15-25	CASP8 and FADD like apoptosis regulator	Homo sapiens	40-50
17487744-5	2007	In KG1a cells, bexarotene downregulated FLIP(Long) and activated caspase-8, thereby allowing for TRAIL-triggered apoptosis.	Bexarotene	15-25	caspase 8	Homo sapiens	65-74
17487744-5	2007	In KG1a cells, bexarotene downregulated FLIP(Long) and activated caspase-8, thereby allowing for TRAIL-triggered apoptosis.	Bexarotene	15-25	TNF superfamily member 10	Homo sapiens	97-102
17487744-7	2007	In unmodified ML-1 cells bexarotene enhanced programmed cell death via truncation of Bid and release of cytochrome C.	Bexarotene	25-35	interleukin 17F	Homo sapiens	14-18
17487744-7	2007	In unmodified ML-1 cells bexarotene enhanced programmed cell death via truncation of Bid and release of cytochrome C.	Bexarotene	25-35	BH3 interacting domain death agonist	Homo sapiens	85-88
17487744-7	2007	In unmodified ML-1 cells bexarotene enhanced programmed cell death via truncation of Bid and release of cytochrome C.	Bexarotene	25-35	cytochrome c, somatic	Homo sapiens	104-116
17487744-9	2007	Thus, the effect of bexarotene on TRAIL-mediated programmed cell death involved proximal events of the extrinsic pathway; however, downstream signals involved the intrinsic pathway in ML-1 but not in KG1a cells.	Bexarotene	20-30	TNF superfamily member 10	Homo sapiens	34-39
17363535-1	2007	PURPOSE: Bexarotene is a rexinoid (selective retinoid X receptor agonist) that affects proliferation, differentiation, and apoptosis in preclinical studies.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	45-64
17363535-8	2007	RESULTS: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells.	Bexarotene	9-19	cyclin D1	Homo sapiens	67-76
17363535-8	2007	RESULTS: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells.	Bexarotene	9-19	cyclin D3	Homo sapiens	78-87
17363535-8	2007	RESULTS: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells.	Bexarotene	9-19	epidermal growth factor receptor	Homo sapiens	95-127
17363535-8	2007	RESULTS: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells.	Bexarotene	9-19	epidermal growth factor receptor	Homo sapiens	129-133
17363535-8	2007	RESULTS: Bexarotene-induced dosage-dependent repression of growth, cyclin D1, cyclin D3, total epidermal growth factor receptor (EGFR), and phospho-EGFR expression in BEAS-2B, BEAS-2B-R1, A427, and H358, but not H226 cells.	Bexarotene	9-19	epidermal growth factor receptor	Homo sapiens	148-152
17204865-0	2007	Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene.	Bexarotene	114-124	retinoid X receptor alpha	Homo sapiens	86-105
17204865-2	2007	In vitro, bexarotene, a retinoid X receptor agonist inhibits the proliferation of non-M3 AML cell lines and induces differentiation of leukemic blasts from patients.	Bexarotene	10-20	retinoid X receptor alpha	Homo sapiens	24-43
17474355-7	2007	The synthetic retinoid bexarotene (Targretin) is taken orally and produces high response rates in CTCL, with a good long-term tolerability profile.	Bexarotene	23-33	TSPY like 2	Homo sapiens	98-102
17474355-7	2007	The synthetic retinoid bexarotene (Targretin) is taken orally and produces high response rates in CTCL, with a good long-term tolerability profile.	Bexarotene	35-44	TSPY like 2	Homo sapiens	98-102
17008586-5	2006	Bexarotene protects from atherosclerosis development in mice, at least in part by improving the circulating cholesterol distribution profile likely via a marked decrease of dietary cholesterol absorption caused by modulation of intestinal expression of genes recently identified as major players in this process, Niemann-Pick-C1-Like1 (NPC1L1) and CD13.	Bexarotene	0-10	NPC1 like intracellular cholesterol transporter 1	Mus musculus	336-342
17008586-5	2006	Bexarotene protects from atherosclerosis development in mice, at least in part by improving the circulating cholesterol distribution profile likely via a marked decrease of dietary cholesterol absorption caused by modulation of intestinal expression of genes recently identified as major players in this process, Niemann-Pick-C1-Like1 (NPC1L1) and CD13.	Bexarotene	0-10	alanyl (membrane) aminopeptidase	Mus musculus	348-352
16634713-5	2006	Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	42-61
17014481-3	2006	Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	retinoid X receptor alpha	Homo sapiens	69-88
17014481-3	2006	Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	153-157
17014481-3	2006	Orally administered bexarotene, the first synthetic highly selective retinoid X receptor retinoid to be approved by the Food and Drug Administration for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	236-240
16844539-0	2006	Bexarotene and systemic disease progression in CTCL?	Bexarotene	0-10	TSPY like 2	Homo sapiens	47-51
16729120-1	2006	Heterodimeric compounds based on tethering the PPARgamma agonist Rosiglitazone to the RXR ligand Targretin have been prepared.	Bexarotene	97-106	peroxisome proliferator activated receptor gamma	Homo sapiens	47-56
16271436-1	2006	This study evaluated the anti-tumor efficacy of combining the RXR agonist, bexarotene, with the PPARgamma agonist, rosiglitazone, in colon cancer.	Bexarotene	75-85	retinoid X receptor alpha	Homo sapiens	62-65
16882161-1	2006	Bexarotene is an oral retinoid therapy that is effective for the treatment of early and advanced-stage cutaneous T-cell lymphoma (CTCL) in patients who have failed on other therapies.	Bexarotene	0-10	TSPY like 2	Homo sapiens	130-134
16882161-3	2006	A pragmatic strategy for minimizing bexarotene-associated hypertriglyceridaemia and hypothyroidism is suggested, based on data from the studies with bexarotene in CTCL and on day-to-day experience with this agent in the clinical setting.	Bexarotene	36-46	TSPY like 2	Homo sapiens	163-167
16634713-7	2006	New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-alpha, denileukin diftitox or phototherapy.	Bexarotene	51-61	interferon alpha 1	Homo sapiens	119-128
16495926-0	2006	A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.	Bexarotene	40-50	retinoid X receptor alpha	Homo sapiens	12-31
16495926-0	2006	A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours.	Bexarotene	61-70	retinoid X receptor alpha	Homo sapiens	12-31
16495926-1	2006	The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours.	Bexarotene	76-86	retinoid X receptor alpha	Homo sapiens	48-67
16495926-3	2006	In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent.	Bexarotene	54-64	vascular endothelial growth factor A	Homo sapiens	108-142
16495926-8	2006	The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma.	Bexarotene	15-25	peroxisome proliferator activated receptor gamma	Homo sapiens	127-175
16247446-10	2006	Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by approximately 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice.	Bexarotene	13-23	transformation related protein 53, pseudogene	Mus musculus	106-109
16247446-10	2006	Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by approximately 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice.	Bexarotene	13-23	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	116-121
16247446-10	2006	Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by approximately 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice.	Bexarotene	13-23	transformation related protein 53, pseudogene	Mus musculus	133-136
16247446-10	2006	Furthermore, bexarotene reduced the progression of adenoma to adenocarcinoma by approximately 50% in both p53(wt/wt)K-ras(ko/wt) and p53(wt/wt)K-ras(wt/wt) mice.	Bexarotene	13-23	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	143-148
15833882-3	2005	LGD1069 (Bexarotene) is a potent RXR-selective retinoid with reduced toxicity compared with naturally occurring retinoids.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	33-36
16245282-0	2006	A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.	Bexarotene	40-50	retinoid X receptor alpha	Homo sapiens	12-31
16245282-0	2006	A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.	Bexarotene	61-70	retinoid X receptor alpha	Homo sapiens	12-31
16245282-1	2006	BACKGROUND: We previously reported that a retinoid X receptor agonist bexarotene prevented and overcame acquired drug resistance in advanced breast cancer and non-small cell lung cancer.	Bexarotene	70-80	retinoid X receptor alpha	Homo sapiens	42-61
16516671-4	2006	Recently, bexarotene, a selective antagonist of the retinoid X receptor, has been approved in the treatment of patients with cutaneous T-cell lymphoma.	Bexarotene	10-20	retinoid X receptor alpha	Homo sapiens	52-71
16710601-0	2006	Extracutaneous tumour mass following bexarotene and interferon therapy of primary cutaneous CD30+ large cell lymphoma.	Bexarotene	37-47	TNF receptor superfamily member 8	Homo sapiens	92-96
16476317-3	2005	Bexarotene is an X receptor-specific retinoid with anti-tumor activity.	Bexarotene	0-10	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	17-27
16314636-2	2005	The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro.	Bexarotene	14-24	cyclin D1	Homo sapiens	36-45
16314636-2	2005	The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in vitro.	Bexarotene	14-24	epidermal growth factor receptor	Homo sapiens	50-54
15993980-0	2005	The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.	Bexarotene	32-42	retinoid X receptor alpha	Homo sapiens	4-23
15993980-0	2005	The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.	Bexarotene	44-53	retinoid X receptor alpha	Homo sapiens	4-23
15993980-1	2005	This study was designed to evaluate, using preclinical models of non-small cell lung cancer (NSCLC), the growth inhibitory effects of the retinoid X receptor (RXR) agonist bexarotene (LGD1069, Targretin) in combination with cytotoxic agents currently used as standard first-line therapy in advanced disease.	Bexarotene	172-182	retinoid X receptor alpha	Homo sapiens	159-162
15993980-6	2005	These results demonstrate that bexarotene can cooperate with widely used cytotoxic agents to decrease the growth of NSCLC tumor cells both in vitro and in vivo, and suggest the potential benefit of adding a RXR-selective agonist in combination with chemotherapy for NSCLC treatment.	Bexarotene	31-41	retinoid X receptor alpha	Homo sapiens	207-210
15811959-2	2005	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	75-85	retinoid X receptor alpha	Homo sapiens	39-58
15811959-2	2005	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	75-85	retinoid X receptor alpha	Homo sapiens	60-63
15811959-2	2005	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	75-85	interleukin 2 receptor subunit alpha	Homo sapiens	173-176
15811959-2	2005	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	75-85	interleukin 2 receptor subunit beta	Homo sapiens	181-184
15811959-2	2005	In vitro studies demonstrated that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 10(-6) M to 10(-8) M, upregulated both the p55 and p75 subunits of the IL-2R and enhanced 5- to 10-fold the susceptibility of T-cell leukemia cells to denileukin diftitox.	Bexarotene	75-85	interleukin 2 receptor subunit beta	Homo sapiens	201-206
15811959-5	2005	Modulation of IL-2R expression was observed at or above a bexarotene dose of 150 mg/day.	Bexarotene	58-68	interleukin 2 receptor subunit beta	Homo sapiens	14-19
15811959-7	2005	Our results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of CD25 expression on circulating leukemia cells.	Bexarotene	141-151	interleukin 2 receptor subunit alpha	Homo sapiens	191-195
15897247-0	2005	The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.	Bexarotene	42-52	retinoid X receptor alpha	Homo sapiens	14-33
15897247-0	2005	The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.	Bexarotene	63-72	retinoid X receptor alpha	Homo sapiens	14-33
15897247-2	2005	We reported previously that the retinoid X receptor-selective agonist bexarotene (LGD1069, Targretin) was efficacious in treating animal models of tamoxifen-resistant breast cancer.	Bexarotene	70-80	retinoid X receptor alpha	Homo sapiens	32-51
15897247-2	2005	We reported previously that the retinoid X receptor-selective agonist bexarotene (LGD1069, Targretin) was efficacious in treating animal models of tamoxifen-resistant breast cancer.	Bexarotene	91-100	retinoid X receptor alpha	Homo sapiens	32-51
16734503-7	2006	Recent novel developments include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL and has been shown to be effective in patients with refractory early-stage disease as well as advanced-stage disease.	Bexarotene	39-49	retinoid X receptor alpha	Homo sapiens	53-72
16734503-7	2006	Recent novel developments include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL and has been shown to be effective in patients with refractory early-stage disease as well as advanced-stage disease.	Bexarotene	39-49	TSPY like 2	Homo sapiens	127-131
16734503-9	2006	Oral bexarotene and topical bexarotene have been approved by the US FDA for the treatment of refractory CTCL.	Bexarotene	5-15	TSPY like 2	Homo sapiens	104-108
16734503-9	2006	Oral bexarotene and topical bexarotene have been approved by the US FDA for the treatment of refractory CTCL.	Bexarotene	28-38	TSPY like 2	Homo sapiens	104-108
16310082-0	2005	Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sezary syndrome.	Bexarotene	54-64	CD8a molecule	Homo sapiens	15-18
15948982-1	2005	BACKGROUND: Apoptosis of malignant cells has been suggested as an important mechanism of the action of bexarotene in the treatment of cutaneous T-cell lymphoma (CTCL).	Bexarotene	103-113	TSPY like 2	Homo sapiens	161-165
15591091-11	2005	Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels.	Bexarotene	96-105	insulin-like growth factor 1	Rattus norvegicus	23-27
15781672-6	2005	Bexarotene inhibited mitogen-induced interleukin 4 production by the peripheral blood cells of patients with Sezary syndrome, and this effect correlated with sensitivity of patients" cells to apoptosis.	Bexarotene	0-10	interleukin 4	Homo sapiens	37-50
15781672-9	2005	Interleukin 4 production, which can play a role in the systemic immunosuppression that characterizes advancing Sezary syndrome, may be inhibited by bexarotene.	Bexarotene	148-158	interleukin 4	Homo sapiens	0-13
15591091-11	2005	Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels.	Bexarotene	96-105	insulin-like growth factor 1	Rattus norvegicus	204-208
15663654-1	2005	BACKGROUND: A 63-year-old man with therapy-resistant Sezary syndrome was enrolled in a multicenter trial of oral bexarotene for advanced-stage cutaneous T-cell lymphoma (CTCL).	Bexarotene	113-123	TSPY like 2	Homo sapiens	170-174
15663654-8	2005	Further studies on the interaction between the skin, lymph nodes, and peripheral blood compartments during bexarotene treatment in this subset of patients with CTCL are needed.	Bexarotene	107-117	TSPY like 2	Homo sapiens	160-164
15623650-0	2004	A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.	Bexarotene	40-50	retinoid X receptor alpha	Homo sapiens	12-31
15623650-0	2004	A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.	Bexarotene	52-61	retinoid X receptor alpha	Homo sapiens	12-31
14988678-2	2004	In December 1999 a new retinoid, bexarotene, was approved by the US Food and Drug Administration for the treatment of CTCL.	Bexarotene	33-43	TSPY like 2	Homo sapiens	118-122
15389192-2	2004	OBJECTIVE: To evaluate the efficacy of combination therapy with bexarotene and psoralen plus ultraviolet A (PUVA) in treating patients with cutaneous T-cell lymphoma (CTCL) that recurred following monotherapy with multiple agents, including electron-beam irradiation, interferon, PUVA, and topical steroids.	Bexarotene	64-74	TSPY like 2	Homo sapiens	167-171
15389192-4	2004	METHODS: Retrospective chart review analysis of eight patients with CTCL ranging from stage Ia to IIb who failed multiple single-agent treatment regimens treated with low-dose oral bexarotene and PUVA combination therapy.	Bexarotene	181-191	TSPY like 2	Homo sapiens	68-72
15389192-6	2004	CONCLUSION: In view of its good safety profile, combination therapy with bexarotene and PUVA may be considered for patients with treatment resistant CTCL refractory to monotherapy.	Bexarotene	73-83	TSPY like 2	Homo sapiens	149-153
15056048-1	2004	Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	114-133
15056048-1	2004	Bexarotene (Targretin, Ligand Pharmaceuticals Inc.) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids.	Bexarotene	12-21	retinoid X receptor alpha	Homo sapiens	114-133
15314509-5	2004	The recent availability and demonstrated efficacy of the oral RXR retinoid, bexarotene, has altered the treatment paradigm of early-stage patients who would not otherwise be exposed to systemic therapies.	Bexarotene	76-86	retinoid X receptor alpha	Homo sapiens	62-65
15280844-1	2004	BACKGROUND: Bexarotene, a novel and unique synthetic P, RXR-selective retinoid, is available as a treatment for cutaneous T-cell lymphoma.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	56-59
15280845-1	2004	BACKGROUND: Bexarotene, a novel synthetic retinoid X receptor (RXR)-selective retinoid, has been reported to have antiproliferative and apoptotic stimulating effects in cutaneous T-cell lymphoma.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	42-61
15280845-1	2004	BACKGROUND: Bexarotene, a novel synthetic retinoid X receptor (RXR)-selective retinoid, has been reported to have antiproliferative and apoptotic stimulating effects in cutaneous T-cell lymphoma.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	63-66
15280845-7	2004	RESULTS: Significant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, epidermal CD8, and inflammation scores were seen after bexarotene treatment in combination with a significant increase in keratin 10.	Bexarotene	139-149	keratin 16	Homo sapiens	42-52
15280845-7	2004	RESULTS: Significant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, epidermal CD8, and inflammation scores were seen after bexarotene treatment in combination with a significant increase in keratin 10.	Bexarotene	139-149	CD4 molecule	Homo sapiens	79-82
15280845-7	2004	RESULTS: Significant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, epidermal CD8, and inflammation scores were seen after bexarotene treatment in combination with a significant increase in keratin 10.	Bexarotene	139-149	CD8a molecule	Homo sapiens	94-97
15280845-7	2004	RESULTS: Significant reductions in Ki-67, keratin 16, transglutaminase, dermal CD4, epidermal CD8, and inflammation scores were seen after bexarotene treatment in combination with a significant increase in keratin 10.	Bexarotene	139-149	keratin 10	Homo sapiens	206-216
15245439-2	2004	Bexarotene is an RXR-selective retinoid that can induce apoptosis of mycosis fungoides (MF) and Sezary syndrome (SS) cells.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	17-20
14988678-3	2004	At the manufacturer"s recommended dose of bexarotene (300 mg/m(2) of body surface area), it has proven to be a highly effective therapy for all stages of CTCL.	Bexarotene	42-52	TSPY like 2	Homo sapiens	154-158
14710892-8	2003	The new generation of retinoids, the RXR selective agonists like bexarotene, represent a promising approach for refractory or persistent MF that is unresponsive to first-line therapies.	Bexarotene	65-75	retinoid X receptor alpha	Homo sapiens	37-40
14996618-3	2004	Examples include the anticancer and retinoic X receptor (RXR)-targeting bexarotene (Targretin, Ligand Pharmaceuticals, Inc.) and the antidiabetic and peroxisome proliferator-activated receptor (PPAR)-gamma-targeting thiaozolidinediones.	Bexarotene	84-93	retinoid X receptor alpha	Homo sapiens	57-60
14996618-3	2004	Examples include the anticancer and retinoic X receptor (RXR)-targeting bexarotene (Targretin, Ligand Pharmaceuticals, Inc.) and the antidiabetic and peroxisome proliferator-activated receptor (PPAR)-gamma-targeting thiaozolidinediones.	Bexarotene	72-82	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	45-55
14996618-3	2004	Examples include the anticancer and retinoic X receptor (RXR)-targeting bexarotene (Targretin, Ligand Pharmaceuticals, Inc.) and the antidiabetic and peroxisome proliferator-activated receptor (PPAR)-gamma-targeting thiaozolidinediones.	Bexarotene	72-82	retinoid X receptor alpha	Homo sapiens	57-60
14996618-3	2004	Examples include the anticancer and retinoic X receptor (RXR)-targeting bexarotene (Targretin, Ligand Pharmaceuticals, Inc.) and the antidiabetic and peroxisome proliferator-activated receptor (PPAR)-gamma-targeting thiaozolidinediones.	Bexarotene	84-93	xenotropic and polytropic retrovirus receptor 1	Homo sapiens	45-55
14576658-1	2003	OBJECTIVES: We sought to determine the safety and efficacy of topical bexarotene (Targretin; Ligand Pharmaceuticals, La Jolla, Calif) gel 1% in patients with refractory or persistent early-stage cutaneous T-cell lymphoma.	Bexarotene	70-80	CCR4-NOT transcription complex subunit 8	Homo sapiens	127-132
12852367-6	2003	In clinical trials, bexarotene gel demonstrated efficacy for the topical treatment of cutaneous lesions in patients with stage IA or IB CTCL who have refractory or persistent disease following other therapies or who cannot tolerate other therapies.	Bexarotene	20-30	TSPY like 2	Homo sapiens	136-140
14510982-2	2003	Bexarotene is a novel retinoid X receptor (RXR)-selective ligand.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	22-41
14510982-2	2003	Bexarotene is a novel retinoid X receptor (RXR)-selective ligand.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	43-46
14510982-15	2003	CONCLUSIONS: The present study indicates a direct effect of RXR activation by bexarotene on the transition of proliferation-associated keratinization into normal keratinization.	Bexarotene	78-88	retinoid X receptor alpha	Homo sapiens	60-63
12852367-10	2003	The availability of bexarotene gel provides patients and physicians with a new skin-directed treatment option for early stage CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	126-130
12637463-1	2003	PURPOSE: Bexarotene is a retinoid X receptor-selective retinoid that has preclinical antitumor activity in breast cancer.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	25-44
14686975-3	2003	Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	retinoid X receptor alpha	Homo sapiens	69-88
12672276-1	2003	Bexarotene is a synthetic retinoid X receptor (RXR)-selective retinoid recently approved for treatment of cutaneous T-cell lymphoma.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	26-45
12672276-1	2003	Bexarotene is a synthetic retinoid X receptor (RXR)-selective retinoid recently approved for treatment of cutaneous T-cell lymphoma.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	47-50
12762834-4	2003	In this setting, the patient was treated with local radiation therapy, total-skin electron beam therapy, and therapy and maintenance with the oral retinoid-X-receptor retinoid bexarotene, and achieved a durable complete remission.	Bexarotene	176-186	retinoid X receptor alpha	Homo sapiens	147-166
12592082-2	2003	Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	29-32
12592082-2	2003	Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.	Bexarotene	12-21	retinoid X receptor alpha	Homo sapiens	29-32
14686975-3	2003	Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	128-132
14686975-3	2003	Orally administered bexarotene, the first synthetic highly selective retinoid-X-receptor retinoid to be approved by the FDA for CTCL, was shown to be active against the cutaneous manifestations of all stages of CTCL.	Bexarotene	20-30	TSPY like 2	Homo sapiens	211-215
14686975-5	2003	Bexarotene treatment induces apoptosis of CTCL cells with down-regulation of its receptors and of survivin, an inhibitor of apoptosis.	Bexarotene	0-10	TSPY like 2	Homo sapiens	42-46
15202526-7	2003	Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL.	Bexarotene	38-48	TSPY like 2	Homo sapiens	30-34
15202526-7	2003	Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL.	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	52-71
15202526-7	2003	Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL.	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	73-76
15202526-7	2003	Among the novel therapies for CTCL is bexarotene, a retinoid X-receptor (RXR)-selective agonist, which has demonstrated efficacy in advanced refractory CTCL.	Bexarotene	38-48	TSPY like 2	Homo sapiens	152-156
12847736-1	2002	Bexarotene has recently been approved in the United States and Europe as a single orally administered retinoid for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.	Bexarotene	0-10	TSPY like 2	Homo sapiens	159-163
12399758-1	2002	BACKGROUND: Bexarotene (Targretin oral capsules), the first RXR-selective retinoid "rexinoid" approved for all stages of cutaneous T-cell lymphoma (CTCL), had a response rate (RR) of 45% at the optimal dose of 300 mg/m(2) per day in 2 multicenter trials.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	60-63
12399758-16	2002	CONCLUSION: This single-center study supports the safety and efficacy of bexarotene as both a monotherapy and a combination therapy for CTCL.	Bexarotene	73-83	TSPY like 2	Homo sapiens	136-140
12399758-19	2002	When bexarotene is combined with other active CTCL therapies, higher RRs were achieved in patients with advanced disease, without unacceptable side effects.	Bexarotene	5-15	TSPY like 2	Homo sapiens	46-50
12148901-0	2002	Response of CD30+ large cell lymphoma of skin to bexarotene.	Bexarotene	49-59	TNF receptor superfamily member 8	Homo sapiens	12-16
12149223-4	2002	Exposure to 10(-6) to 10(-10) M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.	Bexarotene	32-42	interleukin 2 receptor subunit alpha	Homo sapiens	121-124
12149223-4	2002	Exposure to 10(-6) to 10(-10) M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.	Bexarotene	32-42	interleukin 2 receptor subunit beta	Homo sapiens	129-132
12149223-4	2002	Exposure to 10(-6) to 10(-10) M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.	Bexarotene	32-42	interleukin 2 receptor subunit alpha	Homo sapiens	149-154
12149223-4	2002	Exposure to 10(-6) to 10(-10) M bexarotene or Panretin for 48 hours was associated with increased expression of both the p55 and p75 subunits of the IL-2R in T-cell leukemias and p75 in B-cell leukemias.	Bexarotene	32-42	interleukin 2 receptor subunit beta	Homo sapiens	179-182
12130551-1	2002	The retinoid X receptor (RXR) agonist bexarotene can cause clinically significant hypothyroidism in cutaneous T cell lymphoma patients.	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	4-23
12130551-1	2002	The retinoid X receptor (RXR) agonist bexarotene can cause clinically significant hypothyroidism in cutaneous T cell lymphoma patients.	Bexarotene	38-48	retinoid X receptor alpha	Homo sapiens	25-28
12006543-1	2002	PURPOSE: Bexarotene is the first synthetic rexinoid approved for the treatment of all stages of cutaneous T-cell lymphoma (CTCL) however the mechanism of bexarotene action is unknown.	Bexarotene	9-19	TSPY like 2	Homo sapiens	123-127
12006543-3	2002	EXPERIMENTAL DESIGN: CTCL cells were treated with 0.1, 1, and 10 microM bexarotene for 24, 48, 72, and 96 h. Apoptosis was determined by flow-cytometry analysis of sub-G(1) hypodiploid nuclei and annexin V binding populations.	Bexarotene	72-82	TSPY like 2	Homo sapiens	21-25
12006543-6	2002	Bexarotene treatment suppressed the expression of retinoid X receptor alpha and retinoic acid receptor alpha proteins in all three lines compared with untreated controls.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	50-75
12006543-6	2002	Bexarotene treatment suppressed the expression of retinoid X receptor alpha and retinoic acid receptor alpha proteins in all three lines compared with untreated controls.	Bexarotene	0-10	retinoic acid receptor alpha	Homo sapiens	80-108
12006543-7	2002	Bexarotene treatment decreased the protein levels of survivin, activated caspase-3, and cleaved poly(ADP-Ribose) polymerase, but had no obvious effect on expression of Fas/Fas ligand and bcl-2 proteins in all three CTCL lines.	Bexarotene	0-10	caspase 3	Homo sapiens	73-82
12006543-7	2002	Bexarotene treatment decreased the protein levels of survivin, activated caspase-3, and cleaved poly(ADP-Ribose) polymerase, but had no obvious effect on expression of Fas/Fas ligand and bcl-2 proteins in all three CTCL lines.	Bexarotene	0-10	poly(ADP-ribose) polymerase 1	Homo sapiens	96-123
12006543-7	2002	Bexarotene treatment decreased the protein levels of survivin, activated caspase-3, and cleaved poly(ADP-Ribose) polymerase, but had no obvious effect on expression of Fas/Fas ligand and bcl-2 proteins in all three CTCL lines.	Bexarotene	0-10	TSPY like 2	Homo sapiens	215-219
12006543-8	2002	CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin.	Bexarotene	13-23	TSPY like 2	Homo sapiens	92-96
12006543-8	2002	CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin.	Bexarotene	13-23	caspase 3	Homo sapiens	142-151
12006543-8	2002	CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin.	Bexarotene	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	168-195
12006543-8	2002	CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin.	Bexarotene	13-23	retinoid X receptor alpha	Homo sapiens	227-252
12006543-8	2002	CONCLUSIONS: Bexarotene treatment at clinically relevant concentrations causes apoptosis of CTCL cell lines in association with activation of caspase-3 and cleavage of poly(ADP-Ribose) polymerase, as well as down-regulation of retinoid X receptor alpha, retinoic acid receptor alpha, and survivin.	Bexarotene	13-23	retinoic acid receptor alpha	Homo sapiens	254-282
12006543-9	2002	These findings support apoptosis as a mechanism for bexarotene therapy in CTCL.	Bexarotene	52-62	TSPY like 2	Homo sapiens	74-78
12148901-5	2002	We describe a case of CD30 positive large cell lymphoma of skin that responded to bexarotene that is recently approved for refractory mycosis fungoides.	Bexarotene	82-92	TNF receptor superfamily member 8	Homo sapiens	22-26
11902983-1	2002	OBJECTIVE: To evaluate the safety, dose tolerance, and efficacy of topical bexarotene gel in patients with early-stage cutaneous T-cell lymphoma (CTCL).	Bexarotene	75-85	TSPY like 2	Homo sapiens	146-150
11902983-14	2002	CONCLUSIONS: Bexarotene gel was well tolerated, was easily self-applied, and had a substantial response rate in treating patients with early-stage CTCL.	Bexarotene	13-23	TSPY like 2	Homo sapiens	147-151
11978140-8	2002	Recent novel developments in CTCL therapy include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL, and the topical gel formulation of bexarotene, which plays a role in treating localized lesions.	Bexarotene	55-65	TSPY like 2	Homo sapiens	29-33
11978140-8	2002	Recent novel developments in CTCL therapy include oral bexarotene, a retinoid X receptor-selective retinoid that has activity in all stages of CTCL, and the topical gel formulation of bexarotene, which plays a role in treating localized lesions.	Bexarotene	184-194	TSPY like 2	Homo sapiens	29-33
11705358-5	2001	Although milestone drugs such as bexarotene have been approved by the FDA- for treatment of CTCL, other agents such as IL-12 may also have a place in treatment of the disease.	Bexarotene	33-43	TSPY like 2	Homo sapiens	92-96
11712039-0	2001	Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.	Bexarotene	104-114	TNF receptor superfamily member 8	Homo sapiens	43-47
11573857-1	2001	OBJECTIVE: To review the preclinical and clinical information related to oral bexarotene approved by the Food and Drug Administration for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy.	Bexarotene	78-88	TSPY like 2	Homo sapiens	210-214
11573857-5	2001	An evaluation focusing on the pharmacology of bexarotene and its role in the management of the different stages of CTCL was conducted.	Bexarotene	46-56	TSPY like 2	Homo sapiens	115-119
11573857-6	2001	CONCLUSIONS: Bexarotene has demonstrated activity in the treatment of CTCL.	Bexarotene	13-23	TSPY like 2	Homo sapiens	70-74
11573857-7	2001	The oral route of administration and the adverse effect profile of bexarotene appear to make this drug a favorable option for the treatment of CTCL.	Bexarotene	67-77	TSPY like 2	Homo sapiens	143-147
11573857-9	2001	Phase III randomized studies are needed to determine the clinical benefits of bexarotene as monotherapy or combination therapy in the treatment of CTCL.	Bexarotene	78-88	TSPY like 2	Homo sapiens	147-151
11352954-1	2001	PURPOSE: Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in squamous cell cancers.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	81-100
11479234-0	2001	Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.	Bexarotene	139-148	tumor necrosis factor	Homo sapiens	14-46
11479234-0	2001	Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.	Bexarotene	139-148	epidermal growth factor receptor	Homo sapiens	47-79
11479234-0	2001	Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines.	Bexarotene	139-148	retinoid X receptor alpha	Homo sapiens	106-109
11479234-3	2001	LGD1069 (Targretin) is a potent RXR-selective retinoic acid agonist with a reduced toxicity profile compared with other nonselective retinoids.	Bexarotene	9-18	retinoid X receptor alpha	Homo sapiens	32-35
11352954-1	2001	PURPOSE: Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in squamous cell cancers.	Bexarotene	9-19	retinoid X receptor alpha	Homo sapiens	102-105
11352954-1	2001	PURPOSE: Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in squamous cell cancers.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	81-100
11352954-1	2001	PURPOSE: Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San Diego, CA) is a retinoid-X-receptor (RXR)-selective retinoid with preclinical antitumor activity in squamous cell cancers.	Bexarotene	21-30	retinoid X receptor alpha	Homo sapiens	102-105
11249708-1	2000	Bexarotene (LGD-1069), from Ligand, was the first retinoid X receptor (RXR)-selective, antitumor retinoid to enter clinical trials.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	50-69
14700480-0	2001	Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer.	Bexarotene	28-38	retinoid X receptor alpha	Homo sapiens	42-61
11520254-4	2001	The biological response-modifying treatment options currently used to treat CTCL are bexarotene, denileukin diftitox, interferon-alpha, interferon-gamma and interleukin-12, as well as extracorporeal photopheresis and phototherapy.	Bexarotene	85-95	TSPY like 2	Homo sapiens	76-80
11331325-2	2001	Safety and efficacy of a novel RXR-selective retinoid (rexinoid) bexarotene (Targretin, LGD1069; Ligand Pharmaceuticals Inc, San Diego, CA) was evaluated as a single-agent oral therapy administered once daily in an open-label study in patients with refractory advanced-stage CTCL.	Bexarotene	65-75	retinoid X receptor alpha	Homo sapiens	31-34
11331325-2	2001	Safety and efficacy of a novel RXR-selective retinoid (rexinoid) bexarotene (Targretin, LGD1069; Ligand Pharmaceuticals Inc, San Diego, CA) was evaluated as a single-agent oral therapy administered once daily in an open-label study in patients with refractory advanced-stage CTCL.	Bexarotene	77-86	retinoid X receptor alpha	Homo sapiens	31-34
11331325-10	2001	CONCLUSION: Bexarotene is the first in a novel class of pharmacologic agents, the RXR-selective retinoids, or rexinoids.	Bexarotene	12-22	retinoid X receptor alpha	Homo sapiens	82-85
11331325-11	2001	Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL.	Bexarotene	0-10	TSPY like 2	Homo sapiens	159-163
11249708-1	2000	Bexarotene (LGD-1069), from Ligand, was the first retinoid X receptor (RXR)-selective, antitumor retinoid to enter clinical trials.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	71-74
11249708-2	2000	The company launched the drug for the treatment of cutaneous T-cell lymphoma (CTCL), as Targretin capsules, in the US in January 2000 [359023].	Bexarotene	88-97	TSPY like 2	Homo sapiens	78-82
11249708-4	2000	The FDA approved Targretin capsules at the end of December 1999 for once-daily oral treatment of all stages of CTCL in patients refractory to at least one prior systemic therapy, at an initial dose of 300 mg/m2/day.	Bexarotene	17-26	TSPY like 2	Homo sapiens	111-115
11707864-1	2000	The clinical experience with bexarotene for cutaneous T-cell lymphoma (CTCL) at our center is reviewed here.	Bexarotene	29-39	TSPY like 2	Homo sapiens	71-75
11707864-4	2000	Four patients with refractory plaque CTCL were treated with bexarotene gel.	Bexarotene	60-70	TSPY like 2	Homo sapiens	37-41
11707865-5	2000	Bexarotene gel, a new topical retinoid X receptor retinoid will resolve MF lesions, reducing dermal T-cell infiltrates when used as a single agent.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	30-49
10430065-1	1999	LGD1069 [Targretin; 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl) propenyl] benzoic acid] is a novel synthetic retinoid X receptor-selective retinoid that has been recently identified.	Bexarotene	9-18	retinoid X receptor alpha	Homo sapiens	127-146
10194237-1	1999	BACKGROUND: The occurrence of symptomatic central hypothyroidism (characterized by low serum thyrotropin and thyroxine concentrations) in a patient with cutaneous T-cell lymphoma during therapy with the retinoid X receptor-selective ligand bexarotene led us to hypothesize that such ligands could reversibly suppress thyrotropin production by a thyroid hormone-independent mechanism and thus cause central hypothyroidism.	Bexarotene	240-250	retinoid X receptor alpha	Homo sapiens	203-222
10194237-9	1999	CONCLUSIONS: Hypothyroidism may develop in patients with cutaneous T-cell lymphoma who are treated with high-dose bexarotene, most likely because the retinoid X receptor-selective ligand suppresses thyrotropin secretion.	Bexarotene	114-124	retinoid X receptor alpha	Homo sapiens	150-169
9484993-4	1998	We show that the RXR ligand LGD1069 (Targretin), like gemfibrozil, can activate the PPARalpha/RXR signal-transduction pathway, including transactivation of the bifunctional enzyme or acyl-CoA oxidase response elements in a cotransfection assay.	Bexarotene	37-46	retinoid X receptor alpha	Homo sapiens	17-20
9484993-4	1998	We show that the RXR ligand LGD1069 (Targretin), like gemfibrozil, can activate the PPARalpha/RXR signal-transduction pathway, including transactivation of the bifunctional enzyme or acyl-CoA oxidase response elements in a cotransfection assay.	Bexarotene	37-46	peroxisome proliferator activated receptor alpha	Homo sapiens	84-93
9484993-4	1998	We show that the RXR ligand LGD1069 (Targretin), like gemfibrozil, can activate the PPARalpha/RXR signal-transduction pathway, including transactivation of the bifunctional enzyme or acyl-CoA oxidase response elements in a cotransfection assay.	Bexarotene	37-46	retinoid X receptor alpha	Homo sapiens	94-97
11702369-1	2000	Bexarotene is a selective retinoid X receptor (RXR) agonist.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	26-45
11702369-1	2000	Bexarotene is a selective retinoid X receptor (RXR) agonist.	Bexarotene	0-10	retinoid X receptor alpha	Homo sapiens	47-50
11702369-4	2000	In patients with refractory or persistent early stage cutaneous T cell lymphoma (CTCL), the overall response rate was 54% after oral bexarotene 300 mg/m2/day.	Bexarotene	133-143	TSPY like 2	Homo sapiens	81-85
11702369-6	2000	An overall response rate of 63% was reported after topical bexarotene 0.1 to 1% twice daily in patients with early stage CTCL.	Bexarotene	59-69	TSPY like 2	Homo sapiens	121-125
10777552-7	2000	A similar induction of FATP-1 and ACS mRNA levels was also observed in vivo in Zucker diabetic fatty rats treated with the RXR agonist, LGD1069 (4-[1-(3,5,5,8,8-pentamethyl-5,6,7, 8-tetrahydro-2-naphthyl)ethenyl]benzoic acid).	Bexarotene	136-143	solute carrier family 27 member 1	Rattus norvegicus	23-29
10777552-7	2000	A similar induction of FATP-1 and ACS mRNA levels was also observed in vivo in Zucker diabetic fatty rats treated with the RXR agonist, LGD1069 (4-[1-(3,5,5,8,8-pentamethyl-5,6,7, 8-tetrahydro-2-naphthyl)ethenyl]benzoic acid).	Bexarotene	136-143	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	34-37
10777552-7	2000	A similar induction of FATP-1 and ACS mRNA levels was also observed in vivo in Zucker diabetic fatty rats treated with the RXR agonist, LGD1069 (4-[1-(3,5,5,8,8-pentamethyl-5,6,7, 8-tetrahydro-2-naphthyl)ethenyl]benzoic acid).	Bexarotene	145-224	solute carrier family 27 member 1	Rattus norvegicus	23-29
10777552-7	2000	A similar induction of FATP-1 and ACS mRNA levels was also observed in vivo in Zucker diabetic fatty rats treated with the RXR agonist, LGD1069 (4-[1-(3,5,5,8,8-pentamethyl-5,6,7, 8-tetrahydro-2-naphthyl)ethenyl]benzoic acid).	Bexarotene	145-224	acyl-CoA synthetase long-chain family member 1	Rattus norvegicus	34-37
15991942-8	1998	Targretin (LGD1069), a member of the rexinoid family (RXR activator), was shown to decrease triglyceridaemia and to increase HDL levels in hypertriglyceridaemic rats.	Bexarotene	0-9	retinoid X receptor alpha	Homo sapiens	54-57